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tiation and death of (cancer) cells [5]. With the introduction of the  
first tki imatinib in 2001, a whole new era of rationally designed TKIs has 
emerged. Since then, 22 other TKIs have been registered by the European 
Medicines Agency for the treatment of different types of both solid as well 
as hematological cancers [6].
Another important target for anticancer drug design is the mamma- 
lian target of rapamycin (mTOR), a serine-threonine kinase that is a key 
signaling molecule in the phosphatidylinositol 3-kinase (pi3k)/Akt path-
way [7]. This pathway is involved in the regulation of growth, proliferation, 
metabolism, survival and angiogenesis of cells and dysregulated in cancer. 
Everolimus and temsirolimus are examples of oral targeted therapies that 
specifically inhibit mTOR and that are used in oncology. 
In recent years, the clinical pharmacology of oral targeted therapies in-
cluding TKIs and everolimus has been studied extensively [8-10]. Despite 
the large variability in pharmacokinetics (pk) between patients, all TKIs, 
as well as everolimus, are registered at a fixed oral dose. This results in 
large differences in exposure between patients. As evidence for a rela- 
tionship between drug exposure and treatment outcome is growing  
for TKIs, fixed dosing could potentially result in sub- or supratherapeutic 
drug exposure with decreased therapeutic effects in some patients or an 
increased incidence and severity of toxicity in others [11-13]. It can be hy-
pothesized that dose individualization could improve clinical outcomes. 
Interestingly, within transplantation medicine dose individualization  
of everolimus is already the standard of care [14]. However, in the field  
of oncology dose individualization of everolimus is largely unexplored.
A better understanding of the underlying causes of inter-patient variabil- 
ity in drug exposure of oral targeted therapies is warranted. Also, strate-
gies should be developed to easily monitor treatment with these drugs  
in clinical practice. Moreover, studies that investigate the feasibility of 
dose individualization strategies such as therapeutic drug monitoring 
(tdm) are needed. Therefore, the aim of this thesis is to investigate and  
develop dose optimization strategies of oral targeted therapies used  
in oncology, in particular for the TKIs pazopanib and sunitinib and  
the mTOR inhibitor everolimus. 
In chapter 2 a systematic overview is given of current knowledge and  
evidence for individualized dosing of TKIs that are used for the treatment 
of solid tumors. Different criteria should be met to make dose individuali-
zation for a drug of potential interest. This chapter evaluates whether TKIs 
meet these criteria, with an emphasis on the primary requirement; a prov-
en drug exposure-response relationship. 
Cancer is a leading cause of morbidity and mortality [1,2]. In 2012, there 
were worldwide approximately 14 million patients diagnosed with cancer 
and 8.2 million cancer related deaths [1,2]. Considering the Netherlands, 
there were more than 100,000 patients diagnosed with cancer in 2014.  
In addition, over 42,000 patients died of cancer in that year, making it  
the leading cause of mortality in the Netherlands [3,4]. Once diagnosed, 
there are three types of treatment modalities including surgery, radiother-
apy and systemic therapy which can be used both in a (neo)adjuvant and 
palliative setting.
In the last two decades, the systemic treatment options with anti- 
cancer drugs in oncology have changed remarkably. With the increased 
understanding of cancer pathophysiology, the treatment of several can-
cers has shifted from the use of nonspecific chemotherapy aimed at kill-
ing all dividing cells, towards more specific treatment with (oral) targeted 
therapies and immunotherapy. Targeted drugs inhibit the growth of cancer 
by interfering with specific target molecules involved in the growth, acti-
vation and differentiation of cancer cells and therefore act more specific 
when compared to conventional therapies. 
Tyrosine kinases are such specific molecules and these proteins have 
become an important target for anticancer drug design. Tyrosine kinases 
transfer phosphate from adenosine-5’-triphosate (atp) to tyrosine residues 
on cellular proteins which activates signal-transduction pathways [5]. 
Insights into the dysregulation of these pathways in cancer cells led to  
the development of tyrosine kinase inhibitors (TKIs). TKIs compete with 
atp for the atp-binding pocket of tyrosine kinases that are mutated or 
overexpressed in some cancer cells and hereby block the dysregulated  
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A technical prerequisite for dose individualization of a drug, is the 
availability of a quantitative bio-analytical assay to measure drug levels 
and to monitor therapy in clinical practice. In chapter 3 the development 
and validation of a liquid chromatography coupled with tandem mass 
spectrometry (lc-ms/ms) assay to simultaneously detect six TKIs including 
pazopanib and sunitinib and two active metabolites in human serum  
is described. 
Monitoring of drug levels in serum or plasma as described in this  
assay makes blood sampling by venapuncture necessary. This has several 
disadvantages, including its invasive character, the requirement for pa-
tients to come to the clinic and the need for trained personnel. In chapter 
4 we investigate the feasibility of dried blood spot (dbs) sampling as a 
simple, flexible and more patient friendly alternative for the monitoring 
of pazopanib therapy. 
In chapter 5 we describe the feasibility of tdm to optimize the dosing  
of pazopanib. With the use of tdm, dosing can be individualized after 
steady-state pk has been reached.
Another approach for dose individualization could be the use of  
a noninvasive phenotyping probe. With this probe, drug exposure is pre-
dicted before initiation of therapy. In chapter 6 midazolam is evaluated  
as a potential phenotyping probe for cyp3a4 activity to predict sunitinib 
exposure in patients with cancer. 
Patients with gastrointestinal stromal tumors (gist) often have an  
altered anatomy of the gastrointestinal tract due to either resection of  
the primary tumor or subsequent surgery for recurrence and/or metas- 
tasis. This could influence drug absorption and thus lead to differences  
in drug exposure between patients. In chapter 7 the effect of different  
gastrointestinal resections on sunitinib exposure in patients with gist  
is investigated. 
Everolimus is a promising drug for the treatment of different solid  
tumors such as breast cancer and metastatic renal cell carcinoma. However, 
many patients are in need of dose interruptions, reductions and treatment 
discontinuation due to toxicity of this drug. In contrast to transplantation 
medicine where everolimus’ dosing is based on tdm, a fixed oral and high 
dose of 10 mg is used in oncology. In chapter 8 the correlation between 
everolimus exposure and toxicity and its population pharmacokinetics  
in patients with thyroid cancer is evaluated. 
This thesis ends with the general discussion and future perspectives  
in chapter 9.
abstr act Tyrosine kinase inhibitors (TKIs) are registered at a fixed oral 
dose, despite their large variability in pharmacokinetics (pk). Given that 
the evidence for a relation between drug exposure and treatment out- 
come is growing, this one-dose-fits-all approach can unintentionally  
lead to under- and overexposure. Dose individualization could lower  
this variability and thereby beneficially effect treatment outcome. In this 
article, we explore whether TKIs used for solid tumors meet the criteria  
for dose individualization. Despite limitations such as retrospective 
analysis, current data suggest that the following Ctrough levels could  
be used: imatinib 1100 ng/mL, sunitinib when continuously dosed 37.5 
ng/mL, intermittent 50 ng/mL and pazopanib 20 µg/mL. A comprehensive 
review of the literature also shows that prospective trials investigating the 
influence of dose individualization on treatment outcome are warranted.
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the most important criteria that should be met to prove the added value 
of dose individualization are a narrow therapeutic window and a proven 
exposure-response relation [12]. A narrow therapeutic window is appli- 
cable for all anticancer agents, including TKIs. Moreover, it is important 
that variability in pk within patients (intra-patient) is small compared 
with the variability between patients (inter-patient) [12]. In this review,  
we evaluate whether TKIs used for the treatment of solid tumors meet the 
criteria necessary for dose individualization. We emphasize the evidence 
for exposure-response relations and the inter- and intra-patient variability 
in pk.
Search
A PubMed search was performed using different synonyms of the key-
words ‘pharmacokinetics’ and ‘variability’, and the names of the indi- 
vidual TKIs registered by the European Medicines Agency (ema) up until 
February 2014 (Table 1). In addition, reference lists were screened for other 
relevant studies and registration information from the ema and U.S. Food 
and Drug Administration (fda) was used. Results were limited to studies 
in humans and English full-text articles published until the 24th of February 
2014. An overview of pk properties of the selected TKIs is shown in Table 2. 
Evidence for correlations between exposure-efficacy and exposure-toxicity 
is summarized in Tables 3 and 4, respectively. Table 5 describes the inter- 
and intra-patient variability in pk.
Axitinib
Correlation between exposure and efficacy
Recently, a study that used pooled data of 168 patients with metastatic re-
nal cell carcinoma (mRCC) showed that patients with an area under curve 
(AUC)0-24 ≥ 300 ng∙hr/mL after 4 weeks of treatment had significantly 
(P = 0.003) longer progression-free survival (pfs) and significant (P < 0.001) 
longer overall survival (os) compared with patients with an AUC0-24 < 300 
ng∙hr/mL [13]. Moreover, with every 100 ng∙hr/mL increase in AUC0-24, a 1.5-
fold increase in probability of partial response (pr) was found (P < 0.001) 
[13]. In another study, 49 patients with mRCC were grouped into four quar-
tiles based on their day 1, 1-2 hour post-dose axitinib levels. Patients in the 
third quartile (C1-2 45.4 - 56.4 ng/mL and AUC0-12 154-620 ng∙hr/mL) showed 
the best 5-year clinical outcome with longer os, pfs, and higher overall re-
sponse rate (orr) [14]. The better outcomes in the third quartile compared 
with the fourth quartile were explained by the higher incidence of grade ≥ 
3 toxicities leading to early discontinuation and interruptions in the fourth 
quartile. Another pooled analysis found a median os of 69 weeks for pa-
tients with an AUCss ≤ 605 ng∙hr/mL versus 88 weeks for patients with an 
AUCss > 605 ng∙hr/mL, but this difference was not significant (P > 0.05) 
Introduction
With the increased understanding of cancer pathophysiology, tyrosine ki-
nases have become important targets for anticancer drug design. Tyrosine 
kinases activate signal-transduction pathways that are crucial for growth, 
activation, differentiation, and death of cells [1]. Insights into dysregulation 
of these pathways in cancer led to the development of tyrosine kinase in-
hibitors (TKIs). With the introduction of TKIs, a new category of rationally 
designed targeted anticancer agents has emerged. 
Fixed dosing is usually a good option for drugs with a broad thera-
peutic window, small inter-patient variability in exposure, and limited 
toxicity [2]. However, most TKIs show a large variability in their exposure 
(pharmacokinetics; pk) and treatment outcome (pharmacodynamics; pd). 
Different causes for variability in pk are summarized in Figure 1. In addi-
tion, the evidence for a relation between drug exposure and response for 
TKIs is growing fast [3-7]. Consequently, fixed dosing could potentially  
result in sub- or supratherapeutic exposure with decreased therapeutic  
effects in some patients or increased incidence and severity of toxicity  
in others. 
Several studies have focused on reducing the inter-patient variability in 
exposure by dose individualization [8-11]. Some general criteria for dose 
individualization include: repeated administration, no easier assessable 
biomarkers to determine the response (e.g. blood pressure or rash),  
an available quantitative bioanalytical assay, and a validated dose-adapta-
tion strategy. Dose proportional pk is helpful for the development of such 












Abbreviation: ADME, absorption, distribution, metabolism, and excretion.
Figure 1 Variability of tyrosine kinase inhibitor pharmacokinetics 
Pharmacokinetic variability
1918
for dose titration because of dose-limiting toxicities (dlt), including  
hypertension, suggestive of a correlation between exposure and toxicity 
[20]. However, in a pk-pd analysis on axitinib-related bp increase, the  
correlation between exposure and dBP change was only weak (r2 values  
< 0.10) [13,15]. Therefore, dBP could be useful as a predictive biomarker  
to optimize axitinib therapy. However, dBP is potentially also not merely  
a reflection of higher axitinib exposure. Therefore, the most adequate  
biomarker (drug exposure or bp) needs to be established. Thyroid-
stimulating hormone changes have also been suggested as a biomarker  
of axitinib exposure [21,22]. The axitinib drug approval report from the 
fda states that pooled exposure-safety analysis from three phase ii trials 
and a pivotal phase iii trial, showed a significant (P < 0.001) exposure de-
pendent increase in hypertension, proteinuria, fatigue, and diarrhea [23]. 
However, an analysis of 128 patients with metastatic colorectal cancer 
(mCRC) did not find any correlation (P > 0.05) [18].
Inter- and intra-patient variability in exposure
Axitinib shows large inter-patient variability in pk with coefficients of  
variation (cv%) ranging from 17% to 94% for the auc and 17% to 113% for 
the apparent oral clearance (CI/F) [21,22,24-26]. The intra-patient variabil- 
ity is modest, with cv% values for Ctrough and CI/F of 20-22 cv% and for auc 
of 20-33 cv% [25,27]. Population pk analysis found that age, ethnicity, and 
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400 mg BID
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Abbreviations: 3/1, three weeks on therapy followed by 1 week off therapy; 4/2, four weeks on therapy followed by 2 weeks off therapy;  
BID, twice daily; N/A, not available; QD, once daily.
Table 2 Pharmacokinetic parameters of the TKIs
[15]. However, this analysis did show that patients with diastolic blood 
pressure (dBP) ≥ 90 mmHg had longer os compared with patients with 
dBP < 90 mmHg, which was also shown in other analyses [13,16-19].
A double-blind placebo-controlled randomized phase ii study  
prospectively evaluated the effect of axitinib dose titration on treatment 
outcome in 203 patients with mRCC [20]. Patients started with axitinib  
5 mg twice daily (bid) for 4 weeks. Patients with bp ≤ 150/90 mmHg, no 
grade 3/4 axitinib-related toxicities, no dose reductions, and ≤ 2 anti- 
hypertensive treatments, were randomized to receive axitinib 5 mg bid 
plus dose titration up to a total of 10 mg axitinib bid or dose titration with 
placebo. Patients not eligible for titration continued with axitinib ≤ 5 mg 
bid. Patients who were eligible for dose titration showed two times lower 
axitinib exposures compared with patients not eligible (AUC0-24 176 versus 
432 ng∙hr/mL). Furthermore, the axitinib dose titration group showed sig-
nificantly (P = 0.019) more objective responses compared with the placebo 
titration group. Patients not eligible for titration (those with initial higher 
initial axitinib exposure) had comparable objective responses to the ax-
itinib dose titration group. This demonstrates a positive relation between 
axitinib exposure and response, although there was no difference in pfs  
or os between the axitinib and placebo dose titration arm.
Correlation between exposure and toxicity
In the before-mentioned study, patients eligible for titration had over  


































cKIT, PDGFRα,β, VEGFR 1-3
BRAF, cKIT, PDGFRα,β, RAF, RET, TEK, VEGFR 1-3
cKIT, FLT3, PDGFRβ RAF-kinases, VEGFR 1-3
cKIT, CSFR, FLT3, PDGFRα,β, RET, VEGFR 1-3















Abbreviations: ALL, acute lymphoblastic leukemia; Bcr-Abl, fusion protein; BRAF, B-rapidly accelerated fibrosarcoma oncoprotein; CEL, chronic 
eosinophilic leukemia; c-KIT, mast/stem cell growth factor receptor; CML, chronic myeloid leukemia; CRC, colorectal cancer; CSFR, colony stimulating 
factor receptor; DFSP, dermatofibrosarcoma protuberans; EGFR, epidermal growth factor receptor; FLT3, FMS-like tyrosine kinase 3; GIST, gastro-
intestinal stromal tumor; HCC, hepatocellular carcinoma; HER2+, human epidermal growth factor receptor mutation positive; HES, hypereosinophilic 
syndrome; MDS/MPD, myelodysplastic/myeloproliferative diseases; mRCC, metastatic renal cell carcinoma; MTC, medullary thyroid cancer; NSCLC, 
non-small cell lung cancer; PDGFR, platelet derived growth factor receptor; pNET, pancreatic neuroendocrine tumor; RAF, receptor accessory factor; 
RET, rearranged during transfection; STS, soft tissue sarcoma; VEGFR, vascular endothelial growth factor receptor.
Table 1 Overview of indications and targets of TKIs for the treatment of solid tumors 
Chapter 2
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P = 0.042  
and 0.036
P = 0.0014





















































37.4 versus 15.8 months
13.8 versus 7.4 months
1.5 fold increase in probability of a PR for every 100 ng∙hr/mL  
increase in AUC0-24 
NR versus 20.3-27.7 months 
28.3 versus 7.5-11.8 months
81.8% versus 16.7-53.8%
88 versus 69 weeks 
54% versus 34% 
5.22 versus 4.00 versus 3.44 nmol/mL for PR, SD and PD respectively 
HR: 1.424 (95%-CI: 0.677-2.996)
HR: 1.765 (95%-CI: 0.852-3.657)
11.2 versus 5.6 months
OS was related to magnitude Ctrough of OSI-420
TTP was related to magnitude Ctrough of erlotinib and OSI-420 
HR: 1.387 (95%-CI: 1.135-1.695)
HR: 1.054 (95%-CI: 1.008-1.103) and 
1.422 (95%-CI: 1.166-1.735)
HR: 0.452 (95%-CI: 0.237-0.862)
14.6 versus 4.7 months
1,117 versus 520 ng/mL for patients with PR + SD versus PD
> 30 versus 11.3 months 
100% versus 67%
2.6 fold increase in probability of CR+PR for every doubling  
of unbound AUC0-24 
83% versus 0%
ΔT v2 decreased linear with AUC0-24 (r = 0.54)
Δ Ktrans decreased most with Ctrough > 20 µg/mL
49.4 versus 20.3 weeks 
45% versus 18%
37.8% versus 8.8%
86% versus 50% 
80% versus 33% 
21 versus 10 weeks 
12.0 versus 6.5 months
TTP increased with increasing AUC0-24 
OS increased with increasing AUC0-24 
ORR increased with increasing AUC0-24 
SD increased with increasing AUC0-24 
TTP increased with increasing AUC0-24 
OS increased with increasing AUC0-24 
ORR increased with increasing AUC0-24 
SD increased with increasing AUC0-24 
a Ctrough 50-100 ng/mL is the minimum plasma concentration  
required to inhibit Flk-1/KDR and PDGFRβ
HR: 0.653 (95%-CI: 0.503-0.848) 












































AUC0-24 ≥ versus < 300 ng∙hr/mL 
AUC0-24 
C1-2: 45.2-56.4 ng/mL 
AUC0-12: 154-620 ng∙hr/mL 
AUCss ≥ versus < 605 ng∙hr/mL
Dose titration versus no titration 
Ctrough 
Ctrough ≥ versus < 4.6 nmol/mL 
Ratio Ctrough D8/D2 > median  




C5-10 erlotinib and OSI-420 
Ratio Ctrough D8/D3 < versus ≥ 1.587
Ctrough ≥ versus < 200 ng/mL
Ctrough 
Ctrough ≥ versus < 1,110 ng/mL
Ctrough ≥ versus < 1,110 ng/mL
AUC0-24 unbound
Ctrough ≥ versus < 15 µg/mL
AUC0-24 
Ctrough > 20 µg/mL
Ctrough > versus ≤ 20.6 µg/mL
AUCmax ≥ versus < 100 µg∙hr/mL
Cmax ≥ versus < 4.78 µg/mL 
AUC0-24 ≥ versus < 800 ng∙hr/mL
AUC0-24 ≥ versus < 600 ng∙hr/mL
Ctrough 50-100 ng/mL
Ctrough 






















































Abbreviations: AUC, area under 
the concentration-time curve; 
C1-2, concentration 1-2 hours 
post-dose; C5-10, concentration 
5-10 hours post-dose; CR, 
complete response; dBP, 
diastolic blood pressure; GIST, 
gastrointestinal stromal tumor; 
HCC, hepatocellular carcinoma; 
HNSCC, head and neck 
squamous cell cancer; Ktrans, 
volume transfer coefficient: an 
indicator of vascular response; 
PFS, progression free survival; 
mRCC, metastatic renal cell 
carcinoma; mRCC, metastatic 
renal cell carcinoma; N/A, not 
available; NPC, nasopharyngeal 
carcinoma; NR, not reached; 
NSCLC, non-small cell lung 
carcinoma; OR, objective 
response; ORR, objective 
response rate; OS, overall 
survival; OSI-420, active 
metabolite erlotinib; OOBR, 
overall objective benefit rate 
(complete response + partial 
response + stable disease); PD, 
progressive disease; PR, partial 
response; RR, response rate; SD, 

































Correlation between exposure and efficacy
A study in 56 patients with stage iv non-small cell lung cancer (nsclc) 
showed that Ctrough levels after 7 days of therapy were 5.22 nmol/mL in  
patients with pr, 4.00 nmol/mL in patients with stable disease (sd), and 
3.44 nmol/mL in patients with progressive disease (pd), although, statis- 
tically, this was not significantly different (P > 0.05) [33]. In addition, the 
cut-off value of 4.6 nmol/mL for Ctrough associated with skin toxicity (pa-
tients with skin toxicity had better treatment outcome) could not predict 
os (P = 0.351) and pfs (P = 0.127) [33]. In another phase ii study in 19 patients 
with nsclc, Ctrough levels were measured on day 2 and 8 of treatment [34]. 
The Ctrough day 8:Ctrough day 2 ratio represented the accumulation of  
erlotinib over time. A larger ratio was considered to reflect low metabolism 
and thereby higher erlotinib exposure. In this analysis, a higher ratio was 
associated with longer pfs (P = 0.004). However, an effect of this ratio on 
os could not be shown. Although erlotinib is not registered for the treat-
ment of head and neck squamous cell cancer (hnscc), two studies showed 
a correlation in this patient population. In a phase ii study in 18 patients 
with hnscc, time to progression (ttp) was related to Ctrough levels of  
erlotinib (P = 0.042) and its active metabolite osi-420 (P = 0.036) [35].  
A correlation with os was only found for osi-420 Ctrough levels (P = 0.019). 
Another study in patients with hnscc evaluated three sampling windows; 
Ctrough window (20-25 hours post-dose, n = 42), Cmax window (2-5 hours 
post-dose, n = 77) or C5-10 (5-10 hours post-dose, n = 47]. The median C5-10 
of both erlotinib and osi-420 (P = 0.021 and P = 0.0005), as well as Ctrough 
of osi-420 (P = 0.0014) predicted improved os [36].
Correlation between exposure and toxicity 
Besides the correlation between erlotinib exposure and efficacy, several 
studies have reported on associations between the occurrence and severity 
of rash and clinical outcome. In a phase ii study in 57 patients with nsclc, 
the median os for patients with ≥ grade 2 rash was 19.6 months versus  
8.5 for grade 1 rash, and 1.5 months for patients without rash [37]. Com- 
parable results were shown in other trials [33,35,36,38-45]. Surprisingly,  
in the studies that showed correlations between pk and treatment out-
come and/or toxicity and treatment outcome, pk parameters were not  
always related to toxicity [33-36]. This indicates that skin toxicity is not 
merely a reflection of high erlotinib exposure. The largest analysis per-
formed to determine the correlation between exposure and toxicity is  
that of the pivotal br.21 trial in 339 patients with nsclc. In this analysis,  
a correlation between AUC0-24 and Cmax and rash was demonstrated. 
However, because of a large overlap in pk parameters between patients 
with and without toxicity, the correlation was considered not relevant 
[46]. Several smaller analyses have also shown correlations between 
sizes were small, making dose adjustment based on these covariates  
unnecessary [13,28].
Dose individualization
The above-mentioned individualization study shows that titration based 
on toxicity facilitates optimization of plasma exposure and is associated 
with a greater proportion of patients with mRCC achieving a response. 
Therefore, toxicity-driven dose adjustment is beneficial to optimize  
and individualize axitinib therapy [20].
Conclusion 
Axitinib has substantional inter-patient, with relatively modest intra- 
patient pk variability. Several studies showed a clear exposure-response 
relation and bp also seems a potential biomarker to select patients in  
need of dose adjustment. Surprisingly, conflicting data are presented on 
the correlation between exposure and bp. Therefore, the most adequate 
biomarker (drug exposure or bp) needs to be established. However, the 
current available data from the axitinib dose titration trial provide evi-
dence for a toxicity-driven individualized axitinib dosing approach.
Dabrafenib
Correlation between exposure and efficacy and toxicity 
There are currently no data that explore the relation between dabrafenib 
exposure and efficacy or toxicity.
Inter- and intra-patient variability in exposure
The inter-patient variability in pk is large, with cv% for auc, Ctrough,  
and Cl/F of 38-68%, 119% and 58%, respectively [29,30]. Weight, age, and 
gender were not considered clinically relevant in explaining the large  
inter-patient variability [29,31,32]. No data on intra-patient variability  
are available.
Dose individualization 
There are currently no studies investigating dose individualization  
strategies for dabrafenib.
Conclusion 
Dabrafenib shows high inter-patient variability in exposure. However, 
data regarding the intra-patient variability are lacking and, most im- 
portantly, there are no proven correlations between drug exposure  
and response. These main prerequisites need to be met before dose  
individualization of dabrafenib can be considered. 
Chapter 2
2524
Outcome Correlation Significance REF
N/A

























































432 versus 176 ng∙hr/mL for patients  
with and without toxicity
ΔTSH increased linear with AUC0-12  
(r = 0.72 and r = 0.80)
probability for toxicities was AUC0-24 dependent 
no correlation 
severity of rash increased with AUC0-24 and Cmax 
(r = 0.14 and r = 0.13)
incidence of grade 3/4 toxicities  
increased with Ctrough 
OR: 2.83 (95%-CI: 1.10-7.29)
OR: 3.79 (95%-CI: 1.09-13.2)
~1000 versus ~3300 ng/mL for patients  
with and without ILD
54.2 and 59.1 vs 36.2 µg∙hr/mL for patients  
with grade 2 and 3 or grade 1 rash
1.99 and 1.86 vs 1.29 µg/mL for patients  
with grade 2 and 3 or grade 1 rash
severity of skin toxicity increased with AUC0-24 
probability for skin toxicity was AUC0-24 dependent
severity of skin toxicity increased with AUC0-24 
probability for skin toxicity was AUC0-24 dependent
1.18 fold increase in probability of grade ≥ 2 rash  
for every 10 µg∙hr/mL increase in AUC0-24 
1.75-fold increase in probability of grade ≥ 2 rash 
for every 1 µg/mL increase in Ctrough 
18 versus 11.8 µg∙hr/mL for patients  
with and without skin toxicity 
85.7% versus 42.9%
probability for ≥ grade 1 diarrhea  
was Ctrough dependent 
2.2 fold increase in probability of toxicity  
for every doubling of the AUC0-24 
Δ ANC decreased linear with AUC0-24 (r = 0.56) 
76% versus 53%, 51% versus 32%, 30%  
versus 20% and 20% versus 8% respectively
32% versus 17%, 35% vs 12%, 35% versus 17%,  
27% versus 17% and 22% versus 5% respectively
77% versus 39% 
896 versus 367 µg·h/mL for patients  
with and without DLT 
incidence of DLT increased linear  
with AUC0-24 (r = 0.595)
38.8 versus 29.6 µg/mL for patients  
with and without DLT
43.7 versus 29.4 μg/mL for patients with grade  
2/3 hypertension and normotensive patients 
magnitude and duration of elevation in sBP greater 
for patients with AUC0-72 of 1,840 versus 786 µg·h/mL
≥ 2 fold increase in incidence of toxicities  
with increase of Ctrough 
occurrence and severity increased with Ctrough 
61.9 versus 53 µg∙hr/mL for patients  
with and without grade 3-4 toxicities
hypertension, grade 3-4 toxicity,  
dose reductions and ≤ 2 AH-treatments 
ΔTSH level
hypertension, proteinuria, fatigue and diarrhea
diarrhea, fatigue and hypertension
rash 
grade 3-4 toxicities 
grade ≥ 2 rash 






grade ≥ 2 rash 
grade ≥ 2 rash 
skin toxicity
incidence skin toxicity
≥ grade 1 diarrhea 
toxicity
% decrease in ANC
fluid retention, rash, myalgia and anemia
grade 3-4 neutropenia, rash, diarrhea,  














AUC0-24 and Cmax 
Ctrough 













Ctrough > 1,170 versus < 647 ng/mL
Ctrough > 3180 ng/mL























































































Outcome Correlation Significance REF






































high AUC0-12 was associated  
with the occurrence of HFSR 
82 versus 54 µg∙hr/mL for patients  
with and without hypertension
76 versus 61 µg∙hr/mL for patients  
with and without HFSR
OR: 1.07 (95%-CI: 1.01-1.12)
Ctrough lower for patients with grade 0-1 HFS 
versus patients with ≥ grade 2 HFS
Ctrough lower for patients with grade 0-1 hypertension 
versus patients with ≥ grade 2 hypertension
severity of rash increased with AUC0-12 
106.4 versus 56.7 µg∙hr/mL for patients  
with and without DLT
patients with Ctrough > median were  
more likely to develop diarrhea
7.6 versus 4.4 µg/mL for patients  
with and without grade 3 toxicity
most patients with DLT had Ctrough > 100 ng/mL
100% versus 55.6%
90% versus 22.2%
positive correlation between AUC0-24  
and incidence of fatigue
Δ ANC decreased linear with AUCcum28 (r = -0.40)
Δ dBP increased linear with Ctrough (r = 0.29)
15.4 versus 9.6 msec.
34.4 versus 41.4 L/hr for patients  
with and without grade 3 toxicity 
positive correlation between Ctrough  
and occurrence of fatigue
positive correlation between Ctrough  
and probability of diarrhea
positive correlation between Ctrough  
and probability of fatigue
positive correlation between Ctrough  
and risk of SCC
positive correlation between Ctrough  
QTc-interval prolongation
HFSR
≥ grade 2 hypertension 
HFSR
≥ grade 3 toxicity
≥ grade 2 HFS
≥ grade 2 hypertension
rash grade
DLT
grade 2-3 diarrhea 
grade 3 toxicity
DLT
grade ≥ 2 thrombocytopenia 







grade ≥ 2 diarrhea









Ctrough ≥ versus < median
Ctrough 
Ctrough > 100 ng/mL
























solid, GIST  
and mRCC 
solid




















antihypertensive; ANC, absolute 
neutrophil count; AUCcum28, 
28-day cumulative AUC; dBP, 
diastolic blood pressure; CML, 
chronic myeloid leukemia; DLT, 
dose limiting toxicities; GIST, 
gastrointestinal stromal tumor; 
HCC, hepatocellular carcinoma; 
HNSCC, head and neck 
squamous cell cancer; HFS, 
hand-foot syndrome; HFSR, 
hand foot skin reactions; ILD, 
interstitial lung disease; mCRC, 
metastatic colorectal cancer; 
mRCC, metastatic renal cell 
carcinoma; MTC, medullary 
thyroid cancer; N/A, not 
available; NSCLC, non-small cell 
lung carcinoma; p-NET, 
pancreatic neuroendocrine 
tumor; sBP, systolic blood 
pressure; SCC, squamous cell 











AUC0-24, Ctrough, Cmax, and grade 3/4 toxicities, skin toxicity, rash, and  
diarrhea in nsclc, hnscc, ovarian cancer, and brain tumors, as shown  
in Table 4 [45,47-50].
Inter- and intra-patient variability in exposure 
The inter-patient variability in Ctrough, auc, and CI/F is 38-76%, 18-156%,  
and 10-129%, respectively [40,42,47,51-72]. The European Public Assessment 
Report (epar) of erlotinib reports an intra-patient auc variability of 16-24 
cv% measured in healthy volunteers. 
Dose individualization 
A phase ii trial investigated the feasibility of toxicity-driven dosing to  
a maximal level of tolerable target rash (tr) that required symptomatic 
treatment with minocycline [73]. Only 21% of the patients who ultimately 
experienced a tr developed this under dose escalation, whereas most  
patients experienced the tr under the standard dose of 150 mg once  
daily (qd). In addition, no increase in anticancer activity was observed  




Erlotinib shows large inter-patient variability and, although based on  
limited data, the intra-patient variability appears small. Some studies  
have shown exposure-efficacy and exposure-toxicity relations. Rash is  
often suggested as a potential early biomarker to select patients in need 
for dose adjustment, although dosing to rash did not improve clinical  
activity. Furthermore, in studies that showed correlations between pk  
and treatment outcome and/or toxicity and treatment outcome, pk pa-
rameters were not always related to toxicity. In our opinion, it is unlikely 
that rash can be used to individualize erlotinib therapy because dosing  
to rash did not demonstrate improved treatment outcomes. 
Gefitinib
Correlation between exposure and efficacy 
Similar to erlotinib, a study in 44 patients with nsclc measured Ctrough  
levels [74]. A high Ctrough day 8:Ctrough day 3 ratio was associated with bet-
ter pfs (P = 0.0158), although individual Ctrough levels were not related to 
longer pfs. Furthermore, no correlation with os was found. A prospective 
study in 30 patients with nsclc showed that patients with high gefitinib 
exposure (Ctrough ≥ 200 ng/mL) had longer os (P = 0.007) compared with 
patients with low exposure (Ctrough < 200 ng/mL) [75]. Additionally, the 
patients with wild type epidermal growth factor receptor (egfr) appeared 
to be more sensitive to higher exposure levels with longer survival  
(~2 months longer median os) compared with the other patients. Finally, 
in a dose escalation to skin toxicity study with 20 patients with hnscc, 
Intra-patient variability (CV%)


















































Abbreviations: %CV, coefficient of variation; AUC, area under the concentration time curve; Cl/F, apparent oral clearance; Ctrough, minimum plasma 
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Table 5 PK inter- and intra-patient variability of TKIs
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Ctrough levels for patients with disease control (pr + sd) were higher  
compared with patients with pd (1117 versus 520 ng/mL, P = 0.0103) [76].
Correlation between exposure and toxicity 
Different phase i studies explored a possible relation between gefitinib 
plasma concentrations and skin- and gastrointestinal toxicity [77-79]. 
Zhao et al. showed that patients with high gefitinib exposure (Ctrough  
≥ 200 ng/mL) experienced more rash (P = 0.043) compared with patients 
with low exposure (Ctrough < 200 ng/mL [75]. The incidence of gastro- 
intestinal toxicity was not found to differ between the two groups [75]. 
However, in the population pk analysis of Li et al., gefitinib Ctrough level 
was a significant predictor for the incidence of ≥ grade 1 diarrhea 
(P < 0.05) [80].
Inter- and intra-patient variability in exposure 
Gefitinib shows large inter-patient variability in auc (31-112%), CI/F (79-90%) 
and Ctrough (14-166%) [75,77,78,81-98]. The intra-patient variability for Ctrough 
is 2-49% [77,91]. A phase i study designed to determine the intra-patient 
variability, showed a two-fold variability in auc within subjects, whereas 
the variability between patients was 15-fold [85]. Population pk studies  
indicated that gender, age, bodyweight, ethnicity, or creatinine clearance 
cannot explain the large inter-patient variability [99].
Dose individualization 
There are three dose individualization studies published for gefitinib;  
two phenotyping studies and one toxicity-driven dosing study [76,80,100]. 
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Given that cytochrome P450, family 3, sub-family A (cyp3a) is the principal 
enzyme that metabolizes gefitinib, variability in its activity might be an 
explanation of pk variability. The first phenotyping study showed that  
midazolam oral clearance as a measure of cyp3a activity accounted for  
37% of the inter-patient variability in gefitinib oral clearance [80]. 
Furthermore, midazolam clearance was strongly associated with both 
gefitinib clearance (r2 = 0.68) and gefitinib Ctrough (r2 = 0.58). Therefore, 
midazolam could be used to identify those patients at risk for under- or 
overdosing, respectively. The second phenotyping study showed a border-
line significant correlation between midazolam and gefitinib auc [100].  
In a dose escalation study in patients with hnscc, the gefitinib dose was 
escalated from 500 to 750 mg in those patients without grade 2 skin toxic-
ity [76]. In the preplanned analysis of patients with and without ≥ grade 2 
skin toxicity, there was no difference observed in treatment benefit. 
Conclusion 
The intra-patient variability in gefitinib pk appears small compared with 
the large inter-patient variability. Further investigation to determine the 
exact correlation between gefitinib exposure and treatment benefit is re-
quired, because the two studies that showed a correlation were performed 
in small cohorts. Once this has been established and after prospective vali-
dation, dose individualization seems a reasonable option to improve 
treatment efficacy and prevent underdosing.
Imatinib
Correlation between exposure and efficacy 
The most convincing evidence for a correlation in solid tumors comes 
from a retrospective analysis of a phase ii trial including 73 patients with 
gastrointestinal stromal tumors (gist). This analysis showed that patients 
with Ctrough levels < 1100 ng/mL after 29 days of therapy, had shorter ttp 
(11.3 months) compared with patients with Ctrough levels above this con-
centration (> 30 months, P = 0.0029) [4]. Patients with low exposure also 
showed a trend towards a lower overall objective benefit rate (oobr; cr + 
pr + sd). These findings suggest that a minimal concentration of imatinib 
is necessary to achieve and maintain clinical response in patients with 
gist. A prospective population pk study on imatinib Ctrough levels observed 
a decrease in imatinib exposure of approximately 30% after 3 months of 
therapy [101]. Therefore, measuring levels should be time-point specific 
and repeated after 3 months of therapy. Widmer et al. similarly demon-
strated the importance of sufficient drug exposure to achieve and main-
tain therapeutic responses with the use of pk-pd data from 38 patients 
with gist [102]. However, this analysis suggested that it is unbound imati-
nib exposure, rather than total imatinib exposure, which is associated 
with response. 
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Correlation between exposure and toxicity 
Widmer et al. also showed that the occurrence and number of adverse  
effects were associated with both imatinib total and free plasma concen-
trations (P < 0.001) in patients with gist [102]. A phase iii trial in patients 
with gist showed that hematologic toxicity (% decrease in anc and plate-
lets) was also correlated with unbound imatinib AUC0-24 at steady-state 
(P < 0.001) [103]. Larson et al. showed that the discontinuation rate  
of imatinib resulting from toxicity was higher in patients with high  
Ctrough levels (> 1170 ng/mL) compared with patients with low Ctrough  
levels (≤ 1170 ng/mL) [3]. Another study showed that high Ctrough levels 
(Q4, Ctrough > 3180 ng/mL) were associated with the frequency of all-grade 
and grade 3/4 neutropenia, anemia, and leukopenia observed within the 
first 3 months of therapy and, to a lesser extent, all-grade thrombocyto- 
penia. For non-hematologic toxicities, Ctrough levels were associated with 
the frequency of all-grade rash, edema, nausea, diarrhea, vomiting, arthral-
gia, myalgia, and extremity pain within the first 3 months of therapy [104]. 
Inter- and intra-patient variability in exposure
Imatinib shows large inter-patient variability in auc (21-66%) and Ctrough 
(25-64%) [4,105-121]. There are four studies that report both the intra- and 
inter-patient variability in Ctrough; these ranged from 19% to 27% versus 
from 37% to 47%, respectively [117,119,121,122]. A fifth study showed an  
intra-patient variability in auc of 12.4% versus 11.6% for the inter-patient 
variability [123]. In different population pk analysis, body weight, age,  
sex, disease diagnosis, plasma α1-acid glycoprotein, albumin, granulocyte 
count, white blood cells (wbc), hemoglobin (Hb), and major gastrectomy 
were found to explain a certain part of the inter-patient variability, but 
dose adjustment based on these covariates was not considered necessary 
[103,119,124-132]. 
Dose individualization 
Although several retrospective studies are in support of dose individuali-
zation, the results of the first prospective trials assessing the influence on 
treatment outcome are awaited. There are ongoing trials aiming to estab-
lish the optimal use of therapeutic drug monitoring (tdm) for imatinib  
in chronic myeloid leukemia (cml; isrctn 31181395) and two studies to  
determine whether dose adjustments to reach a target exposure will  
improve treatment outcome in gist patients (nct01031628) and cml 
(nct01827930). Meanwhile, several case reports underscore the value  
of dose individualization of imatinib [133-135]. 
Conclusion 
We consider imatinib the tki with currently the most evidence available  
to justify the measurement of Ctrough levels. There is a clear correlation  
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between exposure and efficacy with Ctrough levels > 1000-1100 ng/mL  
associated with better treatment outcome. Moreover, the intra-patient 
variability is small compared with the inter-patient variability. However, 
prospective trials investigating the influence of dose individualization on 
treatment outcome are awaited. Currently, tdm is already applied by some 
clinicians, although it is not part of routine clinical practice yet [136-143]. 
If measurement takes place, this should be time-point specific and repeat-
ed every 3 months because patients with gist show a decrease in exposure 
over time [101].
Lapatinib
Correlation between exposure and efficacy 
The only suggestion for a correlation comes from the first phase i trial  
in which most responders had a Ctrough level within the 0.3-0.6 µg/mL 
range [144]. 
Correlation between exposure and toxicity 
Another phase i study reported that the frequency and severity of rash 
seemed to be related to AUC0-24, Cmax, and Ctrough rather than the dose 
[145]. The fda approval report states that a relation between lapatinib  
concentrations and prolonged QTc-interval is possible, although con- 
vincing evidence is lacking [146]. 
Inter- and intra-patient variability in exposure
The cv% in auc and Ctrough ranged from 42% to 117% and 55% to 97%,  
respectively [147-159,145,160-162]. The only data considering intra- 
patient variability are reported in the epar and is estimated to be 30-36% 
for AUC0-24 [161]. Sex, weight, ethnicity, or age could not explain the inter- 
patient variability in pk [161]. 
Dose individualization 
There are currently no studies considering individualization strategies  
for lapatinib. 
Conclusion 
In theory, lapatinib meets many of the criteria for dose individualization. 
Moreover, the inter-patient variability is relatively large compared with 
the intra-patient variability. However, evidence for a correlation between 
lapatinib exposure and treatment benefit or toxicity is lacking. Currently, 
there is insufficient evidence to support dose individualization of lapatinib.
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Pazopanib 
Correlation between exposure and efficacy 
Several smaller studies with pazopanib have shown a threshold for effi- 
cacy of approximately 20 µg/mL [163-165]. The most convincing evidence 
for this threshold comes from a retrospective pk analysis of a phase ii trial 
in 205 patients with mRCC [7,166]. Patients with a Ctrough > 20.6 µg/mL  
after 4 weeks of pazopanib 800 mg qd, showed significantly longer pfs 
(P = 0.0041) [7]. In addition, the rr as well as the mean percentage tumor 
shrinkage was improved in patients with Ctrough levels > 20.6 µg/mL 
(P < 0.0001) [7]. 
Correlation between exposure and toxicity
The first suggestion for a correlation between pazopanib exposure and 
toxicity comes from the same first phase i study [163]. Twenty out of 26  
patients (77%) with Ctrough levels ≥ 15 µg/mL on day 22 developed hyper-
tension, whereas only 11 out of 28 patients (39%) with Ctrough levels  
< 15 µg/mL did so [163]. In a phase i trial in children, patients with dlt  
had a significantly larger AUC0-24 and Ctrough compared with those  
without (896 versus 367 µg·hr/mL, P < 0.039 and 38.8 versus 29.6 µg/mL, 
P < 0.040, respectively) [167]. Moreover, a significant relation between  
bp and Ctrough was identified. In patients with drug-related grade 2 or 3  
hypertension after a median of two cycles, mean Ctrough was 43.7 µg/mL 
versus 29.4 µg/mL in normotensive patients (P < 0.004) [167]. 
In a food interaction study with pazopanib, the incidence of elevated 
systolic blood pressure (≥ 140 mmHg) was found to be similar in both fed 
and fasted conditions. However, the magnitude and duration of elevated 
bp were greater when the drug was administered with a meal, correlating 
with an increased AUC0-24 [168]. 
The most convincing evidence comes from analysis of the before  
mentioned 205 patients with mRCC included in a phase ii trial [6,166]. 
This analysis showed that the incidence of different pazopanib-induced 
toxicities seemed to be concentration dependent; there was a more than 
twofold increase in the incidence of diarrhea, hair color change, alt in-
crease, hand-foot syndrome (hfs), and stomatitis when Ctrough after 4 weeks 
of treatment increased from 12.6 to 46 µg/mL. Additionally, the occurrence 
and severity of hfs was also correlated with higher week 4 Ctrough levels 
(P < 0.001) [169]. 
Inter- and intra-patient variability in exposure 
Pazopanib shows large inter-patient variability in pk with values ranging 
from 11% to 67% for Ctrough and from 19% to 76% for auc [158,163,165,167, 
168,170,171]. Data considering the intra-patient variability are lacking thus 
far. Our own unpublished results indicate that the intra-patient variability 
3534
is relatively large, possibly because of the large effect of food on the  
low and variable bio-availability of pazopanib. 
Dose individualization 
Different studies are currently investigating the feasibility of tdm for  
pazopanib. We investigated the feasibility of tdm to reach a target expo-
sure within a predefined window. There is also a study designed to reach  
a target pazopanib Ctrough 20 > µg/mL by tdm. Outcomes of these studies  
are awaited.
Conclusion 
In our opinion, a Ctrough level above 20 µg/mL should be targeted in clin- 
ical practice to prevent underdosing and unjustified discontinuation  
of pazopanib treatment. Given that our results show a relatively large  
intra-patient compared with inter-patient variability, measuring Ctrough 
levels should be performed under standardized conditions to make in- 
terpretation possible. The described saturated absorption of pazopanib 
might be challenging for dose adjustment, although we hypothesize that 
dividing the daily dose or the administration with food might overcome 
this problem [163]. Given that pazopanib exposure has been correlated 
with hypertension, bp could be a potential valuable biomarker.
Regorafenib 
Correlation between exposure and efficacy and toxicity 
There are no data available that report on pk-pd relations. Both fda and 
ema approval reports state that this will be investigated post-marketing 
[172,173]. 
Inter- and intra-patient variability in exposure 
The inter-patient variability in pk is relatively large, with cv% for auc  
and Ctrough of 43-88% and 57%, respectively [172,174-176]. The reported  
intra-patient variability in auc is 34% [175]. No significant or clinically  
relevant influence of weight, age or gender, race, or bilirubin on pk  
parameters could be shown [173]. 
Dose individualization 
There are no studies that investigate dose individualization strategies. 
Conclusion 
In theory, regorafenib meets many of the criteria for dose individualiza-
tion. Moreover, the inter-patient variability is relatively large compared 
with the intra-patient variability, although its dose-limited absorption 
might be challenging [172-174]. However, most importantly, there are  
currently no data that show a correlation between regorafenib exposure 
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and treatment benefit or toxicity. Therefore, there is currently insufficient 
evidence to support dose individualization of regorafenib therapy.
Sorafenib
Correlation between exposure and efficacy
Although sorafenib is not registered for this indication, the first pk-pd 
analysis was performed in 27 melanoma patients. Patients with high 
sorafenib exposure (AUCss ≥ 100 µg·hr/mL) showed higher tumor  
control (P = 0.04), tumor response (pr and sd) (P = 0.02) and longer pfs 
(P = 0.005) [177]. Another analysis showed that patients with hepatocellu-
lar carcinoma (hcc) with high exposure (Cmax ≥ 4.78 µg/mL) had a trend 
(P = 0.0824) towards longer os compared with patients below this  
threshold [178]. 
Correlation between exposure and toxicity 
The first suggestion for a relation between sorafenib exposure and toxic- 
ity comes from a phase i trial and different later studies have also reported 
this observation [177-184]. In a retrospective analysis of 83 patients treated 
with sorafenib at a dose of 200-400 mg bid, patients with severe toxicity 
(grade 3-4 adverse events) had significantly higher sorafenib exposure 
than that observed in the remaining patients (61.9 versus 53 µg·hr/mL, 
P = 0.017) [179]. Additionally, a high AUC0-12 on day 30 of treatment was 
significantly (P = 0.03) associated with the occurrence of hand food  
skin reaction (hfsr). 
In the aforementioned study, sorafenib median AUC0-12 after 1 month 
was greater in patients with grade ≥ 2 hypertension compared with those 
with normal bp (82 versus 54 µg·hr/mL, P = 0.02) and patients with grade  
≥ 2 hfsr compared with those without hfsr (76 versus 61 µg·hr/mL, 
P = 0.0008). However, no correlations were observed for other toxicities, 
such as diarrhea, anorexia, allergic, and nonallergic skin rash [177]. 
Another analysis showed that increased AUCcum was associated with  
any grade ≥ 3 toxicity (P = 0.037) [180]. The opposed AUCcum threshold  
acquired by simulation that predicted a toxicity of grade ≥ 3 was 3161 
µg·hr/mL. 
A pk-pd analysis by Fukudo et al. showed that steady-state Ctrough  
in patients with grade ≥ 2 hfsr (P = 0.0045) and hypertension (P = 0.0453) 
were larger than in patients with < grade 2 adverse events. The proposed 
Ctrough threshold for grade ≥ 2 hfsr and grade ≥ 2 hypertension were esti-
mated to be 5.78 µg/mL and 4.78 µg/mL, respectively [178]. Another study 
showed that the severity of rash increased (P = 0.02) with increasing 
AUC0-12 [181]. Additionally, Mir et al. showed that patients who experi-
enced a dlt during the first 4 weeks of treatment had higher AUC0-12 
(106.4 versus 56.7 µg·hr/mL, P = 0.09) [182]. 
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Inter- and intra-patient variability in exposure 
Sorafenib exhibits high variability in Ctrough (25-104%), auc (12-117%)  
and CI/F (13-80%) compared with modest intra-patient variability in  
auc (31-47%) [92,177-180,184-210]. Gender is suggested to be a covariate  
of significant influence on sorafenib pk, whereas bodyweight could only 
explain a clinically non-relevant part of the inter-patient variability 
[180,211]. 
Dose individualization 
There are no studies that investigated sorafenib dose individuali- 
zation strategies. 
Conclusion 
It can be concluded that the inter-patient variability of sorafenib is  
relatively large compared with the intra-patient variability. The dose- 
limited absorption of this drug might be challenging for dose individuali-
zation [212]. Further research to determine the exact correlation between 
sorafenib exposure and treatment benefit is required. Similar to imatinib, 
it seems that sorafenib exposure decreases after 3-4 months of treatment 
[177-179,213]. This might have relevant clinical implications in patients 
with initial clinical benefit who develop subsequent progression. Dose  
escalation in these patients could be supported by measuring plasma  
concentration levels, although routine application of tdm for sorafenib  
is currently not justified.
Sunitinib 
Correlation between exposure and efficacy 
The most convincing evidence for a correlation between exposure  
and treatment response in humans comes from a pk-pd analysis by  
Houk et al. This analysis showed that patients with mRCC (n = 169), gist  
(n = 401), or solid tumors (n = 69) and a sunitinib AUCss ≥ 800, 600, and 
700 ng·hr/mL, respectively, had longer ttp and better os [5]. Extrapolation 
of these sunitinib AUCs would correspond with sunitinib + su12661 Ctrough 
levels of 36.4, 24.6, and 30.5 ng/mL respectively, which are close to the con-
centrations (50-100 ng/mL) found in preclinical in vivo research [214,215]. 
Additionally, there was a significant relation (P < 0.001) between exposure 
and the probability of a pr or cr in patients with mRCC. Finally, a relation 
between the probability of sd and sunitinib exposure was demonstrated 
for patients with mRCC (P = 0.002) and gist (P < 0.001) [5]. Sunitinib is 
also continuously dosed as 37.5 mg qd in patients with pancreatic neuro- 
endocrine tumors (pNET) and sometimes those with gist. For this indica-
tion, it is reasonable to use a lower target for Ctrough that corresponds with 
this lower dose. Given that sunitinib shows dose proportional pk, a realis-
tic recommendation is a target sunitinib + su12661 Ctrough of > 37.5 ng/mL.
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Correlation between exposure and toxicity
The first phase i trial in 28 patients treated with sunitinib showed that  
the occurrence of DLTs was associated with total sunitinib trough levels  
> 100 ng/mL [216]. In an explorative study in 19 patients with mRCC,  
those with high sunitinib exposure (AUC0-24 > 2600 ng·hr/mL and  
Ctrough > 90 ng/mL) experienced more grade ≥ 2 thrombocytopenia 
(P = 0.033) and hypertension (P = 0.0055) compared with patients with 
low sunitinib exposure [217]. The meta analysis by Houk et al. showed  
a positive relation between total auc and the incidence of fatigue; a nega-
tive relation between absolute neutrophil count (anc) and AUCcum after 
28 days; and a positive relation between total Ctrough level and dBP chang-
es [5]. A pk-pd analysis in 24 patients showed that changes in QTc interval 
correlated with sunitinib exposure auc, and Ctrough [218]. In a recently 
published phenotyping study, patients with any type of grade 3 toxicity 
had a significantly lower clearance of sunitinib than patients without 
grade 3 toxicities (34.4 versus 41.4 L/hr, P = 0.025) [219]. Additionally,  
total Ctrough levels were positively correlated with the occurrence of  
fatigue (P = 0.007) [219].
Inter- and intra-patient variability in exposure 
The reported inter-patient variability is large for Ctrough (34-59%), auc  
(13-49%) and CI/F (26-46%) [209,216,220-236]. Data on intra-patient varia-
bility are lacking. A population pk analysis showed that tumor type, race, 
gender, body weight, and Eastern Cooperative Oncology Group (ecog) 
score could explain some of the inter-patient pk variability, although  
dose adjustment based on these covariates is not advised [237].
Dose individualization 
Two phenotyping studies with midazolam have been conducted [214, 
219]. The first study showed that midazolam exposure was highly cor- 
related with both sunitinib and total sunitinib AUC0-24, as well as with 
Ctrough levels and that cyp3a4-activity explained a large proportion of  
the inter-patient variability in sunitinib pk [214]. The second pheno- 
typing study found a significant, although weak correlation between  
the 1’OH-midazolam:midazolam ratio and sunitinib clearance [219].
Data considering tdm as an approach to individualize sunitinib  
therapy are limited to case reports and conference abstracts [238-242]. 
However, all reports show the feasibility of tdm as an approach to  
achieve optimal Ctrough plasma concentrations.
Conclusion 
In our opinion, sunitinib is, after imatinib, the tki with the most evidence 
available to support dose individualization. There is an evident correlation 
between sunitinib exposure and efficacy as well as toxicity and the report-
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ed inter-patient variability is large. In addition, different reports have 
shown the feasibility of tdm to achieve an optimal target sunitinib expo-
sure. However, prospective trials assessing treatment outcome with dose 
individualization are warranted. Alternative biomarkers for dose individ-
ualization could be phenotyping cyp3a(4) activity, although this also 
needs prospective validation. Although it is not yet part of routine clinical 
practice, we believe that a drug level-based dose adjustment with a target 
Ctrough level of > 50 ng/mL for intermittent dosing and > 37.5 ng/mL for 
continuous dosing is justified.
Vandetanib
Correlation between exposure and efficacy
In the phase iii study in 226 patients with medullary thyroid cancer (mtc) 
treated with 300 mg vandetanib qd, no evidence was found for a correla-
tion between Ctrough levels at day 56 and pfs [243,244]. 
Correlation between exposure and toxicity
Significant relations were identified between exposure and diarrhea  
and fatigue, but not for hypertension and rash [274]. In addition,  
the QTc-interval prolongation was concentration dependent [244]. 
Inter- and intra-patient variability in exposure
The first phase i trial with vandetanib in solid tumors showed inter- 
patient variability in exposure of 44-99% [245]. Inter-patient variability  
in auc has also been reported by other studies in both healthy subjects  
as well as in patients with different types of cancer, ranging from 8% to 
59% [245-253]. Intra-subject variability in vandetanib exposure was found 
to be small; auc of 8-10% and Cmax of 11% [253]. The epar describes weight 
as a clinically non-relevant covariate. Race, gender, and age showed no  
effect on vandetanib pk [254]. 
Dose individualization
There are no studies investigating dose individualization strategies. 
Conclusion
The intra-patient variability in vandetanib pk is small compared with  
the described inter-patient variability, although some reported inter- 
patient variability is also not large. Most importantly, evidence for an  
exposure-response relation is lacking and the evidence for a correlation 
with toxicity is marginal. Given that vandetanib is an egfr inhibitor, rash 
might be a relevant early biomarker, although no correlations have yet 
been observed. There is currently insufficient evidence to support dose  
individualization of vandetanib therapy.
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Vemurafenib
Correlation between exposure and efficacy
In a phase iii study in patients with B-rapidly accelerated fibrosar- 
coma oncoprotein (braf) mutant melanoma, a statistically significant 
(P = 0.0014) relation between Ctrough and pfs was shown [255]. The popu- 
lation pk-pd analysis reported in the epar showed that patients with low 
exposure had more increase in tumor size compared with the medium 
and high exposure group, suggestive of a correlation [256]. 
Correlation between exposure and toxicity
Analysis of the pivotal phase iii trial also showed a relation between 
Ctrough and the risk of developing squamous cell carcinomas (P < 0.0001) 
[255]. Exposure-QTc response analysis showed that vemurafenib prolonged 
the QTc interval in a concentration dependent manner (P < 0.0001). 
However, no major changes (i.e., >20 ms) in the mean QTc interval were 
detected and, therefore, the clinical relevance of this observation should 
be considered [256]. 
Inter- and intra-patient variability in exposure
The reported inter-patient variability in vemurafenib auc ranged from 
28% to 52% [255-258]. There are no data available considering the intra- 
patient variability. Covariates including baseline total bilirubin, ast and 
alt, baseline creatinine clearance, age, gender, race, bodyweight, height, 
or body mass index had no influence on vemurafenib pk. 
Dose individualization
There are no studies investigating dose individualization of vemurafenib. 
Conclusion
In theory, vemurafenib meets many of the criteria for dose individualiza-
tion. However, although the inter-patient variability is large, data consid-
ering the intra-patient variability are unreported. Moreover, there is only 
marginal evidence for a correlation between vemurafenib exposure and 
treatment benefit or toxicity. Therefore, there is currently insufficient  
evidence to support dose individualization of vemurafenib therapy.
Concluding remarks
Compared with conventional chemotherapy, TKIs are generally less toxic 
and have the advantage of oral administration. Although convenient  
to patients, oral administration might have the potential disadvantage  
of introducing variability in drug exposure between and within patients. 
Review of the literature shows that there is increasing evidence that treat-
ment outcome of TKIs is related to their exposure. The current available 
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data suggest that a target Ctrough level of > 1100 ng/mL, > 50 ng/mL,  
> 37.5 ng/mL, and > 20 µg/mL could be used for imatinib, sunitinib  
50 mg 4/2, sunitinib 37.5 mg continuously, and pazopanib, respectively. 
For axitinib, dose adjustment should be toxicity driven. 
An important limitation is that most exposure-response correlations 
are defined by retrospective analysis. Therefore, the effect of drug levels  
on treatment outcome is still lacking for most TKIs. In addition, studies 
are generally small, except those with axitinib, imatinib, pazopanib, and 
sunitinib. More attention should be paid to exposure-response relations 
during drug development, which would facilitate dose individualization 
and treatment optimization right after registration of a drug. Surprisingly, 
neither the time a drug is used nor the potential for dose individualiza-
tion seems to be a predictor for the amount of data available on exposure- 
response relations. Most importantly, prospective studies investigating 
the clinical feasibility of dose individualization with treatment benefit  
as the primary outcome are awaited.
Nevertheless, monitoring Ctrough levels of at least imatinib, sunitinib, 
and pazopanib might be indicated in clinical practice, for example in  
cases of extreme or unexpected toxicity, a lack of clinical benefit, sus- 
pected pk drug-drug interactions, in patients with a major gastrectomy  
or in suspected therapy nonadherence, to support clinical decision mak-
ing. A difficulty for drug-level monitoring is the reported high, or some-
times unknown, intra-patient variability of some TKIs, which can depend 
on the individual physicochemical properties of the tki (e.g. low oral 
bioavailability).
Challenges for dose individualization are the facilities required  
(e.g. equipment and trained personnel for the determination of tki  
plasma concentrations). However, pk samples are readily transferable  
and there are multiple laboratories available that can measure the  
drug concentrations of TKIs. Another challenge encountered is that some 
exposure-efficacy/toxicity relations are based on AUCs, which are patient 
unfriendly and time consuming to measure. Effort should be made to  
determine surrogate pk markers (Ctrough or limited sampling) that show  
a good correlation with the auc to make tdm feasible for the clinical 
practice.
Obviously, drug exposure is not the sole determinant of clinical out-
come in patients with cancer. PD factors and patient- or tumor-specific 
characteristics also contribute to the efficacy of TKIs [20]. For different rea-
sons, such as unnecessary toxicity, treatment delay, de novo inefficacy but 
also costs, it is crucial to identify those patients who are most likely to re-
spond to tki therapy. After selecting the most effective drug for a specific 
tumor type, dose individualization could further help to optimize the  
individual treatment benefit-risk ratio, with the highest possible efficacy 
and the lowest possible toxicity of therapy.
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abstr act A sensitive, sophisticated and practical bioanalytical assay  
for the simultaneous determination of six tyrosine kinase inhibitors 
(imatinib, sunitinib, nilotinib, dasatinib, pazopanib, regorafenib)  
and two active metabolites (N-desmethyl imatinib and N-desethyl 
sunitinib) was developed and validated. For the quantitative assay,  
a mixture of three stable isotopes as internal standards was added  
to human serum, standards and controls. Thereafter, samples were  
pre-treated using protein precipitation with methanol. The supernatant 
was diluted with water and injected into an ultra pressure liquid 
chromatographic system with an Acquity TQ tandem mass spectrometry 
detector. The compounds were separated on an Acquity BEH C18 
analytical column (100 mm × 2.1 mm id, 1.7 µm particle size) and eluted 
with a linear gradient system. The ions were detected in the multiple 
reaction monitoring mode. The lower limit of quantification and the 
linearity of all compounds generously met with the concentrations that 
are to be expected in clinical practice. The developed bioanalytical assay 
can be used for guiding tki therapy in daily clinical practice as well as  
for investigator-initiated research.
3
A validated assay for the simultaneous 
quantification of six tyrosine kinase 
inhibitors and two active metabolites  
in human serum using liquid 
chromatography coupled with  
tandem mass spectrometry
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(Groton, USA). Regorafenib and pazopanib hydrochloride were obtained 
from Axon Medchem (Groningen, The Netherlands). Dasatinib base  
was obtained from LC laboratories (Woburn, MA, USA). The isotopes  
2H8 dasatinib base and 13C2H3 pazopanib hydrochloride were obtained 
from Alsachim (Strasbourg, France). DMSO (Uvasol), methanol (Lichrosolv), 
formic acid (Emsure) and ammonium acetate were obtained from Merck 
(Darmstadt, Germany). Methanol absolute (hplc supra-gradient) was  
purchased from Biosolve (Valkenswaard, the Netherlands). Millipore  
quality water was used.
Preparation of stock solutions, calibration standards  
and quality controls samples
Two independent stock solutions were made for each analyte: imatinib, 
N-desmethyl imatinib, nilotinib, sunitinib, N-desethyl sunitinib, dasatin-
ib, pazopanib and regorafenib. One stock solution was used for the prepa-
ration of calibration standards (cs) and the other for the quality control 
(qc) samples. All stock solutions were prepared in dmso and contained  
1 mg/mL free base except for pazopanib solution, which contained  
2 mg/mL free base. 
Stock solutions of different analytes were mixed and diluted with 
methanol to obtain four qc and cs substock solutions. Subsequently, the 
substock solutions were combined and further diluted with methanol to 
prepare the working solution for the cs. The qc samples were prepared by 
adding combinations of the (sub)stock solutions to blank human serum. 
Introduction
In recent years, multiple tyrosine kinase inhibitors (TKIs) have been  
approved as monotherapy for cancer treatment such as in renal cell  
cancer, gastro intestinal stromal tumors and leukemia, and numerous 
others are under investigation. Since these targeted anticancer com-
pounds specifically inhibit cellular processes that are deregulated in vari-
ous types of tumor cells, they were initially considered to be less toxic than 
conventional chemotherapy. However, it appears that similar to conven-
tional chemotherapy, dose interruptions or reductions due to adverse  
effects are necessary in a large number of patients which indicates that 
TKIs have a narrow therapeutic window [1-4]. TKIs show large inter-patient 
variability in pharmacokinetics, which results in highly variable plasma 
concentrations and consequently drug exposure [5-9]. 
For several TKIs an indication for the optimal drug exposure  
(therapeutic window) has been derived from retrospective data-analysis 
[10-16]. The highly variable drug exposure will result in exposure levels 
outside the therapeutic window in a considerable number of patients. 
This might explain, at least in part, the toxicity and suboptimal response 
seen in some individuals. 
Therapeutic drug monitoring (tdm) comprises the measurements,  
interpretation and adjustment of therapy in order to reach exposure  
levels within the target range. TKIs have most of the characteristics that 
are required for tdm, such as a narrow therapeutic window, large inter- 
patient variability compared to intra-patient variability and the chronic 
use until disease progression [17]. Therefore, tdm might be a very promis-
ing tool for this new class of drugs in order to improve treatment benefit 
by reducing toxicity and increasing efficacy. 
To support clinical pharmacological studies and to address observa-
tions (toxicities and inefficacies) in daily clinical practice, it was essential 
to develop and validate a quantitative bioanalytical assay in which the 
mostly used TKIs can be quantified. We hereby present an assay in which 
imatinib, N-desmethyl imatinib, sunitinib, N-desethyl sunitinib, nilotinib, 
dasatinib, pazopanib and regorafenib can be determined simultaneously. 
The described validations were performed according to the fda guidelines 
for bioanalytical method validation [18].
Material and methods
Chemicals and reagents
Imatinib mesylate and N-desmethyl imatinib mesylate were kindly  
provided by Novartis International Pharmaceuticals (Cork, Ireland). 
Nilotinib base and the isotope 13C315N nilotinib hydrochloride were  
kindly provided by Novartis Pharma A.G. (Basel, Switzerland). Sunitinib 















imatinib Nilotinib Sunitinib Dasatinib Pazopanib Regorafenib
Desethyl 
sunitinib 

































































































Abbreviations: LLOQ, lower limit of quantification
Table 1 Target concentrations of the six TKIs and two metabolites in the calibration standards (CS)  
and quality control (QC) samples
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USA). Chromatographic separation of the eight compounds and three  
internal standards in this assay was carried out using an Acquity UPLC 
BEH C18 chromatographic column (100 × 2.1 mm id, particle size 1.7 µm, 
Waters) protected with an Acquity UPLC BEH C18 pre-column (5 × 2.1 mm 
id, particle size 1.7 µm, Waters). 
For the analysis of pazopanib 1 µL and for the other compounds  
10 µL was injected onto the column. The compounds were eluted with  
a linear gradient system at a flow rate of 0.4 mL/min. Mobile phase A con-
sisted of 0.1% (v/v) formic acid and 2 mM ammonium acetate in water and 
mobile phase B consisted of 0.1% (v/v) formic acid and 2 mM ammonium 
acetate in methanol. The following linear gradient was used in this assay 
[time scale (min-min) mobile phase A (%)/mobile phase B (%)]: 0-1 75/25; 
1-3 75/25 → 50/50; 3-5 50/50 → 10/90; 5-6 10/90; 6-6.5 10/90 → 75/25; 6.5-7 
75/25. The column temperature was maintained at 50 °C and the auto- 
sampler temperature at 15 °C. The total run time was 7.0 min.
Mass spectrometry
The lc eluate was directed into a tandem quadruple, atmospheric pressure 
ionization (api) mass spectrometer (TQ detector, Acquity, Waters, Wilford, 
MA, USA). The detector was equipped with an electrospray ionization (esi) 
source operating in the positive ion mode and configured in multiple re-
action monitoring (mrm) mode. The data were acquired and processed  
using Masslynxtm Sofware (version 4.1, Waters). The general ms settings 
and analyte specific parameters for the assay are summarized in Table 2.
The (sub)stock solutions were diluted at least 15-fold. CS were prepared  
by adding 5 µL of the working solution to 50 µL blank human serum.  
The target concentrations of the cs and qc samples are listed in Table 1. 
Stock solutions of the internal standards were also prepared in dmso at  
a concentration of approximately 1 mg/mL. The internal standard working 
solution contained a mixture of the three internal standards in methanol: 
1 mg/L 2H8 dasatinib, 5 mg/L 13C2H3 pazopanib and 5 mg/L 13C315N 
nilotinib.
All stock, substock and working solutions were stored at -20 °C.  
The qc samples were prepared in bulk and divided into aliquots of  
75 µL in polypropylene vials which were stored at -20 °C. The cs were 
freshly prepared before each validation run. 
Sample pre-treatment
Protein precipitation was used as sample pre-treatment for serum sam-
ples. To 50 µL of serum sample, 10 µL internal standard substock and 500 
µL methanol were added. After vortex mixing for 3 min, samples were cen-
trifuged at 13,000 × g for 5 min. To 200 µL supernatant, 200 µL water was 
added and mixed.
Liquid chromatography
The ultra pressure liquid chromatographic (uplc) system used consisted 
of a coupled binary solvent manager, sample manager, column heater  
and mass spectrometry detector (Acquity, UPLC, Waters, Wilford, MA, 
Desethyl 















































Cone gas flow (L/hr)
Desolvation gas flow (L/hr)
Collision gas flow (mL/min)
Parent mass (m/z) 




Typical retention time (min)
General Settings


































Abbreviations: IS-1, 2H8 dasatinib; IS-2,13C2H3 pazopanib; IS-3, 13C315N nilotinib. aDiastereomeric cis/trans isomers: sunitinib → RT 3.2 and 4.3 and 
desethyl sunitinib → RT 2.9 and 4.1 are the trans- and cis-isomers, respectively. 
Table 2 General settings and analyte specific parameters for the analysis of all analytes
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tested at 9 months. Deviations were calculated against the initial concen-
trations. Analytes are considered stable in the matrix if the deviation is 
within ±15%. The stability of the individual stock solutions at -20 °C was 
determined with n = 6. Analytes were considered to be stable in stock  
solution if 90-110% of the initial concentration was found. The stability  




The most simple form of sample pre-treatment was initially tested;  
protein precipitation. Acetonitrile (acn) and methanol were tested for 
protein precipitation. The in vial stability appeared to be less favorable  
for acn sample pre-treatment. Additionally, peak symmetry appeared to 
be less favorably after acn precipitation. Methanol was therefore selected 
as the solvent to precipitate proteins and showed high extraction recover-
ies for all analytes. To improve chromatographic separation water was 
added to the extract.
Chromatography
Two different combinations of mobile phases were tested; mobile phase  
1. A: 0.05% formic acid + 5 mM ammonium acetate in water and B: 100% 
acetonitrile and mobile phase 2. A: 0.1% formic acid + 2 mM ammonium 
acetate in water and B: 0.1% formic acid + 2 mM ammonium acetate in 
methanol. The gradient applied was the same for both combinations.  
Peak separation, shape and sensitivity of the assay was poorer for the  
mobile phase composed of acn (mobile phase 1) than for the mobile phase 
containing methanol. After selection of the mobile phase the gradient was 
further optimized to reduce the run time from 10 to 7 min (Figure 1).
Linearity
The concentration range that needs to be covered for pazopanib is much 
higher than for the other TKIs. Initially 10 µL was injected onto the chro-
matographic column for all the analytes. However, for pazopanib non- 
linearity of the calibration line was seen during method development. 
This nonlinearity problem was solved by reducing the injection volume  
to 1 µL for pazopanib quantification, while keeping the injection volume 
for the other TKIs at 10 µL. In each analytical run the cs, qc and patient 
samples are injected two times. The first injection of 10 µL onto the system 
is for quantification all TKIs except for pazopanib. The second injection of 
1 µL is for quantification of pazopanib. 
Quantification
The six TKIs and two metabolites were quantified in serum by describing 
the relationship between the peak area ratio with the internal standard 
versus the nominal concentration. 2H8 dasatinib,13C2H3 pazopanib and 
13C315N nilotinib were used as internal standards for their target analytes. 
2H8 dasatinib was also found to be a suitable internal standard for the 
quantification of sunitinib and N-desethyl sunitinib. 13C315N nilotinib  
was used as the internal standard for imatinib, N-desmethyl imatinib  
and regorafenib. The calibration lines were chosen to cover the clinically 
relevant range of concentrations that are expected in patients treated  
with the registered dose. 
Validation procedures
The validation of the assay was performed according to the fda  
guidelines for validation of bioanalytical assays including linearity,  
accuracy, precision, selectivity, recovery and stability [18].
The linearity of the assay was assessed by preparing and analyzing  
6 non-zero calibration standards in six independent analytical runs. Least 
squares linear regression analysis was applied to describe the relationship 
between the peak area ratio with the internal standard versus the nominal 
concentration. The lowest total bias and the most constant bias across  
the range were obtained using a weighting factor of 1/χ. 
The within-run and between-run precision and accuracy were deter-
mined. To test the within-run precision, 6 replicates of the qc samples;  
qc low, qc medium and qc high were analyzed in one analytical run.  
To test the between-run precision, the qc samples qc lloq, qc low, qc  
medium and qc high were analyzed in six analytical runs on six different 
days. Precision was expressed as cv values and accuracy as deviations from 
the nominal concentrations.
Initially the cross-analyte interference was investigated by injecting 
dilutions of each analyte (TKIs, metabolites and is) separately. 
The selectivity of the assay was tested in six different batches of blank 
control serum and plasma. The selectivity was analyzed for blank serum, 
blank plasma, low (~ the lloq concentration) and high (~ highest stand-
ard) controls of each analyte prepared in duplo in 6 individual batches  
of blank control serum and plasma. The total recovery, covering sample 
preparation and matrix effect, was determined six times at two concentra-
tion levels for each analyte (~ lloq and highest standard) and the internal 
standards. Carry-over was tested by injecting a blank sample after the 
highest calibration standard.
The stability of imatinib, desmethyl imatinib, nilotinib, sunitinib,  
desethyl sunitinib, dasatinib, pazopanib, and regorafenib in serum was 
tested at ambient temperature and at 2-8 °C after 0, 2, 3 days; 1, 2 weeks; 




Mass spectrometric parameters were optimized by performing direct  
infusion and flow injection analysis of each analyte. In order to achieve 
high specificity and sensitivity, the multiple reaction monitoring scan 
mode was applied to monitor the mass transition to the product ion  
with the highest abundance in the product ion scan for each analyte.  
Table 3 shows the selected transitions and the proposed corresponding 
fragmentation pathways.
Isomerization
As described in the literature, sunitinib and N-desethyl sunitinib showed 
light induced trans to cis transformation with an equal ms response [19]. 
Therefore the sum areas of both isomers of sunitinib and desethyl sunitin-
ib were used for quantification.
Validation
Calibration
The linearity of the assay for all analytes expressed as correlation coeffi-
cients (r2) were at least 0.995. The linear range varied per analyte but was 
in all cases between the corresponding concentration of the lloq and the 
highest cs as listed in Table 1. At all concentration levels the deviations  
of the back-calculated concentrations were within ±15% of the nominal 
concentrations and this is in accordance to fda guidelines.
Precision and accuracy
Precision, expressed as cv values and accuracy, expressed as deviations 
from the nominal concentrations were below 7% and within ±11%, respec-
tively. Therefore, the precision and accuracy were within the acceptance 
criteria of the fda guidelines. 
Additionally, the signal to noise ratio of the six TKIs and two meta- 
bolites at the lloq level was > 5. In conclusion, the acceptance criteria  
for accuracy and precision were met. The assay performance data are  
summarized in Table 4.
Selectivity
No interference of the different compounds was observed in the test 
where dilutions of each analyte were injected separately. Only for the  
Figure 1 Typical MRM chromatograms of calibration standard 6 (CS 6) of dasatinib, nilotinib, imatinib, desmethyl 
imatinib, pazopanib, regorafenib, sunitinib isomers (trans-isomer = snn1 and cis-isomer = snn2), desethyl sunitinib 
isomers (trans-isomer = desnn1 and cis-isomer = desnn2), internal standards (IS) 2H8 dasatinib, 13C315N nilotinib 
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dasatanib 4.37
desmethyl imatinib 4.10
snn 2 / 4.57
snn 1 / 3.43
desnn 1 / 3.18
snn 1 / 3.14


































MRM of 12 channels, ES+
488.1>400.9
9.962e+005
MRM of 12 channels, ES+
480.1>393.9
7.839e+006
MRM of 12 channels, ES+
399.2>282.9
1.024e+006
MRM of 12 channels, ES+
534.1>292.9
9.991e+006
MRM of 12 channels, ES+
488.1>400.9
8.718e+003
MRM of 12 channels, ES+
480.1>393.9
3.196e+005
MRM of 12 channels, ES+
503.1>288.9
5.408e+007
MRM of 12 channels, ES+
438.1>357.0
2.845e+007
MRM of 12 channels, ES+
371.1>282.9
8.518e+005
MRM of 12 channels, ES+
442.1>361.0
5.274e+005
MRM of 12 channels, ES+
530.1>288.9
1.239e+007
MRM of 12 channels, ES+
399.2>282.9
3.261e+005
MRM of 12 channels, ES+
494.1>393.9
1.747e+007
MRM of 12 channels, ES+
483.0>269.9
8.183e+006
MRM of 12 channels, ES+
496.1>405.5
2.169e+005
MRM of 12 channels, ES+
438.1>357.0
1.878e+007
MRM of 12 channels, ES+
494.1>393.9
1.950e+006

































































  2.00  4.00  6.00
  2.00  4.00  6.00
  2.00  4.00  6.00
snn 2 / 4.27 / 1.55e3
snn 1 / 3.15 / 1.01e2
desnn 2 / 4.14 / 1.21e3
desnn 1 / 2.88 / 1.13e2 5.04 / 6.20 / 6.62
dasatanib 4.07 / 8.67e2
MRM of 12 channels, ES+
399.2>282.9
2.260e+004
MRM of 12 channels, ES+
371.1>282.9
1.863e+004
MRM of 12 channels, ES+
488.1 > 400.9
1.168e+004
Table 3 Analytes with their selected mass transitions and proposed fragmentation pathways




































  2.00  4.00  6.00
  2.00  4.00  6.00
imatinib 3.84 / 3.00e4
Desmethyl imatinib 3.83 / 1.42e4
Nilotinib 5.04 / 7.27e4
MRM of 12 channels, ES+
494.1>393.9
4.262e+005
MRM of 12 channels, ES+
480.1>393.9
2.013e+005








































































































































































































































































Abbreviations: conc., concentration; dev., deviation; CV, coefficient of variation. 
















  2.00  4.00  6.00
  2.00  4.00  6.00
  2.00  4.00  6.00  2.00  4.00  6.00   2.00  4.00  6.00
Pazopanib 3.63 / 4.12e4
Regorafenib 5.73 / 1.18e4
IS pazopanib 3.62 / 4.20e4IS dasatinib 4.06 / 1.73e4 IS nilotinib 5.04 / 6.59e5
MRM of 12 channels, ES+
438.1>357.0
6.202e+005
MRM of 12 channels, ES+
483.0>269.9
1.894e+005
MRM of 12 channels, ES+
442.1>361.0
6.260e+005
MRM of 12 channels, ES+
496.1>405.5
2.510e+005
MRM of 12 channels, ES+
534.1>292.9
9.753e+006



























stability of the individual stock solutions was tested at 12 months and  
met the criteria. So, stock solutions of all analytes were at least stable for  
12 months at -20 °C. The data on the stability of the analytes under  
different conditions are summarized in Table 5.
stable isotopes a small amount of the corresponding tki was measured, 
the measured signal was < 5% of the lloq and therefore considered accept-
able. The blank controls (plasma and serum) showed no peaks co-eluting 
with one of the compounds. The variation (cv%) in the relative area of  
the low and high controls prepared in the 6 different batches of blank  
serum were < 10% for all compounds tested. Only the variation of the  
low control of regorafenib was 15.8% which still meets the < 20% variability 
allowed for the lloq. The low and high controls prepared in six different 
batches of blank plasma were all within 10% variation except for imatinib 
with 11.2% and 10.8% variation for the low and high concentration, respec-
tively. The deviation of plasma measurements from serum measurements 
for all analytes ranged from -15.8% to 4.9%. Based on these results we con-
cluded that the selectivity was sufficient and that the assay was suitable  
for the detection of the analytes in both serum and plasma.
Recovery
In serum the mean total recovery of imatinib, N-desmethyl imatinib,  
nilotinib, sunitinib, N-desethyl sunitinib, dasatinib, pazopanib,  
regorafenib, 2H8 dasatinib,13C2H3 pazopanib and 13C315N nilotinib ranged 
from 78% to 93% with cv% of 3.4-11.9% (except for regorafenib, lloq 23.5%). 
The variability of the detected regorafenib concentrations might be im-
proved by introducing a structure analog as internal standard. At this 
point in the method validation we accepted the relative high variability  
in the recovery of regorafenib.
Carry-over
The response of the blank sample at the retention time of the analytes was 
< 10% of the corresponding peak area of the lloq sample and the response 
of the internal standard was < 1% of the normal response. Carry-over was 
therefore considered acceptable.
Stability
Except for regorafenib, all analytes were stable for at least 9 months at  
-20 °C. Regorafenib was stable for 3 months at -20 °C. At ambient temper- 
ature and at 2-8 °C all analytes were stable for 3 months, with the excep-
tion of imatinib qc low which was just outside the range of ±15% (18.1%). 
The effect of six freeze/thaw cycles was tested for the lloq of all analytes  
in serum. The CV’s were < 17.7% and the observed concentrations were 
within 13% of the nominal concentrations. All analytes met the criteria 
that apply for lloq samples and were considered stable during six freeze/
thaw cycles. In-(autosampler)vial stability was tested by reinjecting the  
cs of the calibration line, and the qc low, medium and high samples 24,  
48 and 168 hr after the original analysis. The in-vial stability at ambient 

































































































































Nominal conc. Ambient 3 months 2-8 ºC 3 months -20 ºC 9 months Ambient in vial 168 hr
aRegorafenib is stable for 3 months in the freezer.




multiple TKIs. Six assays that are developed can simultaneously measure 
at most six TKIs [23-27], two methods can simultaneously determine eight 
TKIs [28,29] and one method can simultaneously determine nine TKIs [30].
This present method deviates from previously published assays with 
regard to the TKIs that are simultaneously measured. Thus far, no multi 
tki bioanalytical method has been published that incorporates  
pazopanib and regorafenib. Pazopanib is possibly not incorporated in 
other published methods due to the relatively high concentrations that 
need to be quantified. For pazopanib the serum concentrations are much 
higher than for the other TKIs. We have overcome the problem of nonline-
arity at the highest concentrations by injecting less volume for pazopanib 
quantification on the analytical column. Regorafenib is potentially not  
incorporated yet since it was only very recently registered by the fda for 
the treatment of metastatic colorectal cancer and is pending registration 
as third line treatment for gist. In line with the method of Lankheet et al. 
[28] we have used protein precipitation, which is for routine measure-
ments in the clinical setting a fast and simple sample pretreatment  
procedure manageable for any laboratory. 
The presented method is robust, easy to perform and currently used 
for routine patient care in cases where unexpected toxicity, inefficacy and 
drug interactions are suspected. Additionally, the assay is used to explore 
the benefit of routine therapeutic drug monitoring for TKIs as well as for 
investigator initiated studies.
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Matrix effect
In this study, the potential matrix effect was evaluated by spiking 6 lots  
of heparin plasma, edta plasma and serum at a low (~ the lloq concen- 
tration) and a high level (~ the highest standard) concentration of each 
analyte. The variability of the responses were < 15%. Except for sunitinib, 
su12662 low level in serum which were slightly higher; 15.5% and 16.0%,  
respectively and desmethyl imatinib low level in edta plasma with  
a variability of 15.6%. We concluded based on these data that the  
matrix did not appear to interfere significantly with the integrity  
of our analytical method.
Clinical application
The described validated assay aimed to support investigator initiated 
pharmacokinetic studies with imatinib, nilotinib, sunitinib, dasatinib,  
pazopanib and regorafenib. Additionally, the assay was developed to  
address unexplained cases of inefficacy or toxicity of tki therapy in  
clinical practice. Moreover, the assay can be applied to explore the  
value of therapeutic drug monitoring for this class of drugs. 
To test the assay performance in patient material, we analyzed sam-
ples of patients that were treated with imatinib, pazopanib or sunitinib  
in study protocols and of patients treated with regorafenib in our clinic 
(Figure 1A-D). Additionally, external commercially controls from 
Chromsystems® to check the performance of the imatinib, N-desmethyl 
imatinib, nilotinib and dasatinib quantification were used. These QCs 
were all within 10% of the declared level (level 1-4).
Conclusion
A sensitive, sophisticated and practical bioanalytical assay for the simulta-
neous determination of six tyrosine kinase inhibitors (imatinib, sunitinib, 
nilotinib, dasatinib, regorafenib and pazopanib) and two active metabo-
lites (N-desmethyl imatinib and N-desethyl sunitinib) was developed  
and validated according to fda guidelines. 
This assay has been applied to support an investigator initiated phar-
macokinetic study with pazopanib and sunitinib. Moreover, the assay is 
being used to explore the possibilities of therapeutic drug monitoring 
and further understand the pharmacology of this class of drugs [20]. 
In the literature, multiple bioanalytical assays that quantify TKIs  
in human matrices have been described. Most of them are developed  
to quantify a single tki [19,21,22]. For the clinical practice, it is more  
efficient to have a bioanalytical method available that can simultaneously 
determine the most abundantly used TKIs in the clinic. Thus far, nine meth-
ods have been published that are developed to simultaneously measure 
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Background Dried blood spot (dbs) sampling is potentially a more 
patient-friendly and flexible alternative to venous sampling of pazopanib. 
This study determines the agreement between pazopanib dbs- and plasma 
concentrations to facilitate implementation of pazopanib dbs sampling 
into clinical practice.
Patients and Methods Paired dbs and plasma samples were collected  
in 12 patients. Pazopanib plasma concentrations were calculated from  
dbs concentrations using the formula: plasma concentration  
= DBSconcentration/(1-haematocrit). Passing-Bablok and Bland-Altman 
analyses were used to determine the agreement between calculated  
and measured plasma concentrations. We predefined a clinical  
acceptance limit of 25% for the Bland-Altman analysis.
Results Passing-Bablok analysis showed a small constant (intercept 
estimate -8.53(95%-ci; -12.22 to -4.41)) and slightly proportional (slope 
estimate 1.15 (95%-ci; 1.04-1.24)) bias between calculated and measured 
concentrations. This bias was clinically non-relevant as shown by Bland-
Altman analysis; the mean ratio of calculated to measured concentrations 
was 0.94 (95%-ci; 0.65-1.23). The clinical acceptance limits were well within 
these 95% limits of agreement. More specifically, 92.6% of the data points 
were within the predefined acceptance limits.
Conclusion Pazopanib plasma concentrations can be accurately 
calculated from dbs concentrations. Although validation of dbs cards 
prepared by patients themselves is required, these results show that dbs 
sampling can be used to monitor pazopanib therapy in clinical practice.
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The collection and analysis of dbs and plasma samples was part of a larger 
phase i study that investigated the feasibility of tdm for dose individuali-
zation of pazopanib [4]. Included patients were ≥ 18 years with progressive 
disease from an advanced solid tumor, a who performance status ≤ 2 that 
had no standard treatment options available. All patients had adequate 
haematologic, renal and liver function reserves. The study was approved 
by the institutional ethics committee (Leiden University Medical Center, 
The Netherlands) and all patients gave written informed consent before 
entering the study. Between July 2012 and June 2013, 13 patients were  
included of whom 12 also participated in the dbs part of the study
Sampling
At day 14 of standard 800 mg pazopanib therapy, patients were admitted 
to the hospital for pharmacokinetic sampling. EDTA-blood samples were 
collected by venepuncture pre-dose and 1, 2, 3, 4, 6, 8, 10 and 24 hours  
after pazopanib intake. From these edta blood samples, 15 µL blood was 
collected into an edta capillary tube and spotted onto a pre-marked circle 
on a Whatman FTA® dbs card. This procedure was repeated 2 times to fill 
the 3 pre-marked circles on the card. After spotting the dbs cards, venous 
blood samples were centrifuged at 3,000 rpm for 5 minutes; the superna-
tant plasma was stored at -20˚C until the day of analysis. 
In addition to the dbs sampling cards prepared with venous blood, 
dbs sampling cards prepared by finger prick were collected pre-dose,  
and 3 and 8 hours after pazopanib intake. After disinfection of the skin 
with alcohol 70%, a lancet puncture was performed. The first drop of 
blood was discarded, thereafter 15 µL blood from the finger was collected 
using the above described capillary tube and spotted onto the dbs card. 
This procedure was repeated 2 times to fill the 3 pre-marked circles on  
the card
After drying for at least 2 hours, dbs cards were stored at room  
temperature in a closed plastic bag containing 2 sachets of desiccant. 
Thereafter, finger prick dbs cards (n = 3), venous dbs cards (n = 9)  
and plasma samples (n = 9) were all sent to GlaxoSmithKline, USA  
for further bio-analytical analysis.
Analysis
For the analysis of dbs pazopanib concentrations, a 4 mm diameter disc 
was punched out from the 15 µL dried blood spot. Per subject only 1 blood 
spot out of 3 was analyzed. Pazopanib was extracted from this disc with 
the use of 50 µL formic acid and 400 µL methanol containing an isotopic 
labelled internal standard, [2H3 13C]-pazopanib. After through mixing  
and centrifugation, 200 µL of the extract was taken into an auto-sample 
Introduction
Pazopanib hydrochloride (Votrient®) is an oral multi-targeted tyrosine 
kinase inhibitor (tki) used for the treatment of metastatic renal cell carci-
noma (mRCC) and metastatic soft tissue sarcoma (sts) [1,2]. For patients 
with mRCC, a correlation between pazopanib exposure and treatment 
outcome has been demonstrated [3]. Suttle et al. showed that a higher 
treatment response was seen for patients with a Ctrough level > 20.5 mg/L 
and a higher incidence of toxicity was seen in patients with a Ctrough level 
> 36 mg/L. This implies that the optimal therapeutic window for pazopanib 
in patients with mRCC lies between a Ctrough level of 20.5 - 36 mg/L. There 
is a large variability in pazopanib exposure between patients (40-60 cv% 
in auc) leading to the risk of sub- or supra-therapeutic Ctrough levels  
and therefore to decreased therapeutic effects or more toxicity [3,4]. 
Therapeutic drug monitoring (tdm) can be useful to reach concen- 
trations within the therapeutic window in order to optimize the efficacy 
and minimize the toxicity of therapy. The evidence for usefulness of tdm 
of pazopanib is accumulating and monitoring of Ctrough levels is currently 
indicated in case of extreme or unexpected toxicity, a lack of clinical bene-
fit, suspected drug interactions or suspected non-adherence to therapy  
[4-6]. In the first phase i trial, pazopanib exposure increased as the dose 
increased, although a plateau at 800 mg once daily was seen [7]. 
Theoretically, this might introduce problems when a patient has an  
exposure below the threshold for efficacy and needs an increased dose. 
However, the finding of a plateau is based on a limited number of patients 
and therefore not conclusive yet. In addition, results from two pazopanib 
tdm study suggest that exposure does increase with doses above 800 mg 
[4,8]. 
At present, pazopanib concentrations are monitored in plasma  
collected by venous sampling [9]. However, sampling by venipuncture has 
several disadvantages including its invasive character, the requirement for 
patients to travel to the clinic and the need for trained personnel. 
Compared to venous sampling, dried blood spot (dbs) sampling is a con-
venient, simple, flexible and more patient friendly alternative to collect 
blood in an at home setting. With clear instructions and after adequate 
training, patients should be able to self-collect dbs samples. The added 
value and feasibility of dbs collection for tdm has been shown effective  
for several drugs including anti-epileptics, immunosuppressants and  
antiretroviral drugs [10-12]. 
Here, we describe the results of a study investigating the feasibility  
of dbs for tdm of pazopanib. The objective of this study is to determine 
the agreement between pazopanib dbs- and plasma concentrations in  




clinical relevance of any found bias. As suggested by Bland and Altman,  
a clinical and practical acceptance limit for the found ratio was deter-
mined [18]. A 25% range around the found ratio of the two methods was 
determined to be clinically and practically relevant since pazopanib can 
only be dose adjusted in steps of 25% of the total dose (200 mg tablets are 
the lowest dose available). Hence, the difference should be > 25% to result 
in a possibility to adjust the dose.
Analysis was performed with Microsoft office Excel (Microsoft Inc, 
Redmond, WA) and add-in Analyse-it statistics software (Analyse-it 
Software, Ltd, Leeds, UK). 
Results
Patients
Between July 2012 and June 2013, 12 patients were enrolled in this dbs 
study. Characteristics of the patients included are summarized in Table 1. 
Agreement between dbs concentrations prepared by finger prick  
and with venous blood
Concentrations measured at the same time points in dbs samples prepared 
by finger prick and prepared with venous blood were in good agreement 
with each other (Figure 1A). Passing-Bablok regression showed that that 
there was no constant (intercept estimate -0.71 (95%-ci; -3.41 to 2.23))  
or proportional bias (slope estimate 1.05 (95%-ci; 0.93 to 1.17)) between 
the two sampling methods for the preparation of dbs cards. In this study, 
we collected 3 dbs cards prepared by finger prick per patient compared  
to 9 dbs cards prepared with venous blood. Since both methods for dbs 
card preparation were in agreement with each other and values therefore 
interchangeable, we used the (more extensive) data from the venous dbs 
cards for all further described analysis. 
DBS vs. plasma concentrations
Pazopanib dbs concentrations (uncorrected concentrations in blood) 
were on average 48.0% (sd 8.5%) lower than measured plasma concen- 
trations (Figure 1B). Passing-Bablok regression analysis showed that  
there was a constant (intercept estimate -4.68 (95%-ci; -6.48 to -2.47))  
and proportional bias (slope estimate 0.63 (95%-ci; 0.57 to 0.68)).
Calculated vs. measured plasma concentrations –  
Passing-Bablok analysis
Calculated plasma concentrations using patient specific haematocrit  
values were on average 94.0% of measured plasma concentrations. 
Variability was relatively large (sd 14.7%, range 61.6% - 134.9%). Using  
a fixed haematocrit value, calculated plasma concentrations were on  
tube where it was diluted with 200 µL of water before injection onto a 
hplc-ms/ms system for analysis. This validated method was linear within 
the concentration range of 0.1-50 µg/mL pazopanib. The within- and  
between-run imprecisions were ≤ 11.4% and ≤ 6.2% respectively and the  
accuracy of this method was between -10.5% and 5.5%. Samples were stable 
on the dbs card for at least 75 days at ambient temperature. There was no 
influence of haematocrit levels (0.2 to 0.65) on the performance of  
this assay. 
For analysis of pazopanib concentrations in plasma, 20 µL of plasma 
was extracted by adding 500 µL of acetonitrile/10 mM ammonium acetate 
(80/20 v/v) containing 100 ng/mL of [2H3 13C]-pazopanib as the internal 
standard. This was followed by vortex mixing and centrifugation at  
approximately 6200 g for 20 minutes. The supernatant was transferred 
into clean tubes and injected onto a hplc-ms/ms system for analysis.  
This validated method was linear within the concentration range of  
0.1 - 50 µg/mL pazopanib. The within- and between-run imprecisions  
were ≤ 14.7% and ≤ 2.9% respectively and the accuracy of this method  
was between -4.3% and 5.5%. Samples were stable in plasma for at least  
530 days at -20 °C and 24 hours at ambient temperature.
Calculation of plasma concentration 
Pazopanib plasma concentrations were calculated from dbs concen- 
trations using the previously described formula: plasma concentration  
= DBSconcentration /(1-haematocrit) [13]. The blood:plasma ratio of pazo-
panib ranges from 0.59 to 0.93 which suggests only a minimal association 
of pazopanib with blood cells [14]. In addition, only the unbound fraction 
of a drug can partition into blood cells [15]. Since pazopanib has a high 
protein binding of > 99.9%, the unbound fraction will be negligible [16]. 
Therefore, the fraction of pazopanib bound to red blood cells (haemat-
ocrit) was ignored in the above described formula. Plasma concentrations 
were calculated using both patient specific measured haematocrit values 
and fixed haematocrit values of 0.40 and 0.45 for males and females,  
respectively. A paired Student’s t-test was used to test for a difference  
in calculated plasma concentrations using measured and fixed  
haematocrit values. 
Statistics
Passing-Bablok regression and Bland-Altman analysis were used to deter-
mine the agreement between the two sampling methods [17,18]. Passing-
Bablok regression analysis tests for a constant bias and proportional bias 
between two methods. If the 95%-ci for the intercept of the regression  
line includes 0, no constant bias is observed. If the 95%-ci for the slope  
of regression line includes 1, there is no proportional bias between the  
two tested methods. We used Bland-Altman analysis to define the  
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Figure 1 Agreement between A) DBS concentrations obtained by finger prick and DBS concentrations obtained 
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average 95.0% of measured concentrations with comparable variability 
(sd 15.5%, range 65.0 - 144.0%). No significant differences between both  
approaches (measured and fixed haematocrit values) was observed  
(95%-ci of difference in calculated plasma concentrations; -0.19 to 0.57, 
P = 0.315).
Passing-Bablok analysis showed a small constant bias (intercept  
estimate -8.53 (95%-ci; -12.22 to -4.41)) and slightly proportional bias 
(slope estimate 1.15 (95%-ci; 1.04 to 1.24)) between calculated and meas-
ured plasma concentration when patient specific haematocrit values were 
used (Figure 2). Similar results were found when a fixed haematocrit value 
was used; intercept estimate -9.67 (95%-ci; -13.28 to -5.51) and slope  













  ANC (× 109/L)
  Platelets (× 109/L)
  Hemoglobin (mmol/L)
Chemistry
  AST (U/L)
  ALT (U/L)
  Creatinine (mg/dL)
  Total bilirubin (mg/dL)
Blood pressure (mmHg)
  Systolic




  Pancreatic cancer
  Schwannoma
  Ganglioneuroma
  Granulair cell tumor
12
48 (23 - 68)
11 (92%)
1 (8%)
183 (168 - 186)
90 (71 - 101)
3 (25%)
9 (75%)
0.45 (0.40 - 0.49)
4.12 (2.49 - 6.42)
261 (150 - 394)
9.05 (6.9 - 9.9)
23 (17 - 33)
21 (12 - 33)
0.85 (0.71 - 0.97)
0.52 (0.35 - 0.70) 
129 (113 - 142)








Table 1 Patient baseline characteristics
Data are presented as median (range) unless stated otherwise. Abbreviations: ALT, alanine aminotransferase; ANC, absolute neutrophil count;  
AST, aspartate aminotransferase; ECOG PS, Eastern Cooperative Oncology Group performance score; WBC, white blood count.
 y = 1.05x -0.71
 Line of true identity
 y = 0.63x - 4.68
 Line of true identity
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Figure 3 Bland-Altman plot of A) difference between calculated and measured against mean plasma 
concentrations using patient specific haematocrit. B) ratio of calculated and measured against mean plasma 
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Calculated vs. measured plasma concentrations –  
Bland-Altman analysis
The difference in pazopanib concentrations between calculated and  
measured plasma concentrations using patient specific haematocrit  
values ranged from -19.2 to 13.2 µg/mL with a mean difference of -2.4 
µg/mL (sd 6.8 µg/mL, Figure 3A). The mean ratio of calculated to meas-
ured plasma concentrations was 0.94 with the 95% limits of agreement  
of this ratio being 0.65 to 1.23 (Figure 3B). The clinical acceptance limits 
which were set at 25% around the found mean ratio, fell well within the 
95% limits of agreement (0.71 to 1.18). More specifically, 92.6% (88 out  
of 95) of the data points were within the clinical acceptance limits. 
Similar results were found when fixed haematocrit values were used. 
The difference ranged from -18.7 to 16.7 with a mean difference of -2.0 
µg/mL (sd 7.1 µg/mL). The mean ratio of calculated to measured plasma 
concentrations was 0.95 with the 95% limits of agreement of this ratio  
being 0.65 to 1.25. The clinical acceptance limits (0.71 to 1.19) also fell  
well within the agreement limits. Using fixed haematocrit values, 12.6%  
































Measured plasma concentration (µg/mL)
 0  10 20 30 40 50 60 70  80 90 100
Figure 2 Agreement between measured and calculated plasma concentrations using patient  
specific haematocrit. 
 Mean ratio
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 Mean difference
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 y = 1.15x - 8.53





Previously, Kralj et al investigated dbs sampling and analysis for  
the TKIs imatinib, nilotinib and dasatinib [19]. They used the same for- 
mula and also found good agreement between calculated and measured 
plasma concentrations. In the current study, we used both patient specific 
as well as fixed haematocrit values for the estimation of pazopanib plasma 
concentrations. The percentage of data points within the clinical accept-
ance limits when fixed haematocrit values were used, was slightly lower  
in comparison to when patient specific haematocrit values were used. 
However, no significant difference between calculated plasma concen- 
trations using patient specific or fixed haematocrit levels could be shown. 
In addition, there was no difference in clinical decision making based on 
Ctrough levels when patient specific or fixed haematocrit values were used. 
This indicates that fixed haematocrit values can be interchangeably used 
instead of measured haematocrit values for the calculation of pazopanib 
plasma concentrations when patient haematocrit levels are within the 
normal range. 
The binding of pazopanib to red blood cells is thought to be limited 
and we did not take this into account for the calculation of pazopanib 
plasma concentrations. This may potentially cause bias in the calculation 
of plasma concentrations from dbs concentrations. However, calculated 
plasma concentrations from dbs were on average 6% lower than the meas-
ured concentrations. This demonstrates that the possibility of pazopanib 
partitioning into red blood cells is minimal since the calculated concen-
tration would then have been higher otherwise. In addition, plasma con-
centrations could be readily predicted from dbs concentrations which 
also indicates that the uptake of pazopanib into red blood cells is small. 
This is also in agreement with the fact that pazopanib has a high plasma 
protein binding (> 99.9%) and the assumption that only the free unbound 
amount of a drug can participate into red blood cells. 
In this study, dbs cards contained relatively high concentrations  
of pazopanib since samples were taken as part of rich pk-curves shortly  
after pazopanib intake to calculate pazopanib AUCs. As a consequence, 
there is only a limited number of dbs samples within the lower concen- 
tration range. Although splitting the Passing-Bablok regression into 
Ctrough dbs samples and all other samples or into different concentration 
ranges did not change the results, it can be doubted whether the small 
proportional bias is caused by the fact that there are not enough samples 
in the lower concentration range or whether there is truly a proportional 
bias. In addition, this limits the amount of data on which agreement is 
based within the lower concentration range. Both bio-analytical assays  
for the determination of pazopanib in dbs and plasma were validated  
according to international guidelines, excluding an analytical cause. 
DBS cards were prepared by the research nurse with the use of a  
15 µl capillary. It can be argued that sampling by the research nurse  
Clinical relevance
A pazopanib trough concentration of 20.5 µg/mL is suggested as the 
threshold for efficacy in mRCC patients [3]. In Table 2, decision making 
based on measured and calculated plasma concentrations are compared. 
In 1 case (9.1%), there would have been a difference in decision making 
Table 2 Clinical decision making based on calculated and measured Ctrough levels





≥ 20.5 µg/mL 
Calculated Ctrough level 
< 20.5 µg/mL 
2
1




based on exposure. The measured plasma Ctrough was 24.7 µg/mL  
compared to a calculated Ctrough of 19.5 µg/mL from dbs. In all other  
cases, clinical decision making would have been the same based on either 
the measured or calculated plasma concentration. The same results were 
found when a fixed haematocrit value was used. 
Discussion
The present study shows that pazopanib plasma concentrations calcu- 
lated with the use of dbs, are in good agreement with actually measured 
pazopanib plasma concentrations. This implicates that dbs sampling  
can be used as an alternative sampling strategy for the determination  
of plasma concentrations to monitor pazopanib therapy.
A small constant, and slightly proportional bias was shown between 
calculated and measured pazopanib plasma concentrations. However, 
these biases were clinically not relevant as the vast majority of data  
points were within the predefined clinical acceptance limits. In addition, 
the difference between calculated and measured plasma concentrations 
would have resulted in different clinical decision making in only one out 
of 11 cases. It should be noted that in this case the difference between cal-
culated and measured concentrations was small and concentrations were 
close the defined target of 20.5 µg/mL. Overall, these results show that dbs 
sampling can be used as an alternative – more patient friendly – sampling 
strategy to monitor pazopanib therapy in clinical practice.
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with a capillary does not truly reflect an at home sampling setting where 
patients spot themselves, which is a limitation of this study. On the other 
hand, previous studies with antiretroviral and immunosuppressive drugs 
have shown that 87.5 to 98% of the dbs samples obtained by patients were 
suitable for analysis [20,21]. Although these cards were prepared by blood 
drop and not capillary, it suggests that preparation of a dbs card by pa-
tients after a clear instruction is highly feasible. The perfect agreement  
between dbs cards prepared by finger prick and those prepared with 
whole blood shows that there is no engorgement of blood when a dbs  
is prepared by finger prick. 
Conclusion
This study shows a good agreement between pazopanib levels measured 
in plasma and concentrations calculated from the corresponding dbs card. 
Although validation of clinical utility with dbs cards prepared by patients 
themselves is necessary, the results from this study show the feasibility of 
the use of dbs cards. With the ease and convenience of sample collection, 
dbs could be very useful for tdm of patients treated with pazopanib and 
potentially other TKIs in the future. 
Chapter 4
8786
16  Hamberg, P. et al (2010) (Pre-)clinical pharmacology and 
activity of pazopanib, a novel multikinase angiogenesis 
inhibitor. Oncologist. 15, 539-547.
17  Bablok, W. and Passing, H. (1985) Application of statistical 
procedures in analytical instrument testing. J Automat 
Chem. 7, 74-79.
18  Bland, J.M. and Altman, D.G. (1986) Statistical methods for 
assessing agreement between two methods of clinical 
measurement. Lancet. 1, 307-310.
19  Kralj, E. et al (2012) Simultaneous measurement of 
imatinib, nilotinib and dasatinib in dried blood spot by 
ultra high performance liquid chromatography tandem 
mass spectrometry. Journal of Chromatography B: 
Analytical Technologies in the Biomedical and Life 
Sciences. 903, -156.
20  Cheung, C.Y. et al (2008) Dried blood spot measurement: 
application in tacrolimus monitoring using limited 
sampling strategy and abbreviated AUC estimation. 
Transpl Int. 21, 140-145.
21  Kromdijk, W. et al (2013) Therapeutic drug monitoring of 
antiretroviral drugs at home using dried blood spots: a 
proof-of-concept study. Antivir Ther. 18, 821-825.
References
1  Sternberg, C.N. et al (2010) Pazopanib in locally advanced 
or metastatic renal cell carcinoma: results of a 
randomized phase III trial. J Clin Oncol. 28, 1061-1068.
2  Van der Graaf, W.T. et al (2012) Pazopanib for metastatic 
soft-tissue sarcoma (PALETTE): a randomised, double-
blind, placebo-controlled phase 3 trial. Lancet. 379, 
1879-1886.
3  Suttle, A.B. et al (2014) Relationships between pazopanib 
exposure and clinical safety and efficacy in patients with 
advanced renal cell carcinoma. Br J Cancer. 111, 1909-1916.
4  de Wit, D. et al (2014) Therapeutic Drug Monitoring to 
individualize the dosing of pazopanib: a pharmacokinetic 
feasibility study. Ther Drug Monit.
5  de Wit, D. et al (2015) Individualized dosing of tyrosine 
kinase inhibitors: are we there yet? Drug Discov Today. 
20, 18-36.
6  Yu, H. et al (2014) Practical guidelines for therapeutic drug 
monitoring of anticancer tyrosine kinase inhibitors: focus 
on the pharmacokinetic targets. Clin Pharmacokinet. 53, 
305-325.
7  Hurwitz, H.I. et al (2009) Phase I trial of pazopanib in 
patients with advanced cancer. Clin Cancer Res. 15, 
4220-4227.
8  Verheijen, R. et al (2014) Individualized 
pharmacokinetically-guided dosing of pazopanib: a 
feasibility study in cancer patients. ESMO meeting 2014. 
Abstract 7651.
9  van Erp, N.P. et al (2013) A validated assay for the 
simultaneous quantification of six tyrosine kinase 
inhibitors and two active metabolites in human serum 
using liquid chromatography coupled with tandem mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life 
Sci. 937C, 33-43.
10  Koster, R.A. et al (2013) Fast LC-MS/MS analysis of 
tacrolimus, sirolimus, everolimus and cyclosporin A in 
dried blood spots and the influence of the hematocrit and 
immunosuppressant concentration on recovery. Talanta. 
115, 47-54.
11  Shah, N.M. et al (2013) A simple bioanalytical method for 
the quantification of antiepileptic drugs in dried blood 
spots. J Chromatogr B Analyt Technol Biomed Life Sci. 
923-924, 65-73.
12  Hoffman, J.T. et al (2013) Determination of efavirenz in 
human dried blood spots by reversed-phase high-
performance liquid chromatography with UV detection. 
Ther Drug Monit. 35, 203-208.
13  Li, W and Tse, F.L. (2010) Dried blood spot sampling in 
combination with LC-MS/MS for quantitative analysis of 
small molecules. Biomed Chromatogr. 24, 49-65.
14  Deng, Y. et al (2013) Bioavailability, metabolism and 
disposition of oral pazopanib in patients with advanced 
cancer. Xenobiotica. 43, 443-453.
15  Hinderling, P.H. (1997) Red blood cells: a neglected 
compartment in pharmacokinetics and 
pharmacodynamics. Pharmacol Rev. 49, 279-295.
Chapter 4
abstr act
Background Patients treated with the standard dose of pazopanib  
show a large inter-patient variability in drug exposure defined as the  
area under the plasma concentration time curve (AUC0-24). The primary 
objective of this study was to evaluate the feasibility of pharmacokinetics 
(pk)-guided individualized dosing to reduce the inter-patient variability 
in pazopanib exposure.
Patients and Methods Thirteen patients were treated with pazopanib  
for 3 consecutive periods of 2 weeks. During the first period, all patients 
received 800 mg of pazopanib once daily to reach steady-state exposure. 
During the second period, patients either received a pk-guided 
individualized pazopanib dose or the registered fixed 800 mg  
dose. During the third period, these 2 dosing regimens were switched.
Results The inter-patient variability in pazopanib AUC0-24 during fixed 
dosing (27.3 cv%) was not significantly different when compared with the 
variability in AUC0-24 during pk-guided dosing (24.8 cv%). The percentage 
of patients within the target window during pk-guided dosing (53.9%)  
was not significantly different from the percentage during fixed dosing 
(46.2%). Both Ctrough and C24 were significantly (P < 0.001) correlated to 
pazopanib AUC0-24 (r2 = 0.596 and r2 = 0.940, respectively). Pazopanib 
AUC0-24 decreased 17% over time.
Conclusion PK-guided dosing did not reduce the inter-patient  
variability in pazopanib exposure. In this study, the intra-patient 
variability in pazopanib exposure was relatively large compared with 
inter-patient variability. This makes it challenging to achieve a target 
exposure within a predefined window. The causes of intra-patient 
variability must first be better understood and controlled, before  
pk-guided dosing can reduce the inter-patient variability.
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pk-guided dosing could reduce the inter-patient variability in pazopanib 
exposure and whether a predefined target exposure could be achieved. 
This study was also used to determine the correlation between pazopanib 
Ctrough levels (plasma concentration just before pazopanib intake),  
C24 (plasma concentration 24 hours after pazopanib intake), and pazo-
panib exposure. These analyses may justify the use of trough level measure-
ment for monitoring and guiding pazopanib therapy in clinical practice. 
Further, we explored whether there is a change in pazopanib exposure 
over time, which has been shown for other TKIs [15,16].
Patients and Methods
Patients
Patients eligible for this study were 18 years or older with progressive  
disease from an advanced solid tumor with a World Health Organization 
performance status ≤ 2 and for whom no standard treatment options were 
available. All patients had adequate hematologic, renal, and liver function 
reserves as defined by a hemoglobin ≥ 5.6 mmol/L, absolute neutrophil 
count ≥ 1.5 × 109/L, platelets ≥ 100 ×109/L, creatinine clearance ≥ 50 
mL/min, total bilirubin ≤ 1.5 × the upper limit of institutional normal  
value, alanine aminotransferase, and aspartate aminotransferase ≤ 2.5  
× upper limit of the institutional normal value.
Cytotoxic chemotherapy or radiation therapy for a period of 4 weeks 
before entering the study was not allowed. Further, patients receiving  
concurrent study treatment, patients with clinical evidence of central 
nervous system metastases or with poorly controlled hypertension  
(defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pres-
sure ≥ 90 mm Hg) were not eligible for study entry. Patients were not  
allowed to use substances known or likely to interfere with the pk of  
pazopanib, which included cyp3a4 inhibitors (eg, ritonavir, clarithromy-
cin) or inducers (eg, phenytoin, rifampicin) within 14 days or 5 half-lives 
of the substance (whichever was longer) before study entry. This study  
was approved by the Institutional Ethics Committee (Leiden University 
Medical Center, The Netherlands), and all patients gave written informed 
consent before entering the study. 
Study design and treatment
This study was a multicenter, open-label, 3-period, randomized,  
2-sequence, crossover pharmacokinetic study. Pazopanib (Votrient)  
was supplied as 200 mg tablets for oral administration 1 hour before or  
2 hours after food intake. The study was performed over a timeframe of  
6 weeks. Within these 6 weeks, the patients received pazopanib at the reg-
istered dose of 800 mg once daily for 4 weeks and a pk-guided individual-
ized dose for 2 weeks. This pk-guided individualized dose was based on 
Introduction
Pazopanib hydrochloride (Votrient, GlaxoSmithKline; gw786034)  
is an oral multi-targeted tyrosine kinase inhibitor (tki) with activity 
against vascular endothelial growth factor receptors 1-3, platelet-derived 
growth factor receptors α and β, and c-KIT [1-3]. Pazopanib is approved  
for the treatment of metastatic renal cell carcinoma (mRCC) and metas- 
tatic non-adipocytic soft tissue sarcoma [1-3].
Similar to other TKIs, pazopanib shows a large inter-patient variabil- 
ity in drug exposure of 40-70 coefficient of variation (cv%) [4-6]. Despite 
this large inter-patient variability in pharmacokinetics (pk), pazopanib  
is approved at a fixed oral dose of 800 mg once daily. In addition, a corre-
lation between pazopanib exposure and efficacy and toxicity in mRCC has 
been demonstrated [7,8]. Subsequently, the reported variability in pk can 
potentially result for some patients in subtherapeutic exposure levels 
leading to decreased therapeutic effects. For other patients, the reported 
variability could result in supratherapeutic drug exposure levels with an 
increased incidence of adverse events. If this variability in pk can be  
controlled, the individual benefit – risk ratio for patients treated with  
pazopanib could be optimized.
The use of therapeutic drug monitoring (tdm) could potentially  
lower the inter-patient variability in pazopanib area under the plasma 
concentration time curve (auc). TDM is the measurement of plasma drug 
concentrations to individualize the dosage to achieve a target plasma con-
centration. This individualized dose will ultimately result in an optimal 
exposure to a predefined target drug level with maximal therapeutic  
effects and minimal toxicity. TDM has already shown to be of value for  
the dose individualization of different drugs including antibiotics, anti- 
retroviral drugs, immunosuppressive agents, and anti-epileptics [9-12]. 
However, for the new orally administered targeted anticancer agents  
used in oncology, it has not yet been demonstrated whether the use of 
tdm is feasible or whether it will result in exposures within a predefined 
target window. This must be demonstrated first, before pk-guided dosing 
of pazopanib can be recommended.
Clinically, the main prerequisites for tdm are a proven drug expo-
sure-response relationship, a large inter-patient variability in pk, and a 
well-defined narrow therapeutic window [13,14]. For pazopanib, a drug  
exposure-response relationship seems to be present, and the reported  
inter-patient variability is large. This makes it seem likely that tdm is  
suitable for the individualization of pazopanib therapy. TDM of pazo-
panib could thereby ultimately result in more efficacy and less toxicity  
of therapy.
We conducted a prospective study to evaluate the feasibility of 
pk-guided individualized dosing of pazopanib in patients with cancer. 
The primary objective of this study was to assess whether individualized 
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or if toxicity was unacceptable. This trial was registered at  
www.trialregister.nl under the id: ntr3967. 
Pazopanib pharmacokinetics
For pazopanib pk assessment, edta-blood samples were collected on  
3 days (ie, days 14, 28, and 42 after the start of treatment) at pre-dose 
(Ctrough) and 1, 2, 3, 4, 6, 8, 10, and 24 (C24) hours after pazopanib intake. 
Samples were centrifuged at 1000 relative centrifugal force (rcf) for  
5 minutes at room temperature; plasma was split into 2 aliquots and 
stored at -20 °C until analysis. Pazopanib plasma concentrations were 
measured within 3 days of the last sample being collected. Pazopanib  
plasma concentrations were determined using a validated ultraper-
formance liquid chromatography – tandem mass spectrometric method 
[18]. The calibration line of this method was linear over the range from  
1.0 to 50.0 mg/L of pazopanib. The within- and between-day imprecisions 
were 2.4% and 4.1%, respectively, and the within- and between-day inaccu-
racies were 11% and 9%, respectively. Pazopanib exposures were calculated 
using a non-compartmental trapezoidal approach (Phoenix WinNonlin 
v6.3).
Sample size calculation
In this study design, patients served as their own control. We hypothesized 
that the inter-patient variability (sd) in pazopanib exposure could be re-
duced by 50%, in other words that the variance ratio (SD2 of fixed dosing 
relative to SD2 of pk-guided dosing) would equal 4 by introducing individ-
ualized pk-guided dosing. Because the intra-patient variability was un-
known, we assumed that the correlation between the auc measurements 
within patients equals 0.5, or in other words, that the intra-patient varia-
bility in auc was 50% of the inter-patient variability as has been shown for 
other TKIs. We used simulation (sampling 100,000 times) in spss (version 
20.0) to calculate the power of the appropriate F test taking into account 
this assumed correlation of 0.5 between the 2 variances [19]. A sample size 
of 13 resulted in a power of at least 80% to reject the null hypothesis of 
equal variances.
Statistical analysis
The inter-patient variability in AUC0-24 was evaluated by determining the 
sample variances from the fixed and individualized pk-guided dosing reg-
imen (σ2). To calculate the limits of a 95% confidence interval (ci) for the 
population variance ratio, we used likelihood-ratio tests in linear mixed 
models (profile likelihood-like analysis, sas, version 9.2). To calculate  
the intra-patient variability in exposure, the 2 AUCs0-24 during fixed 800 
mg dosing (pk day 14 and pk day 28 or 42) were used. When there was no 
dose adjustment during pk-guided dosing and patients were dosed with 
the deviation from a predefined target and measured exposure. Because  
a therapeutic window with an optimal balance between exposure (auc) 
and efficacy on the one hand and toxicity on the other hand was lacking 
for pazopanib, a safe and effective target exposure had to be established 
first. For this, we used the results of 2 previous phase i studies in which the 
median steady-state AUCs for 800 mg of pazopanib were determined with 
non-compartmental methods. With the results from these trials, we de-
fined a target exposure of 805 mg·hr/L (range 715 - 920 mg·hr/L) [4,17].
At study entry, patients were allocated to treatment group A or B 
(Figure 1). All patients started with the fixed pazopanib dose of 800 mg 
once daily for a period of 2 weeks to reach steady-state pk. After 2 weeks, 
pazopanib AUCs were assessed. Thereafter, patients allocated to treatment 
group A switched over to a pk-guided individualized dose (based on 
measured pazopanib exposure on day 14), and patients in treatment 
group B continued with the fixed 800 mg dose. After a further 2 weeks  
of pazopanib therapy and having reached a new steady state, the AUCs  
of pazopanib were assessed on day 28. Patients in treatment group  
A returned to the fixed 800 mg pazopanib, and patients in treatment 
group B switched over to the pk-guided individualized dose (based on  
pazopanib exposure on day 28). After another 2 weeks of pazopanib  
therapy and a third pk assessment on day 42, all patients returned to  
the standard dose of 800 mg of pazopanib once daily. This crossover  
design was chosen to test for changes in pazopanib exposure over time.
Patients were instructed to take pazopanib at the same time and  
under the same conditions (1 hour before or 2 hours after breakfast)  
every day. The exact time of pazopanib intake was recorded for the  
3 days preceding pk assessment.
On days 14, 28, and 42, adverse events were monitored using the 
Common Terminology Criteria for Adverse Event version 4.0. Radiological 
response was determined by computed tomography scan using Response 
Evaluation Criteria in Solid Tumors version 1.1, at 7 weeks after the start of 
treatment with pazopanib and reassessed thereafter at 8- to 12-week inter-
vals. Patients were withdrawn from the study if the disease progressed  
Figure 1 Study design





Day 1 Day 15 Day 29 Day 43
PK-guided individualized 
dose 200-1600 mg OD
Fixed dose pazopanib
800 mg OD
Fixed dose pazopanib  
800 mg OD
PK-guided individualized 
dose 200-1600 mg OD
Continue pazopanib  
therapy 800 mg OD
Continue pazopanib  





ratio should be between 0.80 and 1.25 to conclude the absence of a  
decrease or increase of pazopanib exposure over time. Statistical cal- 
culations were performed with spss, version 20.0 and sas version 9.2. 
Results
Patient characteristics
Between July 2012 and June 2013, 14 patients were enrolled in the study. 
One patient withdrew informed consent before starting pazopanib thera-
py. Seven patients were assigned to group A, and 6 patients were assigned 
to group B. Baseline patient characteristics are summarized in Table 1.
Pharmacokinetics
Pazopanib pharmacokinetic data were obtained from all 13 patients on 
days 14, 28, and 42 of treatment. Table 2 summarizes the pharmacokinetic 
parameters of pazopanib during the fixed and individualized pk-guided 
dosing regimens. 
The mean exposures (AUC0-24) were 881 mg·hr/L (range, 600 - 1296 
mg·hr/L) and 838 (range, 361 - 1191 mg·hr/L) during, respectively, fixed 
dosing and pk-guided dosing with accompanying SDs of 241 and 207 
mg·hr/L, respectively. The corresponding inter-patient variability (cv%)  
in AUC0-24 was 27.3% for fixed dosing and 24.8% for pk-guided dosing.  
The inter-patient variability in AUC0-24 was not significantly reduced  













































Parameter Fixed dose D14 PK-guided dose D28/42 Fixed dose D28/42
Table 2 Summary of pazopanib PK parameters during individualized and fixed dosing
Abbreviations: D14/D28/D42, treatment day 14, 28 and 42, respectively; ln AUC0-24, natural log-transformed AUC0-24;  
ln Ctrough, natural log-transformed Ctrough. 
800 mg, this third AUC0-24 was also included to calculate the individual 
intra-patient variability. The mean biases from the target AUC0-24 (ie,  
individual AUC0-24 values minus the target AUC0-24) during fixed and 
pk-guided dosing were compared using a paired sample t-test.
The relationship between pazopanib Ctrough and C24 and AUC0-24  
was examined by Pearson correlation analysis. 
To test for changes in pazopanib AUC0-24 over time, we used the  
statistical method described for the assessment of bioequivalence because 
these studies also determine possible differences in exposure [20]. We cal-
culated the 90% ci of the geometric mean ratios AUCfixed on day 28 (treat-













  ANC (× 109/L)
  Platelets (× 109/L)
  Hemoglobin (mmol/L)
Chemistry
  AST (U/L)
  ALT (U/L)
  Creatinine (µmol/L) 
  Total bilirubin (µmol/L)
Blood pressure (mmHg)
  Systolic





  Pancreas carcinoma
  Schwannoma
  Ganglioneuroma
  Granulair cell myoblastoma
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58 (23 - 68)
6 (86%)
1 (14%)
182 (168 - 183)




4.9 (3.1 - 6.0)
278 (158 - 651)
9.2 (6.8 - 9.9)
22 (17 - 33)
17 (12 - 26)
70 (63 - 88)
7 (5 - 11)
129 (112 - 142)









45 (30 - 60)
6 (100%)
0 (0%)
182 (170 - 184)




4.4 (2.5 - 6.4)
261 (150 - 394)
8.8 (7.8 - 9.9)
25 (17 - 32)
23 (12 - 33)
77 (71 - 86)
10 (7 - 12)
129 (113 - 138)









48 (23 - 68)
12 (92%)
1 (8%)
182 (168 - 184)




4.4 (2.5 - 6.4)
271 (150 - 651)
9.0 (6.8 - 9.9)
22 (17 - 33)
20 (12 - 33)
73 (64 - 88)
10 (5 - 12) 
129 (112 - 142)








Characteristic Treatment Arm A Treatment Arm B Total
Table 1 Patient baseline characteristics
Data are presented as median (range) unless stated otherwise. Abbreviations: ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, 
aspartate aminotransferase; ECOG PS, Eastern Cooperative Oncology Group performance score; mRCC, metastatic Renal Cell Carcinoma; WBC, 



























dose, and 1 patient an increased pazopanib dose. Dose reduction resulted 
in a dose-proportional decrease in pazopanib AUC0-24 in 4 of 6 patients. 
The only patient with an increased dose showed a dose-proportional in-
crease in AUC0-24. The percentage of patients with an AUC0-24 within the 
target window was not significantly different during pk-guided dosing 
when compared with that in fixed dosing (7 versus 6 out of 13 patients, 
53.9% and 46.2%, respectively) (Figure 3). The biases from the target auc  
in the fixed dosing arm and in the individualized arm were 75.9 mg·hr/L 
(95%-ci: 254.9 - 206.7) and 33.1 mg·hr/L (95%-ci: 297.7 - 145.8), respectively 
(P = 0.538). 
Correlation between Ctrough, C24 and AUC0-24 
Both Ctrough and C24 were significantly associated with pazopanib  
AUC0-24 as shown in Figures 4A and 4B (r2 = 0.596, P < 0.001 for Ctrough and 
r2 = 0.940, P < 0.001 for C24, respectively). Ctrough levels were taken after an 
uncontrolled pazopanib intake at home the day before hospital admission 
for pk sampling. The Ctrough levels that were taken earlier or later than 24 
hours after the previous dose tended to be, respectively, higher and lower 
than the controlled intake C24 levels (which is the same as a Ctrough level 
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Figure 4 Correlation between (A) pazopanib Ctrough and AUC0-24; (B) pazopanib C24, and AUC0-24;  
(C) time after prior dose at Ctrough sampling and difference between Ctrough and C24 
during fixed dosing relative to pk-guided dosing was 1.35 (95%-ci: 0.48 - 
3.9) (Figure 2). Individual intra-patient variability was calculated based  
on 3 AUCs for 6 patients and based on 2 AUCs for 7 patients; the mean  
intra-patient variability in AUC0-24 was 24.7 cv% (range, 8.3 - 48.7 cv%). 
During pk-guided dosing, patients received daily doses ranging  
from 400 to 1200 mg of pazopanib. Seven of 13 patients received an  
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Figure 3 AUC0-24 per subject
r2 = .596
P < .001
 Fixed 800 mg dose





















 PK indivudalized dose  Standard fixed dose 800 mg
Figure 2 AUC0-24 during individualized and fixed pazopanib dosing
Target AUC0-24 715-920 mg·hr/L
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this study could not show the feasibility of tdm for the dose individuali- 
zation of pazopanib therapy.
According to the Biopharmaceutics Classification System, pazopanib 
is a class ii active substance and characterized by poor water solubility  
and low oral bioavailability of 14% to 39% [24]. These physicochemical 
properties, when combined with oral administration, cause variability  
in the absorption of pazopanib within and between individuals as shown 
in this study. However, other factors influencing the exposure cannot be 
completely ruled out.
Administration of pazopanib with both low and high fat meals has 
been shown to increase the AUC0-24 by approximately 2-fold compared 
with that in a fasted condition [17]. Although in this study the intake of 
pazopanib has been standardized to the advised administration of 1 hour 
before or 2 hours after the intake of food, the intra-patient variability is 
relatively large. Possibly, this time interval of no food intake around pazo-
panib administration is insufficient to prevent an effect of food on pazo-
panib absorption. In addition, we did not standardize diet composition, 
and this could also have influenced the results. A possible option to re-
duce the intra-patient variability could be to increase the interval between 
food consumption and pazopanib intake. An alternative approach could 
be the administration of pazopanib at a lower dose in combination with  
a standardized meal to regulate the factors that influence its absorption. 
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Figure 4 [Continued] 
Change in pazopanib exposure over time
The ratio of the fixed dose pazopanib AUC0-24 (day 28 or 42) versus fixed 
dose pazopanib AUC0-24 (day 14) was 0.83 (90%-ci: 0.69-0.99) indicating  
a significant decrease in pazopanib AUC0-24 of 17% over time. 
Discussion
The reported large inter-patient variability in pazopanib pk may result  
in subtherapeutic or supratherapeutic exposure, which could potentially 
lead to either decreased efficacy or increased toxicity. In this study, we as-
sessed whether individualized pk-guided dosing could reduce the inter- 
patient variability. The primary aim was to decrease the inter-patient  
variability in pazopanib AUC0-24h by 50%. This aim was not achieved;  
the results of our study indicate that pk-guided dosing to reach a pazo-
panib exposure within a predefined target window is not yet feasible.
Because the intra-patient variability in exposure has not been  
described before, we hypothesized this to be approximately 50% of the  
inter-patient variability. This is comparable with the results seen for other 
TKIs [21-23]. However, in this study, we found that the intra-patient varia-
bility was actually within the same range (24.7%) as that of the inter-patient 
variability (27.3%). Moreover, the inter-patient variability in exposure was 
much lower than that reported in the literature. The relatively large intra- 
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Although the problem of intra-patient variability remains to be 
solved, threshold-driven dosing might be beneficial and safe because  
target levels are much cruder. The concentration window between efficacy 
and toxicity seems to be much larger (> 2-fold (20.5 - 46 mg/L)) than the 
target window used in this study (~1.25-fold (715 - 920 mg·hr/L)). 
Therefore, it seems justified to target a Ctrough level > 20.5 mg/L in clinical 
practice to prevent under dosing and unjustified discontinuation of treat-
ment. Additionally, in patients that experience pazopanib-induced toxici-
ty, measurement of pazopanib concentrations could help to determine 
whether the dose can be reduced or an alternative therapy should be 
initiated.
Conclusion
In this study, the feasibility of pk-guided dosing to reduce the inter- 
patient variability in pazopanib exposure could not be shown due to  
the relatively large intra-patient variability. The causes of the intra-patient 
variability must first be better understood and controlled, before pk-guid-
ed dosing will result in less inter-patient variability. Further research is 
needed to confirm whether there is a decrease in pazopanib exposure over 
time. Measuring of pazopanib plasma concentrations may still be of clini-
cal benefit, especially to target a threshold pazopanib exposure with in-
creased efficacy and limited risk to toxicity. For the interpretation of these 
plasma concentrations in the clinic, samples for Ctrough levels are preferably 
taken exactly 24 hours after pazopanib intake.
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py with pazopanib [25]. The lower inter-patient variability found in this 
study, when compared with what is reported in the literature, is possibly 
the result of the inclusion and exclusion criteria used, controlled drug  
adherence, and the standardized intake of pazopanib [4].
Of the 13 patients included, 7 received an adjusted dose during pk- 
guided dosing. Dose reduction resulted in a dose-proportional decrease  
in AUC0-24 in 4 of 6 patients. Previous research has suggested that the steady- 
state exposure to pazopanib seems to plateau at 800 mg. However, in this 
study, the increased dose from 800 to 1200 mg in 1 patient did result in  
a dose-proportional increase in AUC0-24 [4].
The pazopanib plasma concentration at 24 hours after pazopanib  
intake (C24) was much better correlated with the AUC0-24 than Ctrough  
levels. Besides the intra-patient variability, 2 other reasons could possi- 
bly explain this finding; First, Ctrough levels were taken around 24 hours 
(19.5 - 28.5 hours) after pazopanib intake, whereas C24 levels were taken 
exactly 24 hours after pazopanib intake. When Ctrough levels were drawn  
> 24 hours after pazopanib intake, Ctrough was lower than C24 and vice  
versa supporting our hypothesis. Second, Ctrough levels reflected an at 
home - uncontrolled - pazopanib administration, whereas C24 levels  
were drawn after in hospital - controlled - administration of pazopanib. 
However, these findings are the reality of clinical practice and should  
be kept in mind when interpreting pazopanib Ctrough levels in the clinic.  
A possible option to address this issue may be dry blood spot sampling. 
Patients could then take samples at home at exactly 24 hours after their 
last pazopanib intake. However, the feasibility and accuracy of this at 
home approach needs prospective validation.
A decrease of 17% in pazopanib exposure over time was observed. 
Similar decreases have been shown for imatinib and sorafenib [15,16]. 
Changes in the activity or expression of drug transporters or upregulation 
of liver enzymatic function might explain our observation. However,  
due to the small number of patients, this finding should be regarded  
as hypothesis generating and needs to be confirmed in a larger group  
of patients.
Although this study could not show the feasibility of tdm to reach  
a target exposure, measuring of pazopanib plasma concentrations may 
still be of clinical importance. A plasma concentration of 20.5 mg/L is ret-
rospectively defined as the threshold for improved efficacy of pazopanib 
therapy in patients with mRCC [8]. In this study, 20% of the patients had 
Ctrough levels below this threshold (data not shown). However, the inci-
dence of different pazopanib-induced toxicities has also shown to be  
concentration dependent; there was a ≥ 2-fold increase in the incidence  
of hypertension, diarrhea, hair color change, alanine aminotransferase  
increase, and stomatitis when Ctrough increased from 12.6 to 46 mg/L [7].
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Background Patients treated with sunitinib show substantial  
inter-patient variability in drug exposure (~30-40%), which is largely 
unexplained. Since sunitinib is metabolized by cytochrome P450 (cyp) 
3A4, variability in the activity of this enzyme may explain a considerable 
proportion of this inter-patient variability. Midazolam is widely used  
as a phenotyping probe to assess cyp3a4 activity. The objective of this 
study was to prospectively evaluate the relationship between midazolam 
and sunitinib exposure. Additionally, the correlation between sunitinib 
Ctrough levels and exposure and the influence of sunitinib on midazolam 
exposure was determined.
Patients and Methods Thirteen patients treated with sunitinib in  
a ‘4 weeks on - 2 weeks off’ regimen received twice 7.5 mg midazolam;  
once with and once without sunitinib. Steady-state sunitinib, its active 
metabolite su12662 and midazolam exposures were determined.
Results A significant correlation between midazolam exposure (AUC0-7) 
and steady-state sunitinib and sunitinib + su12662 exposure (AUC0-24)  
was found (P = 0.006 and P = 0.0018, respectively); midazolam exposure 
explained 51% and 41% of the inter-patient variability in sunitinib and 
sunitinib + su12622 exposure. Furthermore, Ctrough was highly correlated 
(r2 = 0.94) with sunitinib AUC0-24. Sunitinib decreased midazolam 
exposure with 24% (P = 0.034).
Conclusion Midazolam exposure is highly correlated with sunitinib 
exposure and explains a large proportion of the observed inter-patient 
variability in sunitinib pharmacokinetics. Consequently, midazolam could 
be used to identify patients that are at risk of under- or overtreatment, 
respectively, at the start of sunitinib therapy. Moreover, sunitinib and 
sunitinib + su12662 Ctrough levels are highly correlated with drug  
exposure and can thus be used in clinical practice to individualize 
sunitinib therapy. The decrease in midazolam exposure by sunitinib  
needs further investigation. 
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samples over the dosing interval. However, for daily clinical practice,  
less intensive sampling would be a more feasible approach. Therefore,  
this study also determined the correlation between Ctrough levels and  
total sunitinib exposure. This potentially justifies the use of only Ctrough 
levels for monitoring and guiding sunitinib therapy in clinical practice. 
Finally, this study evaluated the effect of sunitinib on the pharmacoki- 
netics of midazolam in patients with cancer.
Patients and Methods
Patients
Patients that used sunitinib for the palliative treatment of various tumors 
were eligible for study entry. Patients were ≥ 18 years old, had a who per-
formance status ≤ 2 and a life expectancy of at least 12 weeks. Cytotoxic 
chemotherapy or radiation therapy within 4 weeks before study entry  
and concurrent use of substances known or likely to interfere with cyp3a4 
activity within 14 days before study entry were not allowed. All patients 
had adequate clinical functional reserves as defined by hemoglobin  
≥ 6.0 mmol/L, WBC ≥ 3.0 × 109/L, ANC ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, 
creatinine clearance ≥ 60 mL/min, bilirubin ≤ 1.75 × the upper limit of  
institutional normal value. The study was approved by the institutional 
ethics committee (Leiden University Medical Center, the Netherlands)  
and all patients gave written informed consent before entering the study.
Study design
All patients were treated in a ‘4 weeks on - 2 weeks off’ dosing schedule, 
with commercially available sunitinib malate hard capsules (Pfizer, Kent, 
United Kingdom) at an once daily oral dose of 37.5 or 50 mg. The study 
was performed during one sunitinib treatment cycle of 6 weeks. Patients 
were admitted to the hospital for pharmacokinetic (pk) sampling on two 
separate days. The first pk day was at steady-state sunitinib pharmacoki-
netics (between days 14-20). The second pk day was on day 42, the final  
day of the 2 weeks ‘off period’ after the wash out of sunitinib. On both pk 
days, patients were given one midazolam 7.5 mg tablet (Roche, Woerden, 
The Netherlands) which was used either with (first pk day) or without  
sunitinib (second pk day).
To determine the correlation between midazolam and sunitinib  
exposure, the AUC0-7 of midazolam without the concomitant use of  
sunitinib (second pk day) was related to the AUC0-24 and Ctrough (t = 0)  
of both sunitinib and sunitinib + su12662 at steady-state pharmacokinet-
ics (first pk day). Additionally, the steady-state sunitinib data were used  
to assess the relationship between sunitinib and sunitinib + su12662 
Ctrough levels (t = 0) and exposure (AUC0-24). To determine the influence  
of sunitinib on cyp3a4 activity, midazolam exposures (AUC0-7) with  
Introduction
Sunitinib malate (Sutent®; su11248) is an oral multi-targeted tyrosine  
kinase inhibitor with both antitumor and antiangiogenic activity. It is  
approved for the treatment of metastatic renal cell carcinoma (mRCC), 
metastatic gastrointestinal stromal tumors (gist) and advanced pancreat-
ic neuroendocrine tumors [1-4]. Sunitinib is primarily metabolized by  
cytochrome P450 3A4 to its equally active N-desethyl metabolite su12662, 
which is further metabolized to inactive moieties by cyp3a4 as well [5]. 
Steady-state concentrations of sunitinib and su12662 are approximately 
reached after 14 days of daily dosing [6].
Patients treated with sunitinib show substantial inter-patient varia- 
bility in drug exposure (~30-40%), which is largely unexplained [3,7,8]. 
Previously, a relationship between systemic sunitinib exposure, efficacy 
and adverse events has been demonstrated; Houk et al. showed that pa-
tients with mRCC, gist or solid tumors and a sunitinib AUCss > 800, 600 
and 700 μg·hr/L, respectively, had longer time to progression (ttp) and 
better overall survival (os) [9]. This study also showed that there was a 
positive relationship between exposure and fatigue, decreased absolute 
neutrophil count and change in diastolic blood pressure. Consequently, 
the inter-patient variability in the pharmacokinetics of sunitinib can re-
sult in either sub- or supratherapeutic levels leading to inefficacy or toxic- 
ity, respectively. Since sunitinib is predominantly metabolized by cyp3a4, 
differences in the activity of this enzyme may explain a considerable  
proportion of the unexplained observed inter-patient variability  
in pharmacokinetics.
Midazolam is widely used as a noninvasive phenotyping probe  
to assess cyp3a4 activity. By using this probe, patients potentially at risk  
of under- or overtreatment, respectively, at the standard dosage regimen 
of sunitinib can be identified before the start of therapy. Hence, midazolam 
exposure can be used as a surrogate parameter for sunitinib exposure  
and could possibly prevent inefficacy or toxicity of sunitinib therapy.
The predictive value of different phenotyping probes for the exposure 
of various cytotoxic drugs including vinorelbine, docetaxel, irinotecan 
and tamoxifen, as well as the tyrosine kinase inhibitors gefitinib and  
imatinib has been investigated before [10-20]. Since, cyp3a4 plays an  
important role in the metabolism of nearly all tyrosine kinase inhibitors 
(tki) and these TKIs also show a large inter-patient variability in pharma-
cokinetics, phenotyping with midazolam may also be useful for these 
drugs [21].
This study prospectively evaluated the relationship between midazolam 
and sunitinib exposure in patients with cancer in order to assess the feasi-
bility of midazolam as a phenotyping probe for sunitinib pharmacokinet-
ics. Total drug exposure is usually determined by collecting multiple 
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eluted with the following gradient [time scale (min-min): flow rate 
(mL/min): mobile phase A (%)/mobile phase B (%)] 0-0.5:0.3: 85/15;  
0.5-1.5:0.3: 85/15 → 10/90; 1.5-5.8:0.3:10/90; 5.8-6.2:0.5:10/90 → 85/15; 6.2-
9.5:0.5:85/15. The effluent was monitored with a Micromass Quattro LC  
triple-quadrupole mass spectrometric detector (Waters, Milford, MA)  
using the electrospray positive ionization mode. The retention times for 
midazolam and α-hydroxy midazolam were 4.82 and 4.83 min, respective-
ly; mrm transitions for midazolam 326.0 > 291.0 and for α-hydroxy mida-
zolam 342.0 > 323.9. The calibration line of midazolam (Bufa, IJsselstein, 
Netherlands) was linear over the range from 1 to 100 μg/L. The within day 
and between day imprecision and inaccuracy were less than 5 % within 
this concentration range.
Pharmacokinetic analysis 
Sunitinib and midazolam plasma concentrations were analyzed using  
a non-compartmental trapezoidal approach (Phoenix® Winnonlin® v6.3). 
For sunitinib and su12662 the following pharmacokinetic parameters 
were assessed: auc over the dosing interval (0-24); Ctrough = trough plasma 
concentration; Tmax = time to reach peak plasma concentration and Cmax  
= peak plasma concentration. Since sunitinib and su12662 pharmacoki-
netics are known to be dose-proportional over at least the dose range  
of 25-100 mg, the AUC0-24, Ctrough and Cmax were dose normalized to a  
sunitinib dose of 50 mg in order to account for sunitinib dose differences 
(37.5 and 50 mg) between patients [6]. For midazolam and its metabolite 
Number of patients
Sex 
  Male (n)










WHO performance score 
  0 (n)
  1 (n)
Data are presented as median values with lower and upper limit. Abbreviations: ALT, alanine transaminase; AST, 
aspartate transaminase; Hb, hemoglobin; WBC, white blood count. 
Characteristic





61 (41 - 78)
76 (56 - 122)
9 (6 - 27)
24 (9 - 68)
38 (23 - 203)
8.8 (7.0 - 10.3)
5.0 (3.2 - 38.2)
158 (82 - 318)
53.3 (31.3 - 96.6)
3
12
(first pk day) and without (second pk day) the concomitant use  
of sunitinib were compared (Study Design; Figure 1).
Sunitinib pharmacokinetic analysis
To assess steady-state sunitinib pharmacokinetics, blood samples were 
collected after 14-20 days of sunitinib therapy (first pk day). The samples 
were collected into heparin containing tubes at 0, 10, 20, 40 min and  
1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hr after the sunitinib dose. Blood samples  
were centrifuged at 3,000 rpm for 10 min; plasma was divided into  
two aliquots and stored at -80 °C until the day of analysis. Sunitinib  
and su12662 plasma concentrations were determined using a validated 
Ultra Performance Liquid Chromatography-tandem Mass Spectrometric 
(uplc-ms/ms) assay [22].
Midazolam pharmacokinetic analysis
Blood samples to assess midazolam pharmacokinetics were collected  
on the first and second pk day after a single oral dose of midazolam.  
The samples were collected into heparin containing tubes at the following 
time points: 0, 10, 20, 40 min and 1, 2, 3, 4, 5, 7 hr after the midazolam dose. 
Blood samples were centrifuged at 3,000 rpm for 10 min and plasma was 
stored at -80 °C until the day of analysis. Midazolam and its metabolite 
α-hydroxy midazolam were measured using a validated liquid chromat- 
ographic-tandem mass spectrometric (lc-ms/ms) assay. Briefly, 200 μL 
plasma was extracted by adding 500 μL of acetonitrile containing mida-
zolam D4 (4 μg/L) as the internal standard, followed by vortex mixing  
and centrifugation at 13,000 rpm for 5 min at ambient temperature. The 
supernatant was collected and 10 μL was separated on an Atlantis T3 C18 
analytical column (50 × 2.1 mm i.d. particle size 3 μm) with a linear gradi-
ent. Mobile phase A consisted of 0.1 % v/v formic acid in water and mobile 
phase B consisted of 0.1 % v/v formic acid in acetonitril. Midazolam was 
Sunitinib 37.5 - 50 mg once daily
Day 1 Day 14
Midazolam 7.5 mg
First PK day
Assessment of sunitinib PK and midazolam PK
Midazolam 7.5 mg
Second PK day
Assessment of midazolam PK
Day 20 Day 28 Day 42
Sunitinib wash-out period
Figure 1 Study design
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Sunitinib and midazolam pharmacokinetics
Individual sunitinib, sunitinib + su12662 and midazolam concentration 
versus time profiles are shown in Figure 2. A wide overlap is seen in the 
curves of patients that received 37.5 mg sunitinib and those that received 
50 mg. The two patients that (recently) used mitotane are represented  
by the two lowest curves (indicated with an arrow). Since one of the  
Figure 2 Individual observed concentration versus time profiles for A) sunitinib B) sunitinib +SU12662 C) 
midazolam. The gray lines represent the patients that received 37.5 mg sunitinib, and the black lines patients  
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α-hydroxy midazolam the following pharmacokinetic parameters  
were assessed: auc over the sampling period (0-7), Tmax and Cmax.
Statistical analysis
The relationship between midazolam exposure and both sunitinib and su-
nitinib + su12662 exposure, as well as the relation between both sunitinib 
and sunitinib + su12662 Ctrough and AUC0-24 were examined by correlation 
analysis. The Pearson square correlation coefficient (r2) was used to assess 
the percentage of variability in sunitinib exposure that could be explained 
by midazolam exposure. To determine the influence of sunitinib on mida-
zolam exposure, midazolam AUC0-7 on the first and second pk day were 
compared using a two-tailed paired student’s t-test. P values < 0.05 were 
considered statistically significant. Statistical calculations were performed 
using spss 20.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Patients and treatment
Fifteen patients using sunitinib were included in this pharmacokinetic 
study. Of these patients, 12 received 50 mg and 3 received 37.5 mg sunitinib 
once daily. Patient characteristics are summarized in Table 1. No unexpect-
ed side effects were observed during sunitinib treatment or on the day  
of midazolam co-administration. Two patients used or recently stopped 
using mitotane therapy during the study. At the time of inclusion it was 
unknown that mitotane is a very potent inducer of cyp3a4 and that the 
combination of both drugs would thus result in markedly decreased su-
nitinib and midazolam concentrations. The observed interaction between 
sunitinib and mitotane in this present study is reported separately [23] 





Data are presented as mean values (standard deviation). Parameters were dose normalized to sunitinib 50 mg. 
Abbreviations: AUC, area under the concentration time curve; Cmax, peak plasma concentration and Tmax, time to reach peak plasma concentration.
aMidazolam data from PK day 2 were used; midazolam was then given without the co-administration of sunitinib.
Sunitinib  
(n = 13)
Table 2 Summary of sunitinib and midazolam pharmacokinetic parameters































Figure 3 Correlations between sunitinib pharmacokinetics for A) sunitinib Ctrough levels and AUC0-24  
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exclusion criteria was the use of cyp3a4 inducers, these two patients were 
excluded from further analysis after discovering that mitotane is a potent 
cyp3a4 inducer. Summaries of the pharmacokinetics of sunitinib and  
midazolam are presented in Table 2. The mean dose-normalized AUC0-24 
(standard deviation) for sunitinib and sunitinib + su12662 were 1442 
μg·hr/L (330 μg·hr/L) and 1929 μg·hr/L (423 μg·hr/L), respectively. Ctrough 
levels were 55.2 μg/L (14.6 μg/L) and 74.4 μg/L (19.2 μg/L) for, respectively, 
sunitinib and sunitinib + su12662. The two patients that used mitotane 
had a sunitinib + su12662 AUC0-24 of 1014 and 855 μg·hr/L. Their Ctrough  
sunitinib + su12662 levels were, respectively, 36.7 and 31.6 μg/L.
Correlation between sunitinib and midazolam  
pharmacokinetic parameters
Both sunitinib Ctrough and sunitinib exposure (AUC0-24), as well as suniti- 
nib + su12662 Ctrough and sunitinib + su12662 AUC0-24 were highly corre-
lated (r2 = 0.94, P < 0.001 and r2 = 0.93, P < 0.001, respectively) as shown  
in Figure 3.
Significant correlations were observed between midazolam and  
sunitinib pharmacokinetics: midazolam exposure (AUC0-7) could explain 
51% of the variability in sunitinib AUC0-24 (P = 0.006), 47% of the variability 
in sunitinib Ctrough (P = 0.010), 41% of the variability in sunitinib + su12622 
AUC0-24 (P = 0.0018) and 39% of the variability in sunitinib + su12622 
Ctrough (P = 0.023) (Figure 4).
Influence of sunitinib on midazolam exposure
The mean midazolam exposures (AUC0-7) without and with concomitant 
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tively, sunitinib and sunitinib + su12662 AUC0-24. Finally, this study  
indicates that sunitinib significantly affects midazolam exposure in vivo.
This study not only demonstrates the excellent correlation of  
midazolam exposure with sunitinib pharmacokinetics, but also that up  
to 51% of the previously unexplained inter-patient variability in sunitinib 
pharmacokinetics can actually be elucidated by differences in midazolam 
exposure. By using midazolam as a phenotypic probe, patients at risk for 
either under- or overtreatment with sunitinib at the standard dosage  
regimen can be identified before the start of therapy. In fact, the two pa-
tients that used mitotane had very low sunitinib exposures with almost 
unmeasurable midazolam exposure. Since mitotane turned out to be a 
very potent cyp3a4 inducer which was one of the a priori exclusion criteria 
of this study, these two patients were excluded from statistical analyses. 
However, this interaction was unknown at the time of inclusion and  
actually became apparent by phenotyping these two patients, which 
shows us the clinical value of phenotyping [23]. By starting sunitinib  
therapy at an individualized dose, inefficacy due to under treatment as 
well as dose modifications (~50%) and discontinuations (~19%) due to tox-
icity can be prevented [1]. Moreover, for patients whose correct starting 
dose is debatable (e.g., due to comorbidities), midazolam could be useful 
to establish a safe and effective individualized sunitinib dose. However, 
before midazolam phenotyping can be used in clinical practice, the  
suitability of an individualized dosing strategy for sunitinib based on mi-
dazolam exposure would require prospective validation in a clinical trial.
Another approach to individualize sunitinib therapy could be thera-
peutic drug monitoring (tdm). Whereas tdm can be used to identify those 
patients that are over-/under dosed while on sunitinib therapy, phenotyp-
ing could be used to identify these patients beforehand.
Earlier identified covariates including tumor type, race, gender,  
body weight and elevated ecog score could only explain 2-17 % of the  
observed changes in auc and/or Cmax [7,27]. Additionally, one study  
correlated pharmacogenetics with sunitinib exposure and treatment  
outcome; a significant higher exposure and more toxicity were found  
in patients harboring a polymorphism in the efflux transporter gene 
abcg2 [28,29]. Phenotyping with midazolam might explain such a large 
percentage of the variability in sunitinib pharmacokinetics because it  
represents the influence of both genetic differences as well as environ-
mental covariates (comorbidities, medication, life style, etc.) that might 
affect sunitinib exposure [7].
Although midazolam is officially recommended by the fda for cyp3a4 
activity phenotyping, variability in the oral exposure to midazolam can 
also be caused by co-influencing factors that affect both sunitinib and  
midazolam exposure (e.g., body composition, age, gender). Therefore,  
the percentage of sunitinib variability that can be truly explained by 
cates a decrease of 24% in midazolam exposure due to the co-administra-
tion of sunitinib (P = 0.034).
Discussion
This study shows that midazolam exposure is highly correlated with  
sunitinib exposure and explains a large proportion of the observed inter- 
patient variability in sunitinib pharmacokinetics. In addition, sunitinib 
and sunitinib + su12662 Ctrough levels were highly correlated with, respec-
Figure 4 Correlations between midazolam and sunitinib pharmacokinetics A) midazolam AUC0-7  
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but not all substrates. This mechanism was previously proposed in an  
in vitro study where sunitinib was found to enhance cyp3a5-mediated  
hydroxylation of midazolam [36]. Since sunitinib and midazolam were  
administered simultaneously, a decreased uptake of midazolam due to  
sunitinib cannot be ruled out. Additional investigation is warranted to 
confirm the exact mechanism of the identified interaction observed in  
our current study.
In conclusion, this study demonstrates that midazolam exposure is 
highly correlated with sunitinib exposure and explains a large proportion 
of the observed inter-patient variability in sunitinib pharmacokinetics. 
Midazolam could be useful in clinical practice to identify those patients 
that are at risk of under- or overtreatment, respectively, at start of the 
standard sunitinib dosage regimen. Moreover, using Ctrough levels as  
a surrogate parameter of total sunitinib exposure is a good and feasible 
approach for monitoring and guiding sunitinib therapy in clinical prac-
tice. Finally, the exposure to midazolam is decreased by the co-adminis- 
tration of sunitinib therapy, but this finding needs further investigation.
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cyp3a4-activity will be somewhat lower than the 51 % found in this  
present study. 
The time frame of 0-7 hours over which midazolam samples were  
collected is based on the pharmacokinetic characteristics of midazolam. 
This frame represents 2-3 times the half-life of midazolam and therefore 
adequately describes the exposure to midazolam. Accordingly, the differ-
ence between the calculated midazolam AUC0-7 and extrapolated AUCinf  
is < 15 % (not shown). Therefore, a longer midazolam sampling schedule 
would not have substantially improved the correlation between midazolam 
and sunitinib exposure. Midazolam is, besides cyp3a4, also metabolized 
by cyp3a5. Since sunitinib is only metabolized by cyp3a4, this difference  
in metabolism could have influenced the primary outcomes of this study 
[6, 8]. However, cyp3a5 is only active in 20% of the Caucasian population 
and in Dutch Caucasians even less [30]. Since all included patients were 
Dutch Caucasians, we do not expect that the correlation between mida-
zolam and sunitinib exposure is considerably affected by the influence  
of cyp3a5 activity on midazolam metabolism.
According to the secondary objectives, this study shows the excellent 
correlation between sunitinib Ctrough and sunitinib AUC0-24, as well as su-
nitinib + su12662 Ctrough levels and sunitinib + su12662 exposure. Taking 
into account the long half-life of sunitinib, it was expected that steady-
state Ctrough levels would well represent total drug exposure. However,  
the exact correlation between both parameters has, to our knowledge,  
not been reported before. The results of this present study legitimate  
the use of only Ctrough levels to individualize sunitinib therapy in clinical 
practice. Additionally, the results of this study could be used to translate 
the threshold sunitinib AUCs associated with a beneficial clinical response 
into corresponding sunitinib Ctrough levels [9]. These sunitinib AUCs 
would correspond with sunitinib + su12662 AUCss greater than 1120,  
868 and 994 μg·h/L and Ctrough levels of sunitinib + su12662 greater than 
36.4, 24.6 and 30.5 μg/L for patients with mRCC, gist and solid tumors,  
respectively, to achieve longer ttp and os. Preclinical in vivo research iden-
tified 50 - 100 μg/L as the minimum concentration of sunitinib + su12662 
required to show anti-tumor activity which is in the same range [31].
In the current study, we found that treatment with sunitinib resulted 
in a 24% decrease in midazolam exposure. The mechanism by which this 
interaction occurs is not entirely clear. The prescribing information states 
that sunitinib does not induce cyp3a4 [6]. This is consistent with previous 
studies indicating that sunitinib does not influence the metabolism of the 
cyp3a4 substrates paclitaxel, docetaxel, or irinotecan [32-35]. A possible 
mechanistic explanation for the change in midazolam pharmacokinetics 
observed in this present study is heterotrophic cooperativity, whereby  
reversible binding of sunitinib causes a three-dimensional change in  
enzyme structure that ultimately affects a distant active site for some,  
Chapter 6
119118
I dose-escalation study. Cancer Chemother Pharmacol. 
66, 669-680.
33  de Jonge, M.J. et al (2011) Phase I safety and 
pharmacokinetic study of SU-014813 in combination with 
docetaxel in patients with advanced solid tumours. Eur J 
Cancer. 47, 1328-1335.
34  Boven, E. et al (2010) A phase I, dose-finding study of 
sunitinib in combination with irinotecan in patients with 
advanced solid tumours. Br J Cancer. 103, 993-1000.
35  Sugiyama, M. et al (2011) Sorafenib and sunitinib, two 
anticancer drugs, inhibit CYP3A4-mediated and activate 
CY3A5-mediated midazolam 1'-hydroxylation. Drug Metab 
Dispos. 39, 757-762.
with CYP2D6 genotype and serum endoxifen levels. 
Cancer Chemother Pharmacol.
17  Gurney, H. et al (2007) Imatinib disposition and ABCB1 
(MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther. 82, 
33-40.
18  Hirth, J. et al (2000) The effect of an individual's 
cytochrome CYP3A4 activity on docetaxel clearance. Clin 
Cancer Res. 6, 1255-1258.
19  Slaviero, K.A. et al (2004) Population pharmacokinetics of 
weekly docetaxel in patients with advanced cancer. Br J 
Clin Pharmacol. 57, 44-53.
20  Opdam, F.L. et al (2012) Phenotyping drug disposition in 
oncology. Cancer Treat Rev. 38, 715-725.
21  van Erp, N.P. et al (2009) Clinical pharmacokinetics of 
tyrosine kinase inhibitors. Cancer Treat Rev. 35, 692-706.
22  van Erp, N.P. et al (2013) A validated assay for the 
simultaneous quantification of six tyrosine kinase 
inhibitors and two active metabolites in human serum 
using liquid chromatography coupled with tandem mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life 
Sci. 937C, 33-43.
23  van Erp N.P. et al (2011) Mitotane has a strong and a 
durable inducing effect on CYP3A4 activity. Eur J 
Endocrinol. 164, 621-626.
24  Takeshita, A. et al (2013) Mitotane induces CYP3A4 
expression via activation of the steroid and xenobiotic 
receptor. J Endocrinol. 216, 297-305.
25  Chortis, V. et al (2013) Mitotane therapy in adrenocortical 
cancer induces CYP3A4 and inhibits 5alpha-reductase, 
explaining the need for personalized glucocorticoid and 
androgen replacement. J Clin Endocrinol Metab. 98, 
161-171.
26  Kroiss, M. et al (2011) Drug interactions with mitotane by 
induction of CYP3A4 metabolism in the clinical 
management of adrenocortical carcinoma. Clin Endocrinol 
(Oxf). 75, 585-591.
27  Faivre, S. et al (2006) Safety, pharmacokinetic, and 
antitumor activity of SU11248, a novel oral multitarget 
tyrosine kinase inhibitor, in patients with cancer. J Clin 
Oncol. 24, 25-35.
28  Mizuno, T. et al (2012) Impact of genetic variation in breast 
cancer resistance protein (BCRP/ABCG2) on sunitinib 
pharmacokinetics. Drug Metab Pharmacokinet.
29  van Schaik, R.H. et al (2002) CYP3A5 variant allele 
frequencies in Dutch Caucasians. Clin Chem. 48, 
1668-1671.
30  Mendel, D.B. et al (2003) In vivo antitumor activity of 
SU11248, a novel tyrosine kinase inhibitor targeting 
vascular endothelial growth factor and platelet-derived 
growth factor receptors: determination of a 
pharmacokinetic/pharmacodynamic relationship. Clin 
Cancer Res. 9, 327-337.
31  Kozloff, M. et al (2010) An exploratory study of sunitinib 
plus paclitaxel as first-line treatment for patients with 
advanced breast cancer. Ann Oncol. 21, 1436-1441.
32  Robert, F. et al (2010) Sunitinib in combination with 
docetaxel in patients with advanced solid tumors: a phase 
References
1  Motzer, R.J. et al (2007) Sunitinib versus interferon alfa in 
metastatic renal-cell carcinoma. N Engl J Med. 356, 
115-124.
2  Demetri, G.D. et al (2006) Efficacy and safety of sunitinib 
in patients with advanced gastrointestinal stromal tumour 
after failure of imatinib: a randomised controlled trial. 
Lancet. 368, 1329-1338.
3  Goodman, V.L. et al (2007) Approval summary: sunitinib 
for the treatment of imatinib refractory or intolerant 
gastrointestinal stromal tumors and advanced renal cell 
carcinoma. Clin Cancer Res. 13, 1367-1373.
4  Raymond, E. et al (2011) Sunitinib malate for the treatment 
of pancreatic neuroendocrine tumors. N Engl J Med. 364, 
501-513.
5  Adams, V.R. and Leggas, M. (2007) Sunitinib malate for 
the treatment of metastatic renal cell carcinoma and 
gastrointestinal stromal tumors. Clin Ther. 29, 1338-1353.
6  U.S.Food and Drug Administration. Sutent® (sunitinib): 
Drug Approval Report. Available at http://www.
accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed 
March 25th 2013. 
7  Houk, B.E. et al (2009) A population pharmacokinetic 
meta-analysis of sunitinib malate (SU11248) and its primary 
metabolite (SU12662) in healthy volunteers and oncology 
patients. Clin Cancer Res. 15, 2497-2506.
8  Speed, B. et al (2012) Pharmacokinetics, distribution, and 
metabolism of [14C]sunitinib in rats, monkeys, and 
humans. Drug Metab Dispos. 40, 539-555.
9  Houk, B.E. et al (2010) Relationship between exposure to 
sunitinib and efficacy and tolerability endpoints in patients 
with cancer: results of a pharmacokinetic/
pharmacodynamic meta-analysis. Cancer Chemother 
Pharmacol. 66, 357-371.
10  Puisset, F. et al (2005) Dexamethasone as a probe for 
vinorelbine clearance. Br J Clin Pharmacol. 60, 45-53.
11  de Graan, A.J. et al (2011) Dextromethorphan as a 
phenotyping test to predict endoxifen exposure in patients 
on tamoxifen treatment. J Clin Oncol. 29, 3240-3246.
12  Goh, B.C. et al (2002) Explaining interindividual variability 
of docetaxel pharmacokinetics and pharmacodynamics in 
Asians through phenotyping and genotyping strategies. J 
Clin Oncol. 20, 3683-3690.
13  Mathijssen, R.H. et al (2004) Prediction of irinotecan 
pharmacokinetics by use of cytochrome P450 3A4 
phenotyping probes. J Natl Cancer Inst. 96, 1585-1592.
14  Li, J. et al (2006) CYP3A phenotyping approach to predict 
systemic exposure to EGFR tyrosine kinase inhibitors. J 
Natl Cancer Inst. 98, 1714-1723.
15  Swaisland, H.C. et al (2006) Exploring the relationship 
between expression of cytochrome P450 enzymes and 
gefitinib pharmacokinetics. Clin Pharmacokinet. 45, 
633-644.
16  Opdam, F.L. et al (2012) The use of the (13)
C-dextromethorphan breath test for phenotyping CYP2D6 
in breast cancer patients using tamoxifen: association 
Chapter 6
abstr act
Background GIST patients often undergo gastrointestinal (gi) surgery. 
Previous studies have shown that imatinib and nilotinib exposures were 
decreased in gist patients with prior major gastrectomy. We investigated 
whether major gastrectomy influences the exposure to sunitinib and  
its active metabolite su12662.
Patients and Methods Pharmacokinetic data from 305 gist patients 
included in 4 phase i-iii trials were analyzed. Patients were subdivided 
into 6 groups according to their prior gi surgery. Apparent clearance 
(CI/F) and dose-corrected steady-state plasma exposures (AUC0-24)  
of sunitinib and su12662 were estimated using a population pk  
approach. ANCOVA was performed to test for differences in  
AUC0-24 and CI/F between each surgery subgroup and controls.
Results Major gastrectomy did not influence sunitinib or su12662 
exposure. The geometric mean of sunitinib and su12662 AUC0-24 was 
decreased by 21% and 28% in patients with both gastrectomy and small 
bowel resection (n = 8) compared to controls (n = 63) for sunitinib  
(931 ng·hr/mL (95%-ci; 676 - 1283) versus 1177 ng·hr/mL (95%-ci; 1097 - 
1263); P < 0.05) and su12662 (354 ng·hr/mL (95%-ci; 174 - 720) versus  
492 ng·hr/mL (95%-ci; 435 - 555); P < 0.05). No significant differences in 
exposure were observed in each of the other subgroups versus controls.
Conclusion In contrast to previous results for imatinib and nilotinib, 
gastrectomy alone does not influence sunitinib or su12662 exposure.  
This should be taken into account for the treatment of gastrectomized 
gist patients with TKIs. In patients who had undergone both gastrectomy 
and small bowel resection, sunitinib and su12662 exposures are 
significantly, although clinically not relevantly, decreased.
7
Effect of gastrointestinal resection on 
sunitinib exposure in patients with GIST
Djoeke de Wit, Nielka P. van Erp, Reza Khosravan, Robin Wiltshire, Randy Allred, George D. Demetri,  













tration (Tmax) for these drugs; 2-4 hours for imatinib and 3 hours for  
nilotinib [11,12]. Hence, due to the physicochemical properties of imatinib 
and nilotinib, the stomach is essential for dissolution and absorption  
of these TKIs.
For sunitinib however, solubility does not decline until pH 6.8 [16]. 
This makes in theory the involvement of the stomach less critical for  
dissolution and absorption of sunitinib. This is further supported by  
the relative broad surface over which sunitinib is absorbed from the gi 
tract, reflected by a long time to reach maximum plasma concentration  
of sunitinib, e.g. 6-12 hours [16]. We postulated that major gastrectomy 
would most likely not affect the exposure to sunitinib and its active  
metabolite su12662. 
To confirm this hypothesis, we retrospectively investigated the effect 
of gi resections on sunitinib and su12662 exposures in patients with gist 
across 4 different phase i-iii clinical trials. Our primary objective was to 
investigate the effect of major gastrectomy; secondary objectives were  
to determine the effect of other gi resections on sunitinib exposure.
Patients and Methods
Patient selection
A total of 635 patients were treated with sunitinib in 4 different phase i/ii, 
ii, or iii clinical trials that investigated the safety, efficacy, and/or pharma-
cokinetics of sunitinib in patients with gist [17-20]. Of these 635 patients,  
a total of 364 patients had pharmacokinetic (pk) samples available which 
were included in population pharmacokinetic analysis. Out of these 364 
patients (for sunitinib total number of samples = 3394 and for su12662  
total number of samples = 3410), a total of 305 patients had comprehen-
sive gi resection data available and were therefore eligible for the  
present analysis. 
Inclusion criteria in these trials were: a histopathologically confirmed 
diagnosis of metastatic or unresectable gist with progression on or toxic- 
ity of previous imatinib therapy; age > 18 years or between 20 to 75 years; 
adequate hematologic, renal, liver and cardiac function; an Eastern 
Cooperative Oncology Group (ecog) performance status of 0 or 1; willing-
ness and ability to comply with scheduled visits, treatment plans, labora-
tory test, and other study procedures.
Exclusion criteria in these trials were: current treatment in another 
clinical trial or ≤ 4 weeks prior to starting sunitinib, ≤ 2 weeks for imatinib 
therapy; non recovery from acute toxic effect of previous chemotherapy or 
imatinib; a history of known brain metastases; any serious co-morbidity; 
and pregnancy or breastfeeding.
All studies were done in accordance with Good Clinical Practice and 
under the ethical principles established by the Declaration of Helsinki. 
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common sarcoma  
of the gastrointestinal tract and highly resistant to conventional chemo-
therapy [1]. In 2001, imatinib was registered as first-line therapy for pa-
tients with primary unresectable and/or metastatic gist [2,3]. Thereafter  
in 2006, sunitinib was approved as second-line treatment for patients  
intolerant or refractory to imatinib therapy [4]. Recently, regorafenib  
was approved by the fda as third-line therapy for gist after failure of  
imatinib and sunitinib [5]. With the introduction of imatinib, sunitinib 
and regorafenib, survival of patients with metastatic gist has substantially 
improved [4-6].
Imatinib Ctrough levels and total sunitinib exposure have been report-
ed to correlate with treatment benefit in patients with gist [7,8]. However, 
gist patients often have an altered gi tract due to either resection of the 
primary tumor or subsequent surgery for recurrence and/or metastasis. 
Whether these alterations influence drug absorption and thus exposure 
and clinical outcome of treatment, depends on the physicochemical  
properties of the oral tyrosine kinase inhibitor given (Table 1). 
A cross-sectional study in gist patients treated with imatinib revealed 
that Ctrough levels were significantly lower in patients that previously had  
a major gastrectomy compared to patients without gastric surgery [9]. 
Comparable results, relating decreased plasma exposures with prior  
major gastrectomy, were seen for gist patients treated with nilotinib  
[10]. Since the solubility of imatinib and nilotinib rapidly declines above 
pH 5.5 and 4.5 respectively, it is suggested that in gastrectomized patients 
a decreased acid secretion may contribute to a decreased solubility and 
thereby decreased absorption of both TKIs [9-12]. Each segment of the gas-
trointestinal tract has its own characteristic pH level; acidity declines over 
the gi tract from the stomach (pH 1-3) to the small intestine (pH 5-7) and 
the colon (pH 7-8) [13,14]. For imatinib and nilotinib solubility and ab-
sorption therefore rapidly decreases after the stomach [15]. This is further 




Abbreviation: BCS, Biopharmaceutics Classification System; MW, molecular weight.
MW (g/mol)Drug
Table 1 Physicochemical properties of imatinib, nilotinib and sunitinib







Freely soluble (100-1000 mg/mL) up to pH 5.5. Solubility 
declines at higher pH; lowest solubility is 1 mg/mL. 
Slightly soluble (1-10 mg/mL) at pH 1.0, very slightly soluble 
(0.1-1 mg/mL) in water, at pH 3.0. Practically insoluble (< 0.1 
mg/mL) in buffer solutions of pH ≥ 4.5









All quantifiable plasma samples were included to develop  
population pk models for sunitinib and su12662 using Nonlinear Mixed 
Effect Modeling software (nonmem; version 7.1.2), following exclusion  
of plasma samples with inadequate dosing records and those identified  
to be extreme outliers (eg, 6 < Conditional Weighted Residual (cwres)  
< −6). Sunitinib data were best described by a two-compartment model 
with first-order order absorption with a lag time and first-order elimina-
tion. Similarly, su12662 data were best described by a two-compartment 
model with first-order formation without lag time and first-order 
elimination.
Patients were subdivided into 6 subgroups according to their previous  
gi surgery: 1) Major gastrectomy (defined as total or subtotal gastrecto-
my), 2) Partial gastrectomy, 3) Small bowel resection, 4) Both gastrectomy 
(either partial or (sub)total) and small bowel resection, 5) Colon resection, 
and 6) Controls with no prior surgery. Patients with uncertain or unclear 
defined gi resections (n = 59) were excluded from analysis.
Following population pk analyses, the individual post-hoc estimates 
for CI/F of sunitinib and su12662 were used to calculate steady-state total 
plasma exposures (AUC0-24) of sunitinib and su12662 at 50 mg of sunitinib 
for each individual patient, by dividing the dose (i.e., 50 mg) by individual 
patient post-hoc CI/F estimate. Thereafter, an analysis of covariance  
(ancova) on log transformed data was performed to test for significant 
differences in AUC0-24 and CI/F of both sunitinib and su12662 between 
each surgical subgroup and control. Covariates previously identified by 
Houk et al. which were initially included in the ancova model were sex 
and race for sunitinib CI/F, and sex, race, body weight and ecog perfor-
mance status for su12662 CI/F [22]. Within the ancova models, Multiple 
Comparisons with Control (i.e., mcc) using Dunnett’s test were performed 
and significant increases in CI/F and decreases in AUC0-24 were identified. 
For sunitinib and su12662 CI/F the difference was considered statistically 
significant (P ≤ 0.05), if the 95% lower bound for the difference from con-
trols on the log scale did not include zero. Conversely, for sunitinib and 
su12662 AUC0-24, if the 95% upper bound for the difference from the con-
trol, on the log scale, did not include zero, the difference was considered 
statistically significant (P ≤ 0.05). Subsequently, previously identified  
covariates which were not statistically significant (P > 0.05) within the  
ancova model were later removed from the ancova models for sunitinib 
and su12662. The number of observation for each individual was added  
as an additional covariate to the ancova models to make sure it did not 
affect the final ancova models overall results and conclusions. All statis- 
tical analyses were performed using S-Plus Version 8.0 (TIBCO Software 
Inc., Palo Alto, USA). The population pharmacokinetic and statistical  
analysis on the existing dataset was done by Pfizer Inc. Independent  
Each protocol was reviewed and approved by the Institutional  
Review Board and informed consent was obtained from each patient.  
The sub-analysis on the existing dataset of Pfizer was requested by the 
non-Pfizer affiliated authors of this manuscript and was reviewed and 
granted by Pfizer.
Sunitinib pharmacokinetic data collection and statistical analysis
Patients were treated with sunitinib in doses ranging from 25 mg to  
75 mg once daily on 4/2 (4 weeks on treatment followed by 2 weeks off 
treatment), 2/1 (2 weeks on treatment followed by 1 week off treatment), 
2/2 (2 weeks on treatment followed by 2 weeks off treatment) or cdd  
(continuous daily dosing) schedules. Blood samples for pharmacokinetic 
assessment of sunitinib and its active metabolite su12662 were collected 
pre-dose or post-dose on different days with details provided in Table 2. 
Blood samples were collected in edta tubes and shortly after collection 
centrifuged at 4 °C for 10 minutes at 3500 rpm. Plasma samples were sep- 
arated and stored at -20 °C or lower until shipped. Shipment of samples 
was on dry ice to Bioanalytical Systems Inc (West Lafayette, IN) where they 
were stored at -20 °C or lower until assayed within the established stability 
window. For quantification a validated, sensitive and specific isocratic liq-
uid chromatographic tandem mass spectrometric (lc-ms/ms) method in 
positive ionization mode was used [21].
Abbreviations: 2/1, 2 weeks on treatment followed by 1 week off treatment; 2/2/, 2 weeks on treatment followed by 2 weeks off treatment;  
4/2, 4 weeks on treatment followed by 1 week off treatment; CDD, continuous daily dosing; PK, pharmacokinetics.





Table 2 Summary of characteristics of studies used for analyses
na
Dosing 















2/2: 25, 50, 75 mg
4/2: 50 mg
4/2: 50 mg
4/2: 25, 50, 75 mg
CDD: 37.5 mg
Days 1, 14, 28 (only 4/2) of 
Cycles 1, 2, and 3 (optional) 
Day 1 of Cycles 4, 5 (optional), 
and 6
Days 1, 14, and 28 of Cycle 1; 
Days 1 and 28 of Cycles 2 and 
beyond
Phase I: Days 1, 2, 7, 14, 21, and 
28 of Cycle 1
Phase II: Days 1, 14, and 28 of 
Cycles 1-4
Day 1 of each cycle
Pre-dose
On 1st day of Cycle 1 and on last 
day of Cycles 1 and 2: 0, 1, 4, 6, 
8, 10, 12, 24, and 48 hr post-
dose (10 and 12 hr optional) 
Pre-dose
Pre-dose
On Days 1 and 28 of Cycle 1 
(Phase I Only): 0, 1, 2, 4, 6, 8, 10, 
24 (Only Day 28) and 48 (Only 








reviewers, blinded to the pk and patient data and not related to  
Pfizer, subdivided the included patients into 6 groups according  
to their previous gi surgery.
Results
Patient characteristics
A total of 305 patients had both population pk parameter estimates and 
comprehensive gi resection data available and were therefore included  
in the descriptive statistics presented as well as in the analysis of covar- 
iance (ancova) models for sunitinib and su12662. Of these patients,  
45 underwent major gastrectomy (subgroup 1), 58 partial gastrectomy 
(subgroup 2), 118 small bowel resection (subgroup 3), 8 both gastrectomy 
and small bowel resection (subgroup 4) and 13 patients a colon resection 
(subgroup 5). Sixty-three patients served as controls and did not have any 
prior surgery (subgroup 6). Baseline characteristics including sex, age, 
bodyweight, ethnicity and ecog performing status are shown in Table 3 
per subgroup.
Effect of prior gastrointestinal surgery on sunitinib pharmacokinetics
Sunitinib and su12662 apparent clearance (CI/F) was not increased  
in patients that previously had a major gastrectomy. Consequently,  




Table 3 Patient characteristics for each past GI surgery subgroup
Partial 
gastrectomy  
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Age (years)* 
Bodyweight (kg)*






  ≤ 1
  ≥ 2
30 (66.7%)
15 (33.3%)
56 (36 - 77)







57 (28 - 79)







53 (23 - 81)
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68 (50 - 84)













the geometric mean of sunitinib and su12662 AUC0-24 were not decreased 
in patients with a major gastrectomy, compared to patients in the control 
subgroup for sunitinib (1171 ng·hr/mL versus 1177 ng·hr/mL; P > 0.05)  
and su12662 (520 ng·hr/mL versus 492 ng·hr/mL P > 0.05) (Table 4 and 
Figure 1).
A significant increase in apparent clearance (CI/F) of sunitinib and 
su12662 was seen in patients that had undergone both gastrectomy and 
small bowel resection relative to the controls. The geometric mean of  
CI/F for sunitinib and su12662 was increased by 26% and 39% in subgroup 
4, patients with both gastrectomy and small bowel resection, compared  
to those in the control subgroup for sunitinib (53.7 L/hr versus 42.5 L/hr; 
P ≤ 0.05) and for su12662 (29.7 L/hr versus 21.4 L/hr; P ≤ 0.05), respectively. 
No statistically significant (P > 0.05) increases in apparent clearance for 
each of the other subgroups from controls were observed (Table 4 and 
Figure 1).
Consequently, a decreased total plasma exposure (AUC0-24) to suniti- 
nib and su12662 was seen in patients that had undergone both gastrecto-
my and small bowel resection. The geometric mean of total plasma  
exposure (AUC0-24) to sunitinib and su12662 was 21% and 28% lower in sub-
group 4, patients that underwent both gastrectomy and small bowel resec-
tion, compared to those in the control subgroup sunitinib (931 ng·hr/mL 
versus 1177 ng·hr/mL; P ≤ 0.05) and for su12662 (354 ng·hr/mL versus 492 
Abbreviations: AUC0-24, Area Under the Concentration-time curve from time zero to 24 hours post-dose at steady state; Cl/F, apparent clearance;  
PK, pharmacokinetic. Data are presented as geometric mean (95% CI) unless stated otherwise. * Significantly different compared to controls (p<0.05). 
Parameter Past GI Surgery Subgroup 














(n = 8 )
Colon resection 
(n = 13) 
Controls  
(n = 63)





  AUC0-24  
(ng·hr/mL)
  Cl/F (L/hr)
SU12662
  AUC0-24  
(ng·hr/mL)
  Cl/F (L/hr)
7 (1 - 32)
1171 (1099 - 1248)
42.7 (40.1 - 45.5)
520 (474 - 571)
20.2 (18.4 - 22.1)
9 (1 - 38)
1294 (1228 - 1365)
38.6 (36.6 - 40.7)
567 (522 - 617)
18.5 (17.0 - 20.1)
7 (1 - 35)
1194 (1141 - 1250)
41.9 (40.0 - 43.8)
492 (458 - 529)
21.4 (19.9 - 23.0)
10 (2 - 35)
931 (676 - 1283)*
53.7 ( 39.0 - 74.0)*
354 (174 - 720)*
29.7 (14.6 - 60.4)*
13 (2 - 30)
1325 (1109 - 1583)
37.7 (31.6 - 45.1)
597 (457 - 779)
17.6 (13.5 - 23.0)
7 (1 - 37)
1177 (1097 - 1263)
42.5 (39.6 - 45.6)
492 (435 - 555)




This study shows that major gastrectomy did not affect sunitinib or 
su12662 plasma exposures in patients with gist. This is in contrast to  
prior data regarding the impact of gastrectomy on both imatinib and 
nilotinib exposure [9,10]. Sunitinib and su12662 exposures were however 
significantly decreased in patients who had previously undergone both 
gastrectomy and small bowel resection, although this observation was  
in a small subgroup of patients. All other types of gi resections studied, 
showed no impact on sunitinib or su12662 pharmacokinetics.
The results from this study support our hypothesis that the influence 
of gi resections on tki exposure depends on two variables: the specific 
physicochemical properties of the tki given and the part of the gi tract 
that has undergone resection. So although most TKIs exhibit pH-depend-
ent solubility, small differences in their physicochemical properties  
(e.g. declined solubility in pH conditions higher than pH 5.5 for imatinib 
versus 6.8 for sunitinib) may cause great differences in the impact of gas-
trectomy on their gi solubility and absorption. In addition, the absorption 
characteristics of a drug under normal conditions [i.e. whether it is  
absorbed throughout the gi tract (e.g. sunitinib) or whether it is mainly 
absorbed through the stomach and the upper part of the small intestine 
(e.g. imatinib)] may affect the extent to which site specific gi resections 
can decrease the gi availability (Fgut) and subsequently the bioavailability 
(F = Fgut·Fhepatic) of a drug. The finding that imatinib exposure is not af-
fected by the co-administration of the proton pump inhibitor omeprazole 
somewhat contradicts our hypothesis considering reduced solubility [23]. 
However, 40 mg omeprazole only increases the gastric pH to 4.6 which  
is still an adequate level for imatinib to freely dissolve [24]. Major gas- 
trectomy might result in a further rise in pH equally to that of the small 
intestines and this therefore could interfere with imatinib dissolution.
Currently, the approved and accepted first line treatment for gist  
is imatinib [11]. The stomach is the most common primary site for gist 
(~60%), and a proportion of these patients will therefore undergo major 
gastrectomy procedures prior to systemic imatinib therapy for metastasis 
[25]. Imatinib Ctrough levels in ~80% of the gastrectomized patients were 
reported to be below 1100 ng/mL which has been correlated to shorter 
progression free survival (pfs) [7,9]. In addition, increasing the imatinib 
dose might not result in an increased exposure due to the limited solubil- 
ity of imatinib in a patient with limited gastric physiology. By measuring 
plasma concentrations in patients with prior major gastrectomy, a de-
creased exposure to imatinib could be identified early in treatment,  
prior to development of clinical drug failure. Sunitinib is currently ap-
proved and accepted as the second line treatment for gist patients and 
also for sunitinib a relationship between systemic exposure and efficacy 
has been demonstrated before [8,16]. The results from this present study 
ng·hr/mL; P ≤ 0.05), respectively. No statistically significant (P > 0.05)  
decreases in total plasma exposures for each of the other subgroups  
compared to controls were observed (Table 4 and Figure 1).
Figure 1 Exposures in patients with different GI resections. A) Sunitinib exposure. B) SU12662 exposure.  
Major gastrectomy; 2 = Partial gastrectomy; 3 = Small bowel resection; 4 = Combined gastrectomy  
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show that sunitinib exposure is, in contrast to the results for imatinib,  
not decreased in gastrectomized patients. These findings should be taken 
into account for the treatment of gastrectomized gist patients with TKIs. 
Hypothetically, gastrectomized patients have less and/or shorter treat-
ment benefit from first-line imatinib therapy due to decreased imatinib 
plasma levels. Yet, these patients theoretically have a high chance of  
treatment benefit from second line sunitinib therapy. However, further 
prospective research to investigate this hypothesis and whether there  
is a difference in clinical outcome between gastrectomized patients  
treated with imatinib or sunitinib is needed.
The results from this present analysis also show that patients who  
had undergone both gastrectomy and small bowel resection did have  
statistically significantly (P ≤ 0.05) lower sunitinib and su12662 exposures, 
which is an extension of prior data showing such effects of combined sur-
gery on plasma exposure of both imatinib and nilotinib [9,10]. An effect  
of both gastrectomy and small bowel resection on the exposure to all 
three studied TKIs and other drugs is not surprising, since resections of 
large portions of the gi tract will significantly reduce the absorption sur-
face available. Houk et al. showed that patients with gist and a sunitinib 
AUC0-24 > 600 ng·hr/mL had longer time to progression (ttp) and overall 
survival (os) [8]. The patients with a combined gastrectomy and small 
bowel resection in our study had an average sunitinib exposure of 931 
ng·hr/mL and none of the patients in this subgroup had a sunitinib  
exposure < 600 ng·hr/mL. So although patients with both a gastrecto- 
my and small bowel resection in this study had a statistically significant 
(P ≤ 0.05) decrease in sunitinib and su12662 exposure, this decrease does 
not appear to be clinically relevant.
Hypothetically, the extent of small bowel resection will be critical  
for the remaining absorption surface and whether and to what extent  
sunitinib exposure is affected or not. Unfortunately, the length of resected 
intestine was not registered in the database used for this retrospective study, 
which limits the ability to analyze this variable. Measuring plasma concen-
trations of sunitinib could be suggested in patients that underwent an  
unknown or very large resection of the gi tract to identify those patients 
that do have a clinically relevant decreased sunitinib exposure. In clinics 
where the measurement of sunitinib plasma concentration is not feasible, 
an alternative and practical approach could be to gradually increase the 
dose based on the individual patient safety and tolerability. The relatively 
small number of patients who underwent a combined gastrectomy and 
small bowel resection (n = 8) can be considered as a limitation of this 
present study. Therefore, the results in this subgroup of patients should  
be interpreted with caution and need to be verified in a larger group of 
patients with extended gi resections.
It is generally assumed that for most weakly basic drugs, the disso- 
lution process is often the rate-limiting step for absorption of these drugs 
from the gi tract. However, besides pH and physicochemical properties, 
there are other variables within the gi tract that determine the rate and 
extent of dissolution including the fluid volume available for dissolution 
that is added in the stomach, gastric motility and the maximum dose 
strength. Also the maximum dose strength is rather different between  
imatinib, nilotinib and sunitinib. Imatinib and nilotinib are dosed at  
400-800 mg a day compared to sunitinib which is dosed at 25-50 mg  
a day. This could be an additional explanation why sunitinib exposure  
is not influenced by gastrectomy whereas imatinib and nilotinib exposure 
are. Apparently, pH and dosage rather than fluid volume and gastric mo-
tility is of influence on the absorption of TKIs. An alternative pre-clinical 
explanation for the found differences is the removal due to gastrectomy  
of transporters that facilitate the gastric absorption of TKIs, whereby  
imatinib might depend more on this transporter for absorption than  
sunitinib does [26,27].
Conclusion
In conclusion, major gastrectomy alone does not influence exposure to  
sunitinib or its active metabolite su12662, which is contrary to previous 
results for imatinib and nilotinib. This should be taken into account for 
the treatment of gastrectomized gist patients with TKIs. Patients with  
a combined gastrectomy and small bowel resection had a statistically  
significantly, though clinically not relevant, decreased plasma exposure  
to sunitinib and su12662 which in theory might depend on the length  
of intestine resected.
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abstr act
Background Everolimus is a mTOR inhibitor used for the treatment  
of different solid malignancies. Many patients treated with the registered 
fixed 10 mg dose once daily are in need of dose interruptions, reductions 
or treatment discontinuation due to severe adverse events. This study 
determined the correlation between systemic everolimus exposure and 
toxicity. Additionally, the effect of different covariates on everolimus 
pharmacokinetics (pk) was explored.
Patients and Methods Forty-two patients with advanced thyroid 
carcinoma were treated with 10 mg everolimus once daily. Serial 
pharmacokinetic sampling was performed on day 1 and 15 of treatment. 
Subsequently, a population pk model was developed using nonmem  
to estimate individual pk values which were used for the assessment  
of an exposure-toxicity relationship. In addition, the population pk  
model was used to investigate the influence of patient characteristics  
and genetic polymorphisms in genes coding for abcb1, cyp3a, cyp2c8  
and pxr on everolimus pk.
Results Forty patients were evaluable for pk analysis. Patients who 
required a dose reduction (n = 18) due to toxicity at any time during 
treatment had significant higher everolimus exposures (mean  
AUC0-24 (sd) 600 (274) vs. 395 (129) µg·hr/L, P = 0.008) than patients 
without a dose reduction (n = 22). A significant association between 
everolimus exposure and stomatitis was found in the four-level order 
logistic regression analysis (P = 0.047). The presence of at least one  
ttt haplotype in the abcb1 gene was associated with a 21% decrease  
in everolimus exposure.
Conclusion The current study showed that dose reductions  
and everolimus induced stomatitis were strongly associated  
with systemic everolimus drug exposure in patients with cancer.
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Forty-two patients were enrolled in this phase ii study investigating  
the efficacy and pharmacokinetics of everolimus for the treatment  
of progressive or recurrent, unresectable or metastatic thyroid cancer.  
The efficacy data of this study will be reported separately. Participating 
medical centers were the Leiden University Medical Center and the 
University Medical Center Groningen. Patients were treated continuously 
with everolimus at an once daily oral dose of 10 mg until tumor progres-
sion, unacceptable toxicity, death or discontinuation from the study for 
other reasons. Toxicities were assessed at baseline, day 1, 14 and 28 of ther-
apy and monthly thereafter according to the National Cancer Institute 
(nci) Common Terminology Criteria for Adverse Events (ctc-ae) version 
4.0. Dose adjustments were permitted for adverse events suspected to be 
related to everolimus. The first dose reduction was to 5 mg once daily.  
If another dose reduction was needed, everolimus was dosed as 5 mg  
every other day. The study was approved by the institutional ethics com-
mittees (Leiden University Medical Center and University Medical Center 
Groningen, The Netherlands) and all patients gave written informed  
consent before entering the study.
Pharmacokinetic sample collection and analysis
For everolimus pk assessment, whole blood samples were obtained  
at day 1 and 15 of therapy. Samples were collected into edta-tubes at  
pre-dose and 1, 2, and 3 hours after everolimus intake (sparse schedule). 
More extensive pk sampling at 4, 5, 6, 7 and 8 hours after everolimus  
intake was optional for patients (extensive schedule). Samples were  
stored at -20 °C until the day of analysis.
Everolimus concentrations in whole blood were measured using  
a validated Ultra Performance Liquid Chromatography - Tandem Mass 
Spectrometric (uplc-ms/ms) assay. Validation of the assay was performed 
according to the ema guidelines of bioanalytical method development [9]. 
The calibration line was linear over the range from 2 to 160 µg/L and the 
lower limit of quantification (lloq) was 0.6 µg/L. Assay performance was 
in agreement with guidelines for bioanalytical method development  
and validation.
Introduction
Everolimus is an orally administered rapamycin derivative inhibiting  
the mammalian target of rapamycin (mTOR) [1]. This is a key signaling 
molecule in the phosphatidylinositol 3-kinase (pi3k)/Akt pathway which 
is involved in the regulation of growth, proliferation, metabolism, survival 
and angiogenesis of cells and often dysregulated in cancer [1]. Currently, 
everolimus is registered for the treatment of advanced hormone receptor 
positive (hr+), human epidermal growth factor-2 negative (her2-) breast 
cancer in postmenopausal women in combination with exemestane,  
for metastatic renal cell carcinoma (mRCC), for irresectable or metastatic 
pancreatic neuroendocrine tumors (pNET) and subependymal giant cell 
astrocytoma (sega) [2-4].
Despite its proven efficacy, everolimus is also associated with a num-
ber of serious side effects. Most common toxicities associated with everoli-
mus therapy include stomatitis, rash, fatigue, diarrhea, infections, nausea, 
loss of appetite, hematologic toxicities, dyspnea, noninfectious pneumo-
nitis and metabolic abnormalities such as hypercholesterolemia and  
-glycaemia [5]. While it is reported that the majority of these adverse 
events are manageable and of mild to moderate severity, many patients 
are in need of dose interruptions, reductions or treatment discontinua-
tion due to toxicity [6]. Indeed, in the pivotal breast cancer, mRCC and 
pNET phase iii trials, 10 to 35% of the patients discontinued everolimus 
treatment due to adverse events [2-4]. In addition, ~62% of the patients 
needed dose interruptions or reductions compared to 12-29% in the  
placebo arms [2, 4].
The large number of dose reductions and treatment discontinua- 
tion make toxicity currently one of the main challenges in the optimal  
use of everolimus for the treatment of cancer. In oncology, everolimus  
is registered as a fixed oral dose of 10 mg once daily. However, in trans-
plantation medicine therapeutic drug monitoring (tdm) with individual-
ized dosing is routinely applied due to everolimus’ narrow therapeutic 
window and high inter-patient variability in pharmacokinetics (pk) [7].  
In transplantation medicine, everolimus is used as an immunosuppres-
sant to prevent rejections. Dose individualization is not only applied  
to prevent toxicity, but also to optimize treatment efficacy. In oncology,  
the same high inter-patient variability in pk is seen (auc; 45 cv%, Ctrough; 
60 cv%) [8]. This substantial variability, in combination with the fixed  
10 mg dosing, results in large differences in everolimus exposure between 
patients. This could result in either supra-therapeutic drug exposure with 
an increased incidence of toxicity, but also in sub-therapeutic drug expo-
sure leading to decreased anticancer effects. 
The primary objective of this study was to assess the correlation  
between everolimus exposure and toxicity in patients with advanced  
thyroid cancer. Additionally, we explored the influence of different  
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were explored. It was also assessed whether there was a change in  
clearance from day 1 to day 15 of treatment. Model selection was based  
on goodness of fit and statistical significance. An adjusted model was  
chosen over the original model if the drop in the objective function  
value (ofv) was > 3.84 (P < 0.05 with one degree of freedom (df),  
assuming χ2-distribution).
Since the bioavailability (F) of everolimus is unknown, F was fixed  
at 1 and pk parameter estimates reported are proportional to F except Ka. 
In addition, both clearance (CI/F) and the volume of distribution (Vd/F) 
were allometrically scaled [12]. 
Covariate analysis
After the base model was determined, covariates were tested to explore 
the influence of bilirubin, aspartate aminotransferase (asat), alanine ami-
notransferase (alat), creatinine, body surface area (bsa) and haematocrit 
on CI/F. Individual effect sizes were estimated with the formula Cl/Ftypical 
value = θ1 * (COV/COVmedian)θ2, whereby θ1 is the population estimate for 
CI/F, cov the tested covariate and θ2 the covariant effect size estimate. 
The influence of SNPs and haplotypes were all tested as a covariate  
on CI/F, except for abcb1 haplotypes which were tested for an effect on F  
as this is physiologically more plausible. Effect sizes were estimated with 
the formula Cl/Ftypical value (or F) = θ1 * θ2^pg1 * θ3^pg2, whereby θ1 is the pop-
ulation CI/F or F estimate in wild-type patients, θ2 the covariate effect size 
of the heterozygote mutation status and θ3 the effect size of the homozy-
gote mutation status. The heterozygote (pg1) and homozygote (pg2) mu-
tation status was scored as 1 if present or 0 if not present. If the genotype 
frequency was < 0.1, homozygote mutant and heterozygote mutant  
genotypes were combined (Supplementary Data S1 and S2)
All covariates were first tested for statistical significance with univariate 
forward inclusion into the base model (drop in ofv > 3.84, df = 1, P < 0.05). 
After inclusion of significant covariates in the intermediate model, a step-
wise backward elimination procedure was performed. Covariates were  
remained in the final model if the threshold for statistical significance of 
backward elimination was reached (increase in ofv > 6.64, df = 1, P < 0.01). 
Evaluation of model fit
Next to goodness of fit plots, a visual predictive check (vpc) was used to 
assess the performance of the final model by comparing the 10th and 90th 
percentiles of the simulated concentrations with those of the observed 
concentrations. In addition, a bootstrap analysis was performed to evalu-
ate the precision of parameter estimation. Shrinkage in inter-individual 
variability and residual errors were automatically calculated by nonmem.
Pharmacogenetic analysis
Single Nucleotide Polymorphisms and haplotype selection
Everolimus is metabolized by the cytochrome P450 (cyp) enzymes  
cyp3a4, cyp3a5 and cyp2c8 and is also a substrate for the efflux pump 
P-glycoprotein (P-gp) encoded by the abcb1 gene [10]. The nuclear preg-
nane X receptor (pxr; nr1i2) regulates the expression of cyp3a4 and could 
therefore also influence everolimus pk [11]. Eleven single nucleotide poly-
morphisms (SNPs) in these genes were selected based upon a candidate 
gene approach (Supplementary Data S1). For the abcb1 and cyp2c8 gene, 
selected SNPs were used for haplotype analysis performed in gPLINK 
(Supplementary Data S2). Haplotypes were set at a certainty greater than 
0.97. For the abcb1 and cyp2c8 gene, only haplotypes and no individual 
SNPs were tested. 
Genotyping assays
Germline DNA was isolated from 400 µl edta-blood using MagNa Pure 
Compact (Roche, Almere, the Netherlands). DNA concentrations were 
thereafter measured using Nanodrop (Isogen, De Meern, The 
Netherlands). Genotyping was performed using pre-designed genotyping 
assays (Supplementary Data S1, online). Samples were analyzed on a Viia7 
real-time PCR system according to the manufacturers’ instruction (Life 
Technologies, Bleiswijk, The Netherlands). Call rates of all assays were 
>98%. As a quality control, at least 5% of the samples were genotyped  
in duplicate. No inconsistencies were observed. Minor allele frequencies 
(maf) of all 11 SNPs were calculated and compared with reported maf for 
European Populations (hapmap). No significant deviations were observed 
and derived allele frequencies were all in Hardy-Weinberg equilibrium 
(P ≥ 0.05) (Supplementary Data S1).
Pharmacokinetic modelling
Base model
Thirty patients completed the extensive pk sampling and ten patients  
the sparse pk sampling schedule. After pk sampling, nonlinear mixed- 
effects modeling (nonmem) was used to describe the population pharma-
cokinetics of everolimus. Subsequently, the developed population pk mod-
el was used to estimate individual everolimus exposure. NONMEM version 
7.2 (Icon Development Solutions, Ellicott City, MD, USA) was used with 
Piranã (version 2.9.0) as the modelling environment. Statistical software 
package R (version 2.15.1) was used for handling of data and plots genera-
tion. We also used nonmem to explore the influence of different covariates 
on everolimus pk.
A first-order conditional estimation method with interaction  
(foce-i) was used to fit models throughout the building process.  




The difference in day 15 steady-state everolimus exposure (AUC0-24)  
between patients with and without dose reductions was tested with  
an unpaired t-test. The relationships between day 15 everolimus exposure 
and stomatitis and pneumonitis were evaluated using a four-level ordered 
logistic regression in spss version 20.0 (ibm). 
Results
Patient characteristics
Forty-two adult patients with thyroid carcinoma, 22 men and 20 women 
were included in the phase ii trial that investigated everolimus for the 
treatment of thyroid cancer. Of these patients, 28 (66.7%) had differenti- 
ated, 7 (16.7%) had undifferentiated (anaplastic) and 7 (16.7%) had medul-
lary advanced thyroid carcinoma. Two patients were excluded for pk analy- 
sis; in one patient no pk samples were collected, and in the other patient 
no measurable everolimus levels could be detected. Patient baseline char-
acteristics are shown in Table 1.
Pharmacokinetics 
A total of 669 samples from 40 patients were used to build the population 
pk model. The pharmacokinetic data for everolimus were best described 
by a two-compartmental model with first order absorption and first order 
elimination from the central compartment (Supplementary Data S3).  
No difference in clearance over time between day 1 and day 15 of treatment 
was found.
Forward inclusion of bsa, creatinine, asat, alat, bilirubin and  
haematocrit did not improve the pk model and no association between 
these covariates and clearance was found. With forward inclusion of the 
abcb1 ttt and ccg haplotype the base model significantly improved (ΔOFV 
= -7.2 and -6.4 respectively, P < 0.05). The other SNPs and the cyp2c8 haplo-
type did not improve the model. With multivariate backward elimination, 
only the presence of at least one abcb1 ttt haplotype remained significant 
(ΔOFV = 9.6, P < 0.01). A 21% decrease in F was observed in the presence of 
at least one abcb1 ttt haplotype. Inclusion of this covariate in the final pk 
model, reduced the inter-patient variability in CI/F from 38.1 to 35.1 cv%. 
Parameter estimates of the base and final model are shown in Table 2.
Evaluation of the final model was, next to inspection of the goodness 
of fit plots, done with vpc and a bootstrap procedure. Results of the vpc 
show that predicted and observed concentration intervals are almost 
identical, indicating accuracy and good predictive performance of the  
final model (Figure 1).
There is a small tendency for a difference between predicted and ob-
served concentrations in the absorption part of the curve due to limited 
Assessment of systemic exposure toxicity relationship
Selection of toxicities
In this study, all experienced toxicities were scored according to ctc-ae 
version 4.0. However, due to the number of patients included, only a  
limited number of toxicities were selected to be tested for an association 
with everolimus exposure in order to prevent false positive findings. 
We choose dose reductions as the first outcome of toxicity as this  
is the sum of all different toxicities experienced by patients and these  
are also the toxicities that lead to clinical action by the treating physician. 
In addition, we selected stomatitis and pneumonitis as toxicity outcomes. 
The rationale for selection of these toxicities was based on their preva-
lence and the fact that these toxicities are 1) objectively measurable, 2) 
clinically relevant and 3) untreatable and therefore leading to dose reduc-
tions or discontinuation of therapy. Toxicities were scored as the highest 
grade experienced until dose reduction and if no reduction occurred until 
the end of study.
Data are presented as median (range) unless stated otherwise. Abbreviations: ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, 
aspartate aminotransferase; WBC, white blood count
Characteristic









  WBC (× 109/L)
  ANC (× 109/L)
  Platelets (× 109/L)
  Hemoglobin (mmol/L)
  Haematocrit
Chemistry
  AST (U/L)
  ALT (U/L)
  Creatinine (µmol/L) 
  Total bilirubin (µmol/L)
Tumor type (n)
  Differentiated 
  Undifferentiated 
  Medullary 
40
63 (40 - 80)
21 (52.5%)
19 (47.5%)
173 (154 - 189)
75 (45 - 105)
7.1 (3.6 - 25)
4.8 (2.7 - 13.0)
254 (147 - 995)
7.5 (5.3 - 10.7)
0.39 (0.29 - 0.50)
22 (12 - 61)
22 (7 - 19)
66 (42 - 205)






number of samples during this phase. Since we mainly used the model  
to estimate individual values for CI/F, the modest under-prediction of the 
absorption did not affect our analysis. The successful bootstrap procedure 
with 1000 runs is shown in Table 2. The median values for pk parameters 
found were within 10% of those estimated with the final model indicating 
that the model is precise and reliable in its parameter estimation.
Exposure-toxicity relationship
The relationships between everolimus exposure and dose reductions  
as well as stomatitis and pneumonitis were examined. In total, 45% of the 
patients had their everolimus 10 mg dose reduced to a lower dose due to 
toxicity (Table 3). Toxicities leading to dose reduction included stomatitis, 
pneumonitis, fatigue, loss of appetite, diarrhea, liver and kidney toxicity 
and oedema. Considering stomatitis, 42.5% of the patients experienced 
any grade stomatitis and 7.5% experienced grade 3 stomatitis. In addition, 
10% had a non-infectious pneumonitis. 
Figure 2 shows boxplots of everolimus exposures in patients with  
and without dose reduction. Mean AUC0-24(sd) were 600(274) and 395(129) 


















Table 2 Summary of model parameter estimates
Base model
Estimate EstimateRSE (%) RSE (%)Shrinkage (%) Shrinkage (%) Median value 95%-CI
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Figure 1 Visual predictive check (VPC) of final everolimus PK model











































posure to everolimus was significantly different between the two groups 
(mean difference 204 µg·hr/L (95%-ci; -340 to -69 µg·hr/L, P = 0.008). 
Figure 3 shows boxplots of AUCs in patients experiencing different grades 
of stomatitis. A positive association between everolimus exposure and sto-
matitis was identified (P = 0.047). The odd ratio for stomatitis was 1.16 
(95%-ci; 1.06 to 1.26) for every 50 µg·hr/L increase in AUC0-24. Patients with 
grade 3 stomatitis had an everolimus exposure that was two times that of 
patients with ≤ 2 stomatitis (896 vs. 456 µg·hr/L, P > 0.05). No association 
of everolimus exposure with pneumonitis was found.
Discussion
This study was primarily performed to assess the correlation between 
everolimus exposure and toxicity. Results show that patients who had 
their everolimus dose reduced due to toxicity, had significantly higher 
drug exposures than patients without the need for dose reductions. 
Moreover, everolimus exposure was associated with the probability  
for stomatitis and patients with grade 3 stomatitis had an everolimus  
exposure two times that of patients with ≤ 2 stomatitis. Additionally,  
we found that the presence of at least one ttt allele in the abcb1 gene was 
associated with lower everolimus exposure due to decreased absorption. 
A clear relationship between everolimus exposure and toxicity was  
established in the present analysis. These findings are in line with results 


















































No stomatitisno dose reduction Grade 1 Grade 2 Grade 3dose reduction
Figure 2 Boxplot of everolimus exposure in patient with and without dose reduction Figure 3 Boxplot of CTC-AE v 4.0 severity of stomatitis versus everolimus exposure.  
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Previously, it has been shown that a 2-fold increase in everolimus exposure 
increased the risk of ≥ grade 3 pulmonary events, ≥ grade 3 stomatitis and 
≥ grade 3 metabolic events with 1.9, 1.5 and 1.3-fold respectively in patients 
with advanced solid tumors [13]. The present analysis could not confirm 
the earlier identified association of everolimus exposure with pneumo- 
nitis, but this may be due to the limited number of patients with pneu- 
monitis in our study cohort. 
The present study underscores the high inter-patient variability in 
everolimus pk which is in line with previous observations [8]. This is also 
analogue to the variability in pk seen for other oral targeted therapies  
for the treatment of cancer such as tyrosine kinase inhibitors (TKIs). For 
TKIs the evidence for relationships between systemic drug exposure and 
efficacy or toxicity endpoints is growing [14, 15]. The currently available 
data suggest that an individualized dosing approach seems justified  
in certain circumstances and different studies support the feasibility  
of an individualized dosing approach for TKIs [16, 17]. 
In the exploration of covariates of influence on everolimus pk,  
the presence of at least one ttt haplotype was responsible for a decrease  
in everolimus exposure due to decreased absorption. Previously, the ttt 
haplotype has been demonstrated to be associated with enhanced function 
of the P-glycoprotein transporter and indeed reduced exposure or efficacy 
of treatment [18-20]. However, decreased function of the transporter and 
thus increased exposure have also been reported, as well as studies that 
could not show an effect [7, 21, 22]. The association we found should be  
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regarded as preliminary and needs further validation. If this association  
is confirmed, it might be argued whether a decrease in exposure of 21% 
can be considered as clinically relevant when taking into account the  
inter-patient variability in everolimus pk. 
To the best of our knowledge, we are the first to describe the popu- 
lation pharmacokinetics of everolimus 10 mg once daily in patient with 
cancer. Previously, population pk models have been described, but only 
within the field of transplantation medicine where everolimus is used in  
a much lower dose. Taking this and differences in modeling into account, 
pharmacokinetic parameter estimates were in agreement with those  
previously found [7]. 
Everolimus exposures were assessed at day 1 and 15 of therapy and  
not necessarily at the time when adverse events occurred. This may be  
considered as a limitation and future studies should preferably measure 
everolimus exposure at the time that toxicity occurs. However, the varia-
bility in everolimus pk within a patient (intra-patient) is reported to be 
much smaller than the variability between patients [23, 24]. In addition, 
we observed a constant clearance of everolimus over time. While treated 
at the same dose (10 mg once daily), this restricts the probability for large 
differences between the exposures that we have measured and the actual 
exposures that would have been measured at the moment that toxicity  
occurred. In addition, the study that previously described a correlation  
between everolimus exposure and toxicity, found similar results with  
the use of Ctrough at the time of toxicity or when Ctrough averaged over a 
given time period was used [13]. 
The present results both underscore the correlation between everoli-
mus exposure and toxicity as well as the high inter-patient variability  
in everolimus pk. These observations should be taken into account in the 
use of everolimus for the treatment of solid tumors. Preventing high drug 
exposures by dose individualization may have the potential to reduce the 
side effects of everolimus therapy while remaining its efficacy. However, 
prospective validation within oncology patients in necessary. Moreover,  
it has been shown that high early everolimus exposure (Ctrough >14.1 µg/L) 
is associated with longer progression free survival (pfs) and overall sur- 
vival (os) (13.3 and 26.2 months vs. 3.9 and 9.9 months for pfs and os  
respectively) in patients with mRCC [25]. Hence, an individualized dosing 
approach may also be of value for some patients with treatment inefficacy 
due to subtherapeutic exposures. On the other hand, in this present analy-
sis there were also patients in need of dose reductions in whom the expo-
sure to everolimus was not elevated. This finding suggest that a 
subpopulation may not benefit from dose individualization but maybe 
more from treatment switch if available. In summary, future studies are 
required to define the therapeutic window of everolimus for the treat-
ment of different malignancies and these studies should aim to optimize 
both treatment toxicity as well as efficacy outcomes possibly by using 
everolimus in a more individualized way. 
Conclusion
In conclusion, this study shows a clear association between everolimus  
exposure and toxicity in patients with cancer using a newly developed 
population pk model. Our findings confirm observations from another 
study in patients with cancer and show us that everolimus is a good  
candidate for individualized dosing in patients with cancer.
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Supplementary data 3 Schematic presentation of PK model
























* custom designed assay: PCR primers, forward: 5’-GTATTGGATTGGAGCCCAGGTATTT-3’, reverse: 5’-TGTTTCTCCATCATCACAGCACAT-3’; probes, 
VIC: AAGTCCCTGGTTGTTCCA, FAM: TCCCTGGTTTTTCCA
Gene
Supplementary data 1 Selected polymorphisms in genes involved in the absorption and metabolism  
of everolimus





























































































































Supplementary data 2 Selected haploblocks in genes involved in the absorption and metabolism of everolimus


















































The aim of this thesis was to investigate and develop dose opti- 
mization strategies of targeted therapies used in oncology, in particular 
for the TKIs pazopanib and sunitinib and the mTOR inhibitor everolimus. 
Measurement of drug exposure
One of the goals of this thesis was to develop strategies to easily measure 
drug exposure. Both for the purposes of clinical research and for clinical 
practice, accurate and specific bioanalytical methods are necessary in  
order to retrieve reliable and comparable results. In the literature, differ-
ent assays including liquid chromatography-tandem mass spectrometric 
(lc-ms/ms) and high pressure liquid chromatography -ultraviolet (hplc-
uv) assays have been described for the single quantification of most TKIs 
as well as everolimus [1-14]. However, for clinical practice it is more efficient 
to have a bioanalytical method that can quantify various TKIs within one 
run. We have successfully developed a sensitive lc-ms/ms method for the 
simultaneous determination of six TKIs (pazopanib, sunitinib, imatinib, 
nilotinib, dasatinib and regorafenib) and two active metabolites 
(N-desmethyl imatinib and N-desethyl sunitinib) in human serum or  
plasma as described in chapter 3. This multi-tki bioanalytical assay was 
successfully validated according to fda guidelines. In comparison with  
the existing assays that determine multiple TKIs, we were the first to in- 
corporate pazopanib and regorafenib [15-23]. This assay has been used  
for the clinical pharmacokinetic studies with pazopanib and sunitinib 
that are described in chapter 5 and chapter 6 of this thesis, respectively. 
In addition, this method is used in routine patient care to monitor and  
individualize the treatment with certain TKIs.
Monitoring of drug levels in serum or plasma makes sampling by vena-
puncture necessary. Sampling by dried blood spot (dbs) may be a more 
patient friendly alternative that can be performed at home. In chapter 4 
we studied the feasibility of dbs sampling to monitor pazopanib therapy. 
Thus far, the measurements of imatinib, nilotinib, dasatinib and dabrafenib 
in dbs have been described [24, 25]. However, focus of these studies was  
on assay development and validation, whereas our study focused on the 
next step towards clinical application; the agreement between pazopanib 
levels measured in plasma and calculated plasma concentrations from the 
corresponding dbs card. Results showed that these concentrations were in 
good agreement with each other and thus show the feasibility of measuring 
pazopanib concentrations on dbs cards in a clinical setting. Since dbs 
cards were prepared by the research nurse, validation of dbs cards pre-
pared by patients remains necessary. However, we do not expected major 
problems as previously dbs samples prepared by patients have shown to 
be suitable for analysis [26, 27]. With the ease and convenience of sample 
Introduction
More and more progress is being made in the unraveling of cancer patho-
physiology. With this increased understanding, a whole new era of ration-
ally designed oral targeted therapies has been developed over the last one 
and a half decade. Both tyrosine kinase inhibitors (TKIs) and mammalian 
target of rapamycin (mTOR) inhibitors block the growth of cancer by in-
terfering with specific target molecules involved in the growth, activation 
and differentiation of cancer cells. Therefore, they act more specific when 
compared to conventional therapies.
It is important to continue the development of innovative targeted 
therapies for the treatment of cancer. However, we should also try to opti-
mize the treatment options that are currently available. Especially, since 
not all patients have the same beneficial treatment outcomes in term  
of efficacy when given the same therapy. Moreover, it was expected that 
(oral) targeted therapies would be less toxic than conventional chemo-
therapy due to their selective mode of action. However, still a significant 
number of patients experience, sometimes severe, adverse events leading 
to dose interruption and -reductions and even non-compliance or treat-
ment discontinuation. 
For many TKIs as well as everolimus, correlations between drug  
exposure and treatment outcome have been described, and the evidence 
for such relationships is gradually growing. This, in combination with 
their fixed dosing and reported high inter-patient variability in pharma-
cokinetics, has raised the hypothesis that dose optimization of these drugs 
may lead to better treatment outcomes both in terms of more efficacy  
and less toxicity. 
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sure. Yet, prospective studies that show an effect on clinical outcome  
in terms of overall survival (os) and progression free survival (pfs)  
are needed. 
Next to tdm, another approach for dose optimization is the use of a non-
invasive phenotyping probe in order to predict drug exposure before the 
start of therapy. In Chapter 6 the feasibility of midazolam as a phenotyp-
ing probe for cyp3a4 activity to predict sunitinib exposure is described. 
The results of this study show that midazolam exposure was highly cor- 
related with sunitinib exposure. This suggests that midazolam could  
be useful in clinical practice to identify those patients that are at risk  
for under- respectively overtreatment at the standard sunitinib dosage 
regimen. However, the suitability of an individualized dosing strategy  
for sunitinib based on phenotyping by midazolam would require pro- 
spective validation. 
Explaining Inter-Patient Variability
The third goal of this thesis was to gain more knowledge of the under- 
lying causes of the inter-patient variability in dug exposure of oral target-
ed therapies. The results of our phenotyping study suggest that half of the 
observed inter-patient variability in sunitinib pk can be explained by  
differences in cyp3a4 activity which is much more than earlier identified 
covariates [32, 33]. Phenotyping with midazolam possibly explains such  
a large percentage of the inter-patient variability in sunitinib pharmaco- 
kinetics because it represents the influence of both genetic differences  
as well as environmental covariates. 
Patients with gist often have an altered anatomy of the gastrointestinal 
tract due to either resection of the primary tumor or subsequent surgery 
for recurrence and/or metastasis. Previous research has shown that imati-
nib and nilotinib Ctrough levels were significantly lower in patients that 
previously had a major gastrectomy compared to patients without gastric 
surgery [34]. The suggested cause for this decreased exposure is the lack  
of gastric acid secretion in combination with poor solubility of imatinib 
and nilotinib at a pH above 5.5 and 4.5, respectively. Due to small differences 
in physicochemical properties, we hypothesized that a major gastrectomy 
would not have an influence on sunitinib exposure. 
Indeed, as described in chapter 7, major gastrectomy alone did not 
influence the exposure to sunitinib or its active metabolite su12662. We 
also found that patients with a combined gastrectomy and small bowel 
resection did have a statistically significantly decreased plasma exposure 
to sunitinib and its active metabolite. However, this observation was  
considered as clinically non relevant since exposures were still above  
collection, dbs could be very useful to measure drug exposure in patients 
that are treated with pazopanib in an at home setting. If monitoring  
and dose optimization of oral targeted therapies is becoming more  
widespread, dbs will potentially also be of use for the measurement of 
other oral anticancer drugs that are mainly used in an at home setting.
Dose Optimization Strategies
A second goal of this thesis was to investigate the feasibility of dose  
optimization strategies for oral targeted therapies. The use of therapeutic 
drug monitoring (tdm) is one of such strategies. In chapter 5 we investigat-
ed the feasibility of tdm to reduce the inter-patient variability in pazopanib 
exposure. The previously unreported high intra-patient variability in pk 
was the main reason why this study could not show the feasibility of tdm 
to reduce the inter-patient variability in exposure. Pazopanib intake was 
standardized to the advised use of pazopanib; 1 hour before or 2 hours  
after the intake of food as stated in the drug label. However, in the food 
interaction study that showed a 2-fold increase in exposure when pazo-
panib was administered with food, fasted was defined as no food intake 
for at least 8 hours [29]. Hence, the time interval of no food in our study 
was possibly insufficient to prevent an effect of food on pazopanib absorp-
tion. In addition, we did not standardize diet composition. A main lesson 
learned from this study is that, when there is an interaction of a particular 
drug with food (which is present for several TKIs), one should always keep 
in mind the interval of no food consumption and also try to standardize 
the composition of meals taken by patients. This is support by the prelim- 
inary results from two ongoing studies (nct02138526 and nct01995981)  
in which a much smaller intra-patient variability is found, most likely as  
a consequence of standardization of pazopanib intake in relation to food.
Recently, the final data that show an exposure-response relationship 
for pazopanib are reported [30]. These data indicate that the optimal  
window for pazopanib exposure is a Ctrough level between 20.5 to 36 mg/L. 
Compared to the target window that we used in our study, this concentra-
tion window is much wider. Possibly, we might have been too stringent  
in our study. This is supported by the (preliminary) results from a study 
that also investigated the feasibility of pk-guided dosing of pazopanib 
[31]. This study was designed to reach a target Ctrough > 20 mg/L. Dose 
modifications were based on measured Ctrough levels as well as the grade 
of toxicity experienced. Of the patients with a Ctrough < 20 mg/L that expe-
rienced no grade ≥ 3 toxicity, 40% achieved an exposure above the target  
at week 8 of treatment after dose modification. During study follow up 
this percentage was further increased to 70%. These results suggest that 
individualized dosing of pazopanib with the aim to reach a target Ctrough 
level is feasible and leads to additional patients reaching the target expo-
Chapter 9
157156
were published until February 2014, several new relationships have been 
shown [30, 49-52]. Furthermore, a few studies that investigated the fea- 
sibility of dose optimization to either reach a target exposure or reduce 
the inter-patient variability in pk have been conducted since then [31, 53-
55]. Moreover, a recent study showed that about half of the plasma concen-
trations for imatinib, sunitinib and erlotinib in the outpatient population 
appear to be below their supposed target level [56]. However, thus far  
only one randomized controlled study that prospectively investigated  
the effect of imatinib tdm on clinical outcome has been published [57]. 
In this study, event free was defined as remaining without treatment 
failure, disease progression, occurrence of moderate clinical or severe  
laboratory adverse events or treatment discontinuation. In contrast to 
what was expected, this study could not demonstrate a benefit of tdm in 
terms of the percentage of patients that were event free. However, failure 
of this trial can be fully explained by the fact that adherence to dosage  
recommendations by prescribers was only 50% in the tdm arm. Of the pa-
tients that did receive the recommended tdm guided dose, 71% remained 
event free compared to 23% of the patients who did not or only partially 
received this recommended dose (absolute risk reduction 48%, P = 0.033). 
Therefore, I would like to oppose that this study actually does show us  
the beneficial effect of tdm to improve treatment outcome. Nevertheless, 
this study also highlights the challenges to prospectively investigate the 
benefit of tdm of targeted therapies on treatment outcome. Despite oral 
and written communication of dose recommendations, dose adjustments 
were not adhered to by the treating physician. Moreover, this study could 
only include 56 of the supposed 300 patients within the planned time-
frame. Possibly, at present tdm does not belong as much to the culture  
of oncological patient care and is actually rarely used [37]. Hence, edu- 
cation about dose optimization within the field of oncology will become 
very important in the nearby future. This should lead to adequate patient 
recruitment and adherence to dose recommendations. Another challenge 
is the reimbursement by health insurances of the costs of administration 
of higher than registered doses of TKIs.
The main arguments for withholding dose optimization of oral targeted 
therapies from clinical practice are the lack of 1) studies that prospectively 
determine the relation between, or thresholds for, systemic drug exposure 
and treatment outcome and 2) studies that prospectively assess the influ-
ence of dose optimization on primary treatment outcome parameters both 
in terms of efficacy as well as toxicity. However, as long as the assessment 
of exposure-response relationships will not become a requirement by  
the regulatory agencies and the assessment of pharmacokinetics are  
not involved in phase iii trials in which the efficacy of a new treatment  
is assessed, the lack of prospectively assessed correlations will remain.  
the threshold previously associated with sunitinib efficacy. Due to the  
retrospective character of our analysis, the length of intestine resected  
was unfortunately unknown. Theoretically, the influence of a combined 
gastrectomy and small bowel resection depends on the length of intestine 
resected and monitoring of sunitinib plasma concentrations is indicated 
in such situations.
The lack of an effect of major gastrectomy on sunitinib exposure,  
is in contrast to the results found for imatinib. This should be taken  
into account when treating gastrectomized gist patients with TKIs. 
Hypothetically, gastrectomized patients have less and/or shorter treat-
ment benefit from first-line imatinib therapy, when administered as a 
fixed dose, due to decreased imatinib plasma levels. Yet, these patients 
might have a high chance of benefit from second line sunitinib therapy. 
Another approach could be the administration of imatinib with an acidic 
containing beverage analogue to administration of, for example, itracona-
zol with coca cola when a proton pump inhibitor is used to increase expo-
sure. This hypothesis is currently investigated in an ongoing study in the 
lumc and Radboud UMC (nct02185937). For now, depending on the type 
of resection of the gi tract, measuring exposure levels to imatinib, sunitin-
ib and presumably also regorafenib could be helpful to decide whether 
there is sufficient exposure to these drugs. 
In chapter 8 we assessed the correlation between everolimus exposure 
and toxicity. Results show that patients who had their everolimus dose  
reduced due to toxicity, had significantly higher drug exposures than  
patients without reductions. Moreover, everolimus exposure was asso- 
ciated with the probability for stomatitis. Results were in line with find-
ings from another study in patients with cancer [35]. The results of our 
study underscore the high inter-patient variability in everolimus pk as 
well as its correlation with toxicity. We should take this inter-patient  
variability, in combination with the growing evidence for a correlation  
between exposure and treatment efficacy and toxicity in the field of on- 
cology, into account in the use of everolimus for the treatment of solid  
tumors. Future studies should first aim to clearly identify the optimum 
therapeutic window of everolimus exposure for different cancers. As tdm 
of everolimus is already the standard of care within transplantation med- 
icine, dose individualization of everolimus in the field oncology is maybe 
not that far away. 
Future Perspectives
Multiple opinion articles and reviews about the dose optimization of  
oral targeted therapies have been published in the last few years [36-48]. 
Next to the exposure-response relationship described in chapter 2 which 
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Association of Hospital Pharmacists published a document regarding tdm 
of imatinib [59]. This shows us that the dose optimization of oral targeted 
therapies is starting to become part of clinical practice. For targeted thera-
pies without clearly defined thresholds, the average exposures identified 
in phase i or ii trials on the registered dose could be used as second best 
alternative in specific circumstances. 
Obviously, drug exposure is not the sole determinant of clinical outcome 
in patients with cancer and other factors such as patient- or tumor specific 
characteristics also contribute to the efficacy of oral targeted therapies. 
For different reasons, such as unnecessary toxicity, treatment delay, com-
pliance, de novo inefficacy but also costs, it is crucial to identify those pa-
tients who are most likely to respond to oral targeted therapies. However, 
after selecting the most effective drug for a specific tumor type, dose indi-
vidualization could further help to optimize the individual benefit-risk  
ratio, with the highest possible efficacy and the lowest possible toxicity  
of therapy.
In the future ‘ideal, evidence based, dose optimized world’, when we  
have more results from prospective randomized trials on dose optimi- 
zation, dose adjustments and treatment switch are made according to  
the algorithm depicted in Figure 1. I expect that this strategy will lead to 
better treatment outcomes. Especially, since normally the dose of an oral 
targeted therapy is not increased when a patient does not show any toxic 
effects. However, this absence of toxicity is potentially also a sign of under 
exposure that could lead to treatment failure. On the other hand, in case 
As suggested by others, regulatory incentives for drug developers and 
healthcare providers maybe need to be put in place in order to generate 
forces that reward the exploration of exposure-response relationships and 
also dose optimization approaches [47]. At first it may seem that there are 
no apparent benefits for pharmaceutical companies to investigate dose 
optimization. However, actually it can be argued whether the failure  
of some clinical studies due to a lack of efficacy is possibly also a result  
of fixed dosing leading to under exposure of oral targeted therapies in  
a significant number of patients [42]. In addition, fixed dosing can lead  
to over exposure resulting in therapies that are effective but also ex- 
tremely toxic in a significant number patients, such as everolimus  
and regorafenib.
Meanwhile, for oral targeted therapies that are already registered,  
retrospective data are the best we have and it can be discussed whether 
this is perhaps also good enough. In addition, it can be argued whether  
it is ethical to not measure since this means that we ignore the data on  
exposure-response relationships that we currently have. In my opinion 
and as also proposed by others, we should therefor just ‘quit guessing  
and start measuring’ [38]. Only by starting to measure, we can build  
comprehensive databases that can be used for further investigation of  
exposure-response relationships. Oral targeted therapies have different 
indications for sometimes small patient populations and exposure- 
response relationships should be defined separately per drug for each  
tumor type. Therefore, I believe that collaboration between research 
groups is of utmost importance. An example of such collaborations is  
the Dutch gist consortium. Another novel example of such collaboration 
is the Dutch Pharmacology Oncology Group which aims at collaboration 
on dose optimization studies within oncology (www.dpog.nl). 
As said, future research should focus on the added value of routine dose 
optimization strategies (such as tdm) of oral targeted therapies on clinical 
outcome to make dose optimization an evidence based approach. In my 
opinion, the thresholds defined by retrospective analysis could be used  
as target exposure for these dose optimization studies. With such an  
approach it can be tested at the same time within one study whether  
retrospectively defined correlations hold when prospectively investigated. 
Meanwhile, I suggest that the measurement of drug exposure is indicated 
in clinical practice in case of extreme or unexpected toxicity, a lack of ex-
pected clinical benefit, suspected pk drug-drug interactions, in patients 
with an altered anatomy of the gi tract or in case of suspected therapy 
nonadherence, to support clinical decision making for at least imatinib, 
sunitinib and pazopanib. Actually, the esmo guideline for the diagnosis, 
treatment and follow-up of gist recognizes the potential of measuring  
imatinib concentrations in these situations [58]. Recently, also the Dutch 
Standard fixed dose
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Figure 1 Supposed dosing algorithm for future treatment with oral targeted therapies. 
All patients start with the registered fixed dose of an oral targeted therapy. When steady-state is reached, 
exposures are measured. Based on exposure and clinical outcomes, the dose should be increased, decreased 




1  Bai, F. et al (2011) Determination of vandetanib in human 
plasma and cerebrospinal fluid by liquid chromatography 
electrospray ionization tandem mass spectrometry (LC-
ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life 
Sci. 879, 2561-2566.
2  Sparidans, R.W. et al (2012) Liquid chromatography-
tandem mass spectrometric assay for therapeutic drug 
monitoring of the tyrosine kinase inhibitor pazopanib in 
human plasma. J Chromatogr B Analyt Technol Biomed 
Life Sci. 905, 137-140.
3  Escudero-Ortiz, V. et al (2015) Development and 
validation of an HPLC-UV method for pazopanib 
quantification in human plasma and application to 
patients with cancer in routine clinical practice. Ther Drug 
Monit. 37, 172-179.
4  Etienne-Grimaldi, M.C. et al (2009) A routine feasible 
HPLC analysis for the anti-angiogenic tyrosine kinase 
inhibitor, sunitinib, and its main metabolite, SU12662, in 
plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 
877, 3757-3761.
5  Lankheet, N.A. et al (2013) Quantification of sunitinib and 
N-desethyl sunitinib in human EDTA plasma by liquid 
chromatography coupled with electrospray ionization 
tandem mass spectrometry: validation and application in 
routine therapeutic drug monitoring. Ther Drug Monit. 35, 
168-176.
6  Qiu, F. et al (2012) Simultaneous determination of sunitinib 
and its two metabolites in plasma of Chinese patients with 
metastatic renal cell carcinoma by liquid chromatography-
tandem mass spectrometry. Biomed Chromatogr.
7  Rodamer, M. et al (2011) Development and validation of a 
liquid chromatography/tandem mass spectrometry 
procedure for the quantification of sunitinib (SU11248) and 
its active metabolite, N-desethyl sunitinib (SU12662), in 
human plasma: application to an explorative study. J 
Chromatogr B Analyt Technol Biomed Life Sci. 879, 
695-706.
8  Sparidans, R.W. et al (2009) Liquid chromatography-
tandem mass spectrometric assay for the light sensitive 
tyrosine kinase inhibitor axitinib in human plasma. J 
Chromatogr B Analyt Technol Biomed Life Sci. 877, 
4090-4096.
9  Sparidans, R.W. et al (2012) Liquid chromatography-
tandem mass spectrometric assay for the mutated BRAF 
inhibitor vemurafenib in human and mouse plasma. J 
Chromatogr B Analyt Technol Biomed Life Sci. 889-890, 
144-147.
10  Sparidans, R.W. et al (2013) Liquid chromatography-
tandem mass spectrometric assay for the mutated BRAF 
inhibitor dabrafenib in mouse plasma. J Chromatogr B 
Analyt Technol Biomed Life Sci. 925, 124-128.
11  Wang, L.Z. et al (2011) Rapid determination of gefitinib and 
its main metabolite, O-desmethyl gefitinib in human 
plasma using liquid chromatography-tandem mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life 
Sci. 879, 2155-2161.
12  Zhao, M. et al (2003) Specific method for determination of 
OSI-774 and its metabolite OSI-420 in human plasma by 
using liquid chromatography-tandem mass spectrometry. 
J Chromatogr B Analyt Technol Biomed Life Sci. 793, 
413-420.
13  Zhao, M. et al (2005) Specific method for determination of 
gefitinib in human plasma, mouse plasma and tissues 
using high performance liquid chromatography coupled to 
tandem mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci. 819, 73-80.
14  Moes, D.J. et al (2010) Liquid chromatography-tandem 
mass spectrometry outperforms fluorescence polarization 
immunoassay in monitoring everolimus therapy in renal 
transplantation. Ther Drug Monit. 32, 413-419.
15  Lankheet, N.A. et al (2012) Method development and 
validation for the quantification of dasatinib, erlotinib, 
gefitinib, imatinib, lapatinib, nilotinib, sorafenib and 
sunitinib in human plasma by liquid chromatography 
coupled with tandem mass spectrometry. Biomed 
Chromatogr.
16  Chahbouni, A. et al (2009) Simultaneous quantification of 
erlotinib, gefitinib, and imatinib in human plasma by liquid 
chromatography tandem mass spectrometry. Ther Drug 
Monit. 31, 683-687.
17  de Francia, S. et al (2009) New HPLC-MS method for the 
simultaneous quantification of the antileukemia drugs 
imatinib, dasatinib, and nilotinib in human plasma. J 
Chromatogr B Analyt Technol Biomed Life Sci. 877, 
1721-1726.
18  Gotze, L. et al (2012) Development and clinical application 
of a LC-MS/MS method for simultaneous determination of 
various tyrosine kinase inhibitors in human plasma. Clin 
Chim Acta. 413, 143-149.
19  Haouala, A. et al (2009) Therapeutic Drug Monitoring of 
the new targeted anticancer agents imatinib, nilotinib, 
dasatinib, sunitinib, sorafenib and lapatinib by LC tandem 
mass spectrometry. J Chromatogr B Analyt Technol 
Biomed Life Sci. 877, 1982-1996.
20  Honeywell, R. et al (2010) Simple and selective method for 
the determination of various tyrosine kinase inhibitors 
used in the clinical setting by liquid chromatography 
tandem mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci. 878, 1059-1068.
21  Hsieh, Y. et al (2009) Hydrophilic interaction liquid 
chromatography/tandem mass spectrometry for the 
simultaneous determination of dasatinib, imatinib and 
nilotinib in mouse plasma. Rapid Commun Mass 
Spectrom. 23, 1364-1370.
22  Couchman, L. et al (2012) An automated method for the 
measurement of a range of tyrosine kinase inhibitors in 
human plasma or serum using turbulent flow liquid 
chromatography-tandem mass spectrometry. Anal 
Bioanal Chem. 403, 1685-1695.
23  Bouchet, S. et al (2011) Simultaneous determination of 
nine tyrosine kinase inhibitors by 96-well solid-phase 
extraction and ultra performance LC/MS-MS. Clin Chim 
Acta. 412, 1060-1067.
of toxicity the dose if often pragmatically lowered. However, for patients 
that already have exposures below the threshold associated with efficacy,  
a treatment switch to another therapy might be a better option compared 
to reducing the dose. I believe that in the ‘ideal, evidence based, dose op- 
timized world’ drug exposure should be measured in all patients treated 
with oral targeted therapies. As said, this a future world and obviously  
trials that asses the feasibility of dose optimization on clinical outcome 
are warranted.
In 1892 Sir William Osler, a Canadian physician and one of the four  
founding professors of the Johns Hopkins Hospital, said: ‘If it were not  
for the great variability among individuals, medicine might as well be  
a science, not an art’. He referred to the decisions that doctors make  
when prescribing medication as an art since objective data considering 
the benefits and harms on an individual patient level were lacking at that 
time. However, about one century later we should maybe reconsider these 
words as we are actually getting closer to a more evidence based approach 
for individualized treatments. This eventually should not only lead to the 
right drug for the right patient, but also to the administration of this drug 
in the right dose in order to achieve the right drug exposure level within 
each individual patient.
Conclusion
Future research should focus at showing the added value of dose optimi-
zation of oral targeted therapies on clinical outcome. The thresholds de-
fined by either retrospective or future prospective analysis could be used 
as target exposure for these dose optimization studies Education about 
dose optimization within the field of oncology will become important  
in the nearby future both for the recruitment of trials as well as adherence 
to recommendations considering dosing. Meanwhile, the measurement  
of drug exposure seems justified in situations of extreme or unexpected 
toxicity, a lack of expected clinical benefit, suspected pk drug-drug inter-
actions, in patients with major resections of the gi tract or in case of  
suspected therapy nonadherence, to support clinical decision making.
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ies described in chapter 5 and 6 of this thesis and is currently also used  
for routine patient care. 
In chapter 4 we studied the feasibility of dried blood spot (dbs)  
sampling as an alternative for venous sampling to monitor pazopanib 
therapy in clinical practice. A good agreement between pazopanib levels 
measured in plasma and concentrations calculated from the correspond-
ing dbs card was demonstrated. Although validation of dbs cards pre-
pared by patients remains necessary, the results show that dbs could  
be very useful to measure drug exposure in patients that are treated  
with pazopanib. 
In chapters 5, 6, 7, and 8 the causes and extent of inter-patient variabil- 
ity in drug exposure as well as the feasibility of different dose individual- 
ization strategies for oral targeted therapies are described. In chapter 5 
we investigated the possibility of therapeutic drug monitoring (tdm) to 
reduce the inter-patient variability in pazopanib exposure. In this study, 
the previously unknown intra-patient variability in pazopanib exposure 
was relatively large compared to inter-patient variability. This made it 
challenging to achieve a target exposure within a predefined window and 
this study could not show that individualized dosing results in a reduction 
of the inter-patient variability in pazopanib exposure. The most plausible 
explanation for the large intra-patient variability in pk, is the major effect 
of food on pazopanib absorption which should be tightly controlled. 
Interestingly, this study also suggested a decrease in pazopanib  
exposure over the studied period of 6 weeks. 
In chapter 6 the results of a phenotyping study for the dose individu-
alization of sunitinib are described. It was hypothesized that with the use 
of midazolam as a phenotyping probe for cyp3a4 activity, patients that are 
potentially at risk for under- or overtreatment at the standard sunitinib 
dosage regimen could be identified before the start of therapy. The results 
of this study showed that midazolam exposure was highly correlated with 
sunitinib exposure and could explain up to 51% of the inter-patient varia-
bility in sunitinib exposure. This suggests that midazolam could be useful 
in clinical practice to dose individualize sunitinib therapy. However,  
prospective validation in a clinical study remains required.
In chapter 7 the effect of a major gastrectomy on sunitinib exposure 
in patients with gist was investigated. Our retrospective analysis across  
4 phase i-iii trials showed that major gastrectomy alone did not influence 
the exposure to sunitinib or its active metabolite. However, it was shown 
that patients with a combined gastrectomy and small bowel resection did 
have a statistically significantly decreased plasma exposure to sunitinib 
and its active metabolite. This change was considered clinically not rele-
vant as exposures were still above the threshold associated with sunitinib 
efficacy. The lack of an effect of major gastrectomy on sunitinib exposure, 
Both tyrosine kinase inhibitors (tki) and mammalian target of rapamycin 
(mTOR) inhibitors are oral targeted therapies that are used for the treat-
ment of a variety of malignancies. Due to the growing evidence for drug 
exposure-response relationships, in combination with their high inter- 
patient variability in pharmacokinetics (pk) and a fixed dosing regimen,  
it is hypothesized that dose individualization of oral targeted therapies 
may lead to better treatment outcomes both in terms of efficacy as well  
as toxicity. This thesis describes the results of different studies that inves- 
tigated dose optimization strategies of oral targeted therapies used in  
oncology, with a focus on the TKIs pazopanib and sunitinib and the  
mTOR inhibitor everolimus. 
In chapter 2 an overview of the current knowledge and evidence for  
individualized dosing of TKIs used for the treatment of solid tumors is  
given. Despite limitations such as retrospective analysis, the monitoring  
of Ctrough levels of imatinib, sunitinib, and pazopanib seems indicated  
in certain circumstances such as extreme or unexpected toxicity, a lack  
of clinical benefit, suspected pk drug-drug interactions or suspected  
therapy nonadherence.
In chapter 3 and 4 different strategies to measure drug exposure of oral 
targeted therapies are investigated. In chapter 3 the successful develop-
ment and validation of a lc-ms/ms method for the simultaneous determi-
nation of six TKIs and two active metabolites in human serum or plasma  
is described. In comparison with the existing assays that simultaneously 
determine multiple TKIs, we were the first to incorporate pazopanib and 
regorafenib in the assay. This method has been used for the clinical stud-
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is normaalgesproken nauwkeurig gereguleerd. Bij verschillende soorten 
kanker is deze regulatie echter weggevallen en kan er dus ongecontroleer-
de celgroei plaatvinden. Voorbeelden van dit soort coördinerende eiwit-
ten zijn tyrosine kinasen en de mammalian target of rapamycin (mTOR). 
De ontdekking van de rol van tyrosine kinasen bij kanker heeft geleid 
tot de ontwikkeling van verschillende tyrosine kinase remmers (‘tyrosine 
kinase inhibitors’, TKIs). Sinds de registratie van imatinib in 2001, zijn  
er nog 22 andere TKIs geregistreerd voor de behandeling van kanker. 
Tevens zijn er ook remmers van het eiwit mTOR beschikbaar gekomen  
zoals bijvoorbeeld everolimus en temsirolimus.
Dosis Optimalisatie
Hoewel de ontwikkeling van nieuwe geneesmiddelen voor de behande-
ling van kanker moet worden voortgezet, is het ook van belang het effect 
van de huidige beschikbare geneesmiddelen te optimaliseren. Niet iedere 
patiënt behaalt namelijk dezelfde mate van effectiviteit met de zelfde  
therapie. Daarnaast ervaren veel patiënten, soms ernstige, bijwerkingen 
welke er voor zorgen dat de behandeling moet worden onderbroken,  
de dosis verlaagd of de therapie soms zelfs in zijn geheel moet worden  
gestopt. Dit ondanks de verwachting dat orale doelgerichte therapieën 
vanwege hun specifieke karakter minder bijwerkingen zouden veroorzaken.
Voor verschillende TKIs en ook everolimus zijn er relaties aangetoond 
tussen de blootstelling of concentratie (farmacokinetiek) van het genees-
middel in het bloed en de effectiviteit en bijwerkingen van het geneesmid-
del. Dit betekent dat wanneer de blootstelling te laag is, er een kans is  
dat de therapie daardoor niet effectief is. Wanneer de blootstelling te 
hoog is kan dit juist leiden tot (onnodige) bijwerkingen. Daarnaast is  
er veel variatie in de mate van blootstelling tussen patiënten. Ondanks 
deze verschillen in blootstelling tussen patiënten en de relaties tussen 
blootstelling en effect, krijgen alle patiënten standaard eenzelfde dosis  
bij de behandeling met orale doelgerichte therapie. De combinatie van 
deze eigenschappen vormt de basis voor het idee dat dosis optimalisatie 
mogelijk kan zorgen voor meer effectiviteit en minder bijwerkingen van 
deze therapieën.
Doel van het onderzoek
Het is belangrijk om de kennis over de onderliggende oorzaken van deze 
variatie in blootstelling tussen patiënten te vergroten. Ook is het belang-
rijk om methoden te ontwikkelen waarmee we gemakkelijk de genees-
middelblootstelling in patiënten kunnen bepalen. Ten slotte is er meer 
onderzoek nodig naar de geschiktheid van dosis individualisatie van  
orale doelgerichte antikanker geneesmiddelen met als streven om de  
verschillen in blootstelling tussen patiënten te verkleinen. 
is in contrast to the results found for imatinib and should be taken  
into account when treating gastrectomized gist patients with TKIs.
In chapter 8 the correlation between everolimus exposure and toxic- 
ity was assessed in patients with thyroid cancer. It was shown that patients 
who had their everolimus dose reduced due to toxicity, had significantly 
higher drug exposure levels than patients without dose reductions. 
Moreover, everolimus exposure was found associated with the risk to  
develop stomatitis. These results suggest that the high inter-patient varia-
bility in everolimus exposure, in combination with the growing evidence 
for a correlation between exposure and treatment outcome should be tak-
en into account in the treatment with everolimus of patients with cancer. 
In chapter 9 the results from the studies performed are discussed  
and future perspectives are described. Future research should focus on 
showing the added value of dose optimization of oral targeted therapies 
on clinical outcome. Also education about dose optimization within the 
field of oncology will become important in the nearby future. Meanwhile, 
the measurement of drug exposure seems justified in situations of ex-
treme or unexpected toxicity, a lack of expected clinical benefit, suspected 
pk drug-drug interactions, in patients with major resections of the gi tract 
or in case of suspected therapy nonadherence, to support clinical  
decision making.
>
Kanker behoort wereldwijd tot een van de meest voorkomende doods- 
oorzaken. In Nederland kregen in 2012 ongeveer 100.000 mensen de  
diagnose kanker te horen. Daarnaast overleden in datzelfde jaar 42.000 
mensen aan de gevolgen van kanker. Na diagnose zijn er vaak verschillen-
de behandelingen en combinaties mogelijk voor patiënten waaronder 
chirurgie, radiotherapie en systemische behandeling met geneesmiddelen.
Doelgerichte Orale Antikanker Geneesmiddelen
Met de toegenomen kennis over de onderliggende ziekteprocessen van 
kanker, is het aantal beschikbare systemische behandelingen in de afgelo-
pen 20 jaar enorm toegenomen. Naast de behandeling met conventionele 
niet-specifieke chemotherapie die aangrijpt op alle snel delende cellen,  
is er nu ook behandeling mogelijk met meer specifieke middelen zoals 
doelgerichte orale geneesmiddelen (‘oral targeted therapies’) en mono- 
klonale antilichamen en sinds recent ook immunotherapie. Doelgerichte 
orale antikanker geneesmiddelen grijpen aan op eiwitten die specifiek  
betrokken zijn bij de activering en coördinatie van processen van belang 
voor de groei en overleving van cellen. De activiteit van deze eiwitten  
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kan zijn voor het meten van de geneesmiddel blootstelling in patiënten 
die met pazopanib worden behandeld. 
In hoofdstuk 5, 6, 7, en 8 worden de oorzaken en mate van variabiliteit  
in geneesmiddel blootstelling tussen patiënten, als ook de geschiktheid 
van verschillende dosis individualisatie strategieën voor orale doelgerich-
te antikanker geneesmiddelen beschreven. 
In hoofdstuk 5 is gekeken naar het toepassen van therapeutic drug  
monitoring (tdm) voor het verminderen van variabiliteit in pazopanib 
blootstelling tussen patiënten. TDM is een vorm van dosis optimalisatie 
waarbij de dosering van een geneesmiddel wordt aangepast op basis van 
gemeten geneesmiddelconcentraties. Op deze manier wordt geprobeerd 
een streefblootstelling (therapeutisch venster) te bereiken met zoveel  
mogelijk effectiviteit en zo min mogelijk toxiciteit van de therapie.  
Voor geneesmiddel blootstelling geldt dat deze niet alleen varieert tussen 
patiënten, maar ook binnen één patiënt. Dit wordt intra-patiënt variatie 
genoemd en ontstaat bijvoorbeeld doordat de opname van het genees-
middel per dag beïnvloed kan worden door verschillende factoren zoals 
voedsel. Omdat de intra-patiënt variatie van pazopanib blootstelling  
onbekend was, hadden we ingeschat dat deze ongeveer de helft van  
de variatie tussen patiënten zou zijn, zoals ook voor andere TKIs is aange-
toond. Echter, de eerder onbekende intra-patiënt variatie van pazopanib 
bleek achteraf relatief groot te zijn in ons onderzoek en ongeveer gelijk 
aan de variatie tussen patiënten. Deze grote variatie binnen een patiënt is 
de voornaamste reden waarom het in deze studie niet gelukt is de variatie 
in blootstelling tussen patiënten te reduceren. De lage biologische beschik-
baarheid van pazopanib in combinatie met de invloed van voedsel op de 
opname van pazopanib worden als de voornaamste redenen beschouwd 
voor de gevonden resultaten. In dit onderzoek leek tevens een afname  
in pazopanib blootstelling in de tijd op te treden zoals ook voor enkele 
andere TKIs is aangetoond.
In hoofdstuk 6 zijn de resultaten weergegeven van een fenotypering 
studie naar de dosis individualisatie van sunitinib. Hierbij is midazolam 
blootstelling in het bloed gebruikt als maat voor de cyp3a4 activiteit.  
cyp3a4 is een enzym in voornamelijk de darm en lever dat betrokken is  
bij het omzetten en afbreken van sunitinib in andere stoffen (metabolis-
me). De veronderstelling is hierbij dat iemand met veel cyp3a4 activiteit, 
midazolam (en dus ook sunitinib) sneller zal omzetten en dus mogelijk 
een hogere dosering sunitinib nodig heeft. Omgekeerd geldt dat personen 
met weinig cyp3a4 activiteit mogelijk een lagere dosering nodig hebben. 
Op deze manier kunnen voor de start van de behandeling patiënten  
worden geïdentificeerd die het risico lopen op onder- dan wel over- 
behandeling met sunitinib. Onze studie toonde aan dat de midazolam 
blootstelling als maat voor cyp3a4 activiteit sterk gecorreleerd was aan 
Het doel van het onderzoek beschreven in dit proefschrift is om  
verschillende dosisoptimalisatie strategieën te ontwikkelen en te onder-
zoeken voor orale doelgerichte geneesmiddelen die binnen de oncologie 
worden gebruikt. De focus lag hierbij op de TKIs pazopanib en sunitinib 
en de mTOR-remmer everolimus.
In hoofdstuk 2 van dit proefschrift is een overzicht gegeven van de eer- 
dere onderzoeken die zijn gedaan naar dosis optimalisatie van TKIs die 
worden gebruikt voor de behandeling van solide tumoren. Hoewel deze 
onderzoeken een aantal beperkingen kennen, lijkt het meten en monito-
ren van de blootstelling aan het geneesmiddel in het bloed op dit moment 
voldoende onderbouwd voor de TKIs imatinib, sunitinib en pazopanib. 
Vooral in situaties zoals extreme of onverwachte bijwerkingen, het uit- 
blijven van een klinisch effect, verdenking van een interactie met andere 
geneesmiddelen en bij verdenking van therapieontrouw lijkt het meten 
van bloedspiegels aangewezen. 
In hoofdstuk 3 en 4 worden verschillende strategieën onderzocht om  
de blootstelling in het lichaam aan TKIs te meten. In hoofdstuk 3 wordt 
de ontwikkeling en validatie van een analytische bepalingsmethode voor 
het meten van de concentratie geneesmiddel in serum of plasma van zes 
verschillende TKIs en twee actieve metabolieten beschreven. Het gaat  
hierbij om een liquid chromatography - tandem mass spectrometry (lc-ms/
ms) bioanalytische bepalingsmethode. In vergelijking met bestaande  
bepalingsmethoden die ook tegelijkertijd verschillende TKIs kunnen  
bepalen, hebben wij als eerste pazopanib en regorafenib aan de methode 
toegevoegd. Deze methode wordt gebruikt voor de onderzoeken die zijn 
beschreven in hoofdstuk 5 en 6 van dit proefschrift en wordt tevens  
gebruikt in de dagelijkse patiëntenzorg.
Voor het bepalen van geneesmiddelconcentraties in serum of plasma 
is het afnemen van een bloedmonster noodzakelijk. Dit is echter niet zo 
patiëntvriendelijk, o.a. omdat bloedprikken soms als belastend wordt  
ervaren en patiënten hiervoor naar het ziekenhuis dan wel naar een  
dokterspost moeten komen. In hoofdstuk 4 is er gekeken naar de  
geschiktheid van de droge bloedspot methode (‘dried blood spot’, dbs)  
als meer patiëntvriendelijk alternatief voor het monitoren van de behan-
deling met pazopanib. Dit is een methode waarbij patiënten na een vin-
gerprik een druppel bloed opvangen op een speciaal dbs kaartje. In het 
beschreven onderzoek werd een goede overeenkomst tussen pazopanib 
concentraties gemeten in plasma en de concentraties zoals berekend  
met behulp van de dbs aangetoond. Ondanks dat controle van de bruik-
baarheid van deze methode met dbs kaarten die door patiënten zelf zijn 
gemaakt nog nodig is, laten onze resultaten zien dat dbs zeer waardevol 
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beeld ook gewichtsverlies door verminderde inname van voedsel. 
Stomatitis is een frequent voorkomende reden de dosering te verlagen  
of de behandeling te staken. De resultaten van het beschreven onderzoek 
suggereren dat de grote variatie in everolimus blootstelling tussen patiën-
ten in combinatie met het groeiende bewijs voor relaties tussen everoli-
mus blootstelling en behandeluitkomst in overweging moeten worden 
genomen. 
In hoofdstuk 9 van dit proefschrift worden de uitgevoerde onderzoeken 
bediscussieerd en in een toekomstig perspectief geplaatst. Toekomstig  
onderzoek moet zich richten op het aantonen van de toegevoegde waarde 
van dosis optimalisatie van orale doelgerichte geneesmiddelen op klinische 
uitkomsten. Educatie over dosis optimalisatie aan medisch oncologen  
zal daarbij een belangrijke plaats moeten krijgen. Totdat resultaten van 
genoemde onderzoeken beschikbaar komen, lijkt het gerechtvaardigd om 
blootstelling in patiënten te meten in situaties van extreme of onverwach-
te toxiciteit, het uitblijven van een klinisch effect, verdenking van interactie 
met andere geneesmiddelen, in patiënten die een grote resectie van het 
maagdarmkanaal hebben gehad of bij verdenking van therapieontrouw 
ter ondersteuning van het maken van klinische keuzes.
sunitinib blootstelling en tot 51% van de variatie tussen patiënten in  
sunitinib blootstelling kon verklaren. Dit suggereert dat midazolam  
zinvol kan zijn voor dosis optimalisatie van sunitinib, hoewel prospec- 
tieve validatie nodig blijft.
In hoofdstuk 7 is het effect van chirurgische verwijdering van een 
groot gedeelte van de maag (gastrectomie) op sunitinib blootstelling  
onderzocht. Imatinib, sunitinib en regorafenib zijn de TKIs die op dit  
moment geregistreerd zijn voor de 1e, 2e en 3e lijns behandeling van  
patiënten met gastro-intestinale stroma tumoren (gist). Bij een aan- 
zienlijk deel van de patiënten wordt (een groot gedeelte van) de maag 
(maagresectie) of de darmen of beiden verwijderd om zodoende de  
tumor te verwijderen. Na orale inname moeten TKIs eerst oplossen in  
het maagdarmkanaal voordat ze via de darmwand in het bloed kunnen 
worden opgenomen. Eerder onderzoek heeft aangetoond dat patiënten 
met een maagresectie, een verminderde blootstelling aan imatinib laten 
zien. De oorzaak hiervoor wordt gezocht in het feit dat imatinib een zure 
omgeving nodig heeft (de maag) om op te lossen en deze door een 
maagresectie ontbreekt. Voor sunitinib geldt dat deze zure omgeving  
iets minder van belang is voor oplossen en opname in het bloed. Dit komt 
door verschillen in de fysische chemische eigenschappen van sunitinib ten 
opzichte van imatinib. Dit is de reden dat wij geen verminderde bloot- 
stelling verwachtten in patiënten die een maagresectie hebben gehad  
en worden behandeld met sunitinib. Dit is retrospectief onderzocht in  
een grote groep patiënten die deelnamen aan verschillende fase i-iii on-
derzoeken. De resultaten lieten zien dat patiënten die een maagresectie 
hadden ondergaan geen verminderde sunitinib blootstelling hadden  
ten opzichte van de controle groep zonder die ingreep. De resultaten  
lieten ook zien dat patiënten bij wie de maag samen met een gedeelte  
van de dunne darm was verwijderd, wel een iets verminderde blootstelling 
hadden. Klinisch wordt dit echter niet relevant geacht omdat de blootstel-
ling nog steeds boven de afkapwaarde was die is gerelateerd aan effectivi-
teit. Het feit dat de sunitinib blootstelling niet, en imatinib blootstelling 
wel verminderd is in patiënten die een maagresectie hebben gehad moet 
in overweging worden genomen voor de behandeling van de patiënten 
met dit type kanker met TKIs.
In hoofdstuk 8 is gekeken naar de correlatie tussen blootstelling van de 
mTOR inhibitor everolimus en toxiciteit in patiënten met schilklierkanker. 
De resultaten lieten zien dat patiënten bij wie de dosis everolimus verlaagd 
moest worden vanwege bijwerkingen aan aanzienlijk hogere blootstelling 
hadden dan patiënten die geen dosisreductie nodig hadden. Daarnaast 
was de blootstelling aan everolimus geassocieerd met de kans op stomatitis. 
Dit is een pijnlijke ontsteking van het mondslijmvlies welke in sommige 
gevallen heel ernstig kan zijn en kan leiden tot infecties, maar bijvoor-
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